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Abstract
As modern drug formulations become more advanced, pharmaceutical companies face the
need for adequate tools to permit them to model complex requirements and to reduce
unnecessary adsorption rates while increasing the dosage administered. The aim of the
research presented here is the development and application of a general stochastic framework
with agent-based elements for building drug dissolution models, with a particular focus on
controlled release systems. The utilisation of three dimensional Cellular Automata and
Monte Carlo methods, to describe structural compositions and the main physico-chemical
mechanisms, is shown to have several key advantages: (i) the bottom up approach simplifies
the definition of complex interactions between underlying phenomena such as diffusion,
polymer degradation and hydration, and the dissolution media; (ii) permits straightforward
extensibility for drug formulation variations in terms of supporting various geometries
and exploring effects of polymer composition and layering; (iii) facilitates visualisation,
affording insight on system structural evolution over time by capturing successive stages
of dissolution. The framework has been used to build models simulating several distinct
release scenarios from coated spheres covering single coated erosion and swelling dominated
spheres as well as the influence of multiple heterogeneous coatings. High-performance
computational optimisation enables precision simulations of the very thin coatings used
and allows fast realisation of model state changes. Furthermore, theoretical analysis of the
comparative impact of synchronous and asynchronous Cellular Automata and the suitability
of their application to pharmaceutical systems is performed. Likely parameter distributions
from noisy in vitro data are reconstructed using Inverse Monte Carlo methods and outcomes
are reported.
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Chapter 1
Introduction
1.1 Introduction to drug dissolution modelling
Drug delivery systems (DDS) are systems for transporting drugs into the body. The main
components of a typical DDS include one or more active agents (i.e. drugs) and one or
more polymers forming the vehicle by which the agents are delivered to the desired area
of the body. The behaviour and breakdown of those polymers, as they traverse the route
of administration (e.g. parenteral, transdermal, oral, through the nervous system, etc.),
influence the time to, and the area of, delivery of the active substances. The intricacies of
drug development require collaboration between scientists of different expertise, notably,
pharmaceutical scientists, bioengineers, computer scientists and others, because there is a
growing need to bring the drug to market faster while maintaining safety of treatment. At
the same time, complex factors that influence drug pharmacokinetics and dissolution must
be taken into account.
The computer modelling of a DDS is a constantly developing field with potential to
become an integral part of pharmaceutical research. In silico simulation of DDS can be useful
for a number of reasons; specifically, (i) it has the potential to reduce the cost of experiment
by reducing the amount of in vitro testing needed, (ii) to reduce the time needed for bringing
the drug to market, (iii) to increase performance during the design phase by allowing more
complex analysis, (iv) to provide better understanding of drug transport processes and
(v) to help identify the required DDS composition and manufacturing procedure. Drug
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dissolution modelling can provide good predictive capability, and improved agreement with
experiment and can help in achieving the desired drug release profile.
A benefit of modelling is that it can be used to explore the influence of many parameters,
such as dissolution device1, geometry, dimension and composition during the drug design
phase and well before the in vivo phase of drug testing.
This is of particular importance as pharmaceutical companies today face a growing
demand for more complex drug designs. Novel formulations are required to reduce side
effects, such as unnecessary absorption, while improving the dosage administered, through
controlled and targeted release. Knowledge about drug release kinetics from such formula-
tions is limited, due to complex interactions between different underlying phenomena and
the environment, often known only through their combined effects. This makes computer
models essential tools in the design of experiments. Unlike classical differential-equation
models, stochastic modelling is applicable to a wide range of systems without requiring
detailed initial knowledge on dissolution mechanisms.
1.2 Controlled DDS Examples
Controlled DDS in general can be classified into reservoir and matrix systems. Reservoir
systems are defined by utilising one or more coating polymers to surround a core of active
substance, which acts as a release-rate controlling material. Matrix systems, also known as
monolithic systems, are characterised by a structural network consisting of a mixture of
polymers and drugs, (Siepmann and Siepmann, 2012a).
Each of these groups can have various different geometries and various release scenarios
and therefore very different complexities. Figure (1.1) illustrates the amount of possible
combinations for diffusion controlled DDS. It can be observed that systems are distinguished
depending on their inner structure and amount of initial drug concentration, together with its
solubility and dispersion, resulting in a relationship which is not always entirely understood.
1The term device is a generic term used here for any kind of drug formulation, including capsules, tablets,
spheres etc. It refers to the formulation consisting of an active substance (the drug) and various carriers
(usually polymers).
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Figure 1.1: An example of DDS classification for diffusion controlled DDS, (Siepmann and
Siepmann, 2012a) described by the ratio of initial (cini) vs saturation concentration (cs) of
the active substance.
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1.3 Thesis scope and contribution
A detailed overview of the status of DDS modelling is given in Chapter 2, which discusses
the main classification of models and analyses key examples from the literature. The chapter
also includes an explanation of the main pharmaceutical phenomena, (as these will be
discussed throughout the thesis), together with the role of in vitro testing in understanding
these. We describe the modelling of polymeric behaviour in general and, specifically, in the
the gastro-intestinal tract, as this plays a central role in controlled drug delivery systems.
In Chapter 3 we cover probabilistic modelling methodology in detail, as this will be the
main focus of the thesis. We introduce key terms and application of Cellular Automata,
Monte Carlo methods, (both in direct and inverse variants) and Agent-Based modelling.
At the end of the chapter, we give an overview of the project performed in collaboration
with the industrial partner which served as initial motivation and reference for this work.
Chapter 4 introduces a novel Cellular Automata based integrative framework and a
meta-model used to create and analyse a series of stochastic models applied to different
controlled release DDS. The meta-model introduces common features which capture the
essence of controlled drug delivery and serve as a basis for deriving the intrinsic models.
The framework allows for easy parameterisation, separation of release mechanisms or their
superposition, (whichever is of interest), graphical visualisation and high performance
execution. Several models are constructed and described in detail, covering the main
pharmaceutical phenomena, namely erosion, swelling and diffusion in the presence of single
and multiple polymeric coatings. The influence of the environment on release is also
investigated.
In Chapter 5 we discuss computational and implementation aspects of the framework
itself. We introduce, for the first time, a discussion of parallelisation strategies in the context
of pharmaceutical models and compare several viable solutions that can be applied depending
on the available computational power. As an addendum, we compare the advantages
and disadvantages of synchronous and asynchronous Cellular Automata implementation,
something that has not been addressed previously for pharmaceutical models.
Chapter 6 presents a detailed high-level analysis of the data, obtained from the various
models described in Chapter 4. Each model was validated against experimental data, which
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served as a test case for performance and predictive potential.
Chapter 7 introduces a different approach to stochastic modelling, which uses Inverse
Monte Carlo methods to “reverse engineer” unknown model parameters from (generally)
noisy experimental data. This approach is then integrated with the previous framework
and models, connecting all stages of the stochastic modelling process, allowing for its use in
concrete industrial applications.
Finally, we present the main conclusions for the work and outline possible future
directions, improvements and developments in Chapter 8.
The appendices include the additional material, including UML diagrams and description
of the underlying code, glossary of abbreviations, definitions and terms, and a list of
publications with selected abstracts, Appendices A - D.
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Chapter 2
Literature review: Pharmaceutical
and Modelling background
In this chapter we present the fundamental theories used in drug dissolution modelling and
review the various approaches available. Representative equations and theory, described
here, have been a basis for all main DDS modelling approaches to date. The focus of this
thesis is in building stochastic models for controlled drug delivery, (where polymers play
an important role), targeting the gastro-intestinal tract. In consequence, the chapter also
reviews models for polymer behaviour in DDS and gives an overview of the main phenomena
involved in simulating dissolution in the gastro-intestinal tract.
2.1 Important phenomena in drug dissolution
In order to choose or develop an appropriate release model, it is of fundamental importance
to understand the underlying mechanisms of release, (Kaunisto et al., 2011). Therefore,
before reviewing DDS modelling itself, we provide short explanations of the key physical
phenomena involved:
1. Diffusion represents the motion of the molecules from a region of higher concentration
to one of lower concentration (i.e. flux). In modelling DDS, diffusion is often described
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by Fick’s laws, (Higuchi, 1960). In one dimension, Fick’s first law can be written as:
J = −D∂c(x, t)
∂x
(2.1)
where J is the diffusion flux, D is the constant diffusion coefficient and ∂c(x, t)/∂x is
the concentration gradient.
Fick’s second law predicts how diffusion causes the concentration to change with time:
∂c(x, t)
∂t
= D
∂2c(x, t)
∂x2
(2.2)
To calculate diffusion mass transport processes in modelling DDS, Fick’s second law
is used in different forms, depending on the geometry of the device, (e.g. Muschert
et al. (2009), Cuppok et al. (2011), Kreye et al. (2011), Seidenberger et al. (2011)).
A finite-difference approximation for determining the drug mass transfer rate, from
cylindrical components consisting of multi-layers, was applied, (McMahon et al., 2003,
2007), and (McMahon, 2008).
Mathematical solutions of the diffusion equations, including detailed explanations
of diffusion processes in solutions, have previous been derived, (Crank, 1975) and
have been used as the basis for similar scientific problems. This work is particularly
relevant to the area of drug dissolution, given that the author investigated different
geometries including plane-sheets, cylinders and sphere and examined both Fickian
and Non-Fickian diffusion.
2. Advection in its general sense represents transfer of material from one region to
another due to the bulk motion of the surrounding fluid. In drug release, it is a
second possible mechanism involved in mass transport, (in addition to diffusion), and
refers to transport with specified velocity along the surface of the drug device, (Crane
et al., 2004b).
3. Degradation is one of the two most important processes in dissolution of polymeric
drug delivery systems. A widely used definition states that it is the process by
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Figure 2.1: Bulk erosion vs. surface erosion.
which chain scission occurs, (during which polymer chains become monomers1 and
oligomers2). Monomers and oligomers have the ability to break down and therefore
dissolve easily, (Göpferich, 1996).
4. Erosion is a consequence of degradation and represents the loss of material from a
polymer. It is an important parameter because it determines the release rate of the
drug, (Siepmann and Göpferich, 2001), (Lao et al., 2011). When a polymer erodes it
leaves space for the drug to be released from the device or for water ingress. Two
types of erosion are defined, (Langer and Peppas, 1983), (von Burkersroda et al.,
2002):
Surface erosion is a homogeneous process and represents the stage during which the
size of the device decreases while preserving its shape; the device loses material only
from its surface;
Bulk erosion is a heterogeneous process, with material being lost from the whole
device, although the device dimensions remain unchanged as the polymer erosion
occurs throughout, (Figure (2.1)). For instance, surface eroding polymers like PLA,
(polylactide), are often used with a co-polymer such as PLGA, (polylactic-co-glycolic
acid), to achieve bulk erosion. PLGA is a bioerodible polymer and is therefore often
used in controlled release.
In general, it is more complex to model erosion than degradation (Siepmann and
Göpferich, 2001), since there is a long list of possible factors that can influence the
1Monomers are the simplest units of polymer. A number of monomers form complex networks of polymer
chains.
2Oligomers are simple molecules, formed of a few monomers only.
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former, (Göpferich and Langer, 1993, 1995a), (Siepmann and Göpferich, 2001); these
include:
• the nature of the chemical bonds - for example, poly(anhydrides) have highly
reactive bonds and a short half-life so that this determines velocity of degradation
• pH changes
• polymer chain length
• bond cleavage velocity
• swellability
• crystallinity
• water diffusivity in the polymer matrix
• composition of the co-polymers - affects the velocity of release rate
• water uptake - influences the speeding of hydrolysis.
In the work presented in this thesis, both bulk and surface erosion play a role in
controlled drug delivery within the gastro-intestinal tract and are modelled explicitly.
5. Swelling represents a process driven by the disentanglement and diffusion of individ-
ual polymer chains from non-hydrated polymer material, caused by solvent intake
(Braido, 2011),(Kimber et al., 2012). It occurs as a response to changes in environment
acidity or temperature conditions, (Gehrke and Cussler, 1989). During this process,
polymer chains transition from a state of low chain motion (glassy) to one of a higher
motion (rubbery). This occurs until thermodynamic equilibrium (relaxation) of the
chains is achieved (Lee and Peppas, 1987). Long polymer chains disentangle and
detach outwards from the main mass, causing a natural concentration gradient to
form from the inside of the device outwards. At the very end of the gradient, polymer
erosion becomes a dominant factor as polymer concentration is very low. This process
essentially characterises swelling as a polymer diffusion process, not unlike drug
diffusion.
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Figure 2.2: Schematic representation of the USP II Paddle Apparatus.
2.2 In vitro dissolution testing
The first step in modelling dissolution of a drug is to determine the in vitro dissolution rate
under various external conditions. To emulate these conditions, a dissolution test apparatus
is used, with standardised measuring methods outlined in the pharmacopoeias, United
States Pharmacopeia (The United States Pharmacopeial Convention, 2007), and European
Pharmacopoeia (Council of Europe, 2007). Conditions in the intestine and stomach, (change
of temperature, pH and dynamic flux), are mimicked in the paddle apparatus II, (USP
II), by varying either the speed of the paddle, or the physico-chemical properties of the
buffer and by monitoring their influence on the drug dissolution rate, (Figure (2.2)). Whilst
these instruments produce overall release profiles, they do not give good insight into the
underlying physical properties and processes within the device, (coating, filling etc.), that
determine the dissolution characteristics, (Kimber et al., 2011b). Diffusion layer thickness,
(the region immediately surrounding the drug device), in the USP II apparatus is important
as not only diffusion but also advection can have significant impact on velocity in the
boundary layer, (McMahon et al., 2003), (Crane et al., 2004a), (Crane et al., 2004b).
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2.3 Fundamental modelling methods in DDS
Existing DDS models can be classified into three broad categories: The first two are based
on a top-down approach where the main underlying phenomena must be known in some
detail. Both mechanistic and empirical models are included in this category. Models in the
third category are stochastic and simulate the probabilistic behaviour of individual particles
in the system with system effects dependant on aggregation.
Modelling drug dissolution is a topic which has attracted attention for more than a
century, so that various alternatives exist; it is necessary to define the area of interest
more precisely, in order to provide a focused review of relevant developments. In the
following sections, therefore, we describe the main equations and models used in complex
drug delivery. For additional information on possible models, a number of reviews have
appeared in the literature over the last ten years or so, (e.g. Narasimhan (2001), Siepmann
and Göpferich (2001), Siepmann and Peppas (2001), Costa and Lobo (2001), Grassi and
Grassi (2005), Barat et al. (2006a,b), Siepmann and Siepmann (2008, 2012a), Sackett and
Narasimhan (2011), Lao et al. (2011), Kaunisto et al. (2011), and from these different
classifications of DDS models can be summarised.
2.4 Mechanistic and empirical models
Mechanistic, sometimes called “phenomenological models” (Sackett and Narasimhan, 2011),
use differential equations for explaining dissolution processes, providing some insight
into their nature at a lab-based level. The main characteristics and advantages of such
models is that they enable investigation of the physical mechanisms influencing release
and, by varying the relevant parameters, can be used not only to mimic experimental
conditions but also as predictive tools. In order to validate such predictions, two options are
possible: (i) comparison of modelling results with experimental data and (ii) validation of
all parameter values included in the model, (as these have physical significance, (Kaunisto
et al., 2011). Another important advantage of using these models is that good matches
with experiment can be obtained since equations are developed to describe accurately the
underlying phenomena for a specific drug formulation. However, this is also the main
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disadvantage as considerable initial knowledge of the important properties is required either
from the manufacturing process itself or to be determined by calculation. Therefore, a
major consideration is to determine the appropriate level of complexity to be reproduced,
in relation to the main release rate-limiting processes, (such as the boundary conditions
and the main mass transport mechanism). Defining models, which accommodate these
requirements is non-trivial, particularly where multiple-parameterisation and fitting are
essential.
Newer pharmaceutical compounds have even more complex behaviour, (Barat et al.,
2006b), so that defining all processes involved is extremely difficult, particularly if knowledge
of the drug delivery system is incomplete, as is often the case. It is sometimes more
appropriate to use empirical models that do not reflect all possible processes and therefore
are easier to implement, while still giving good prediction for drug release. This parsimonious
approach to modelling the complex behaviour has obvious attractions. Such models usually
assume zero-order release kinetics3, where zero-order release can involve superposition of
various mass transport processes, such as diffusion of liquid/drug, polymer swelling or
polymer degradation, (Siepmann and Göpferich, 2001), without requiring exact information
on the way in which each of these influence the release. By paying careful attention to
the assumptions made in these models, sufficient information is obtained for generation of
comparative release curves from different laboratory designs, (Siepmann and Siepmann,
2008). The main disadvantage is limited applicability, i.e. models are based on experimental
behaviour of the particular system studied, so cannot be used to predict the effects of
hypothetical changes on the system behaviour, e.g. influence of coating thickness on the
drug release rate, (Kaunisto et al., 2011).
2.4.1 The principal classical equations
Noyes-Whitney equation
The earliest mathematical models, mechanistic in nature, used to describe system behaviour
in drug dissolution research appeared more than a century ago, (Noyes and Whitney,
3Zero-order release kinetics implies that the release rate is steady with time and is independent of the
concentration of drug. Increasing the concentration will not speed up the rate of the reaction.
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1897), with the derivation of an equation to describe the dissolution of multiparticle
systems, (powders). The authors discovered the dissolution rate of a solid in solution to be
proportional to the difference between the current concentration of the solution and the
maximal concentration of the saturated solution:
dc
dt
= kNW (Cs − c), (2.3)
where Cs is the saturation concentration, c is the concentration of the solute at time t
and kNW is a constant. Since this equation follows first order kinetics4 kNW is considered
to be a first order proportionality constant.
Later models emphasised the assumptions for which the Noyes-Whitney equation (N-W)
is applicable namely (i) a constant area available for dissolution and (ii) a constant and
intense rate of stirring, (Hixson and Crowell, 1931). The N-W equation is used widely in
many applications, particularly to investigate the influence of the particle size distribution
on dissolution profiles, (Hixson and Crowell, 1931), (Higuchi and Hiestand, 1963) where the
complexity of the particle size effect is emphasised. In the analysis of polydisperse multi-sized
systems, (using complex reverse engineering techniques and taking into account variations
of the number of particles), dissolution profiles were found to be strongly influenced by
particle size distribution, (Simões et al., 1996), (de Almeida et al., 1997). An estimation
of particle size from multi-sized powder dissolution was published recently, (Avdeef et al.,
2009) for two scenarios in which particle size either changes or remains constant during
dissolution. A good historical review of applications of the Noyes-Whitney is given by
Dokoumetzidis and Macheras (2006).
Higuchi equation
A second important equation, empirical in nature, and used to describe controlled release
is due to Higuchi (1961). Considered “the father for a mechanistic understanding of
controlled DDS”, (Siepmann and Peppas, 2011), Higuchi derived an equation, which follows
Fick’s first law and relates diffusion-controlled release of drugs from non-swellable and
4First order kinetics describes a release proportional to the concentration of active substance.
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non-biodegradable films under perfect sink conditions, to the diffusivity and solubility5 of a
drug and its initial concentration. With increasing drug solubility, drug release occurs as a
linear function of the square root of time:
Mt = kH
√
t (2.4)
where Mt is the cumulative amount of drug released from the ointment film during time
interval t and where constant kH has a specific meaning and should not be ignored, i.e.
kH = A
√
2ciniDCs (2.5)
where cini is the initial drug concentration and A is the surface area available for
dissolution.
The Higuchi equation must be used with caution, however, since several assumptions
are made: (i) the initial drug concentration in the system is much higher than the drug
solubility, cini >> Cs ; (ii) the diffusivity of the drug is constant; (iii) no swelling occurs; (iv)
perfect sink conditions apply; (v) the geometry is thin film. In consequence, the equation
cannot be applied readily to systems with complex release, e.g. in describing biphasic
release from coated formulations, (Siepmann and Siepmann, 2008), (Siepmann and Peppas,
2011).
Peppas equation
The last of our general equation was derived by Korsmeyer et al. (1983) and Ritger and
Peppas (1987). Adapting the Higuchi equation, the authors provided a generalisation,
which permits application to any geometry, (thin films, cylinders and spheres) and enables
the dominant nature of the release process, (Fickian or non-Fickian/anomalous), to be
determined. This adaptation represents the fraction of drug release Mt/M∞ as a simple
5Solubility is a property of a substance (the solute, e.g. drug) to be dissolved within another substance
(the solvent). The amount of drug which can be dissolved in some volume is defined by the saturation
concentration (Cs). This means that further increase of drug concentration will not result in faster drug
dissolution for given volume.
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Value of n for different geometries
Drug release mechanism
Thin film Thin Cylinder Sphere
n = 0.5 n = 0.45 n = 0.43 Fickian transport: diffusion is
the leading process
0.5 < n < 1.0 0.45 < n < 0.89 0.43 < n < 0.85 Non-Fickian transport, anoma-
lous behaviour: interference of
more than one mass release
mechanism
n = 1.0 n = 0.89 n = 0.85 Zero-order release
Table 2.1: Values for exponent n in the Peppas equation for different geometries and
analogous drug release characteristics in polymeric controlled delivery systems.
power-law equation:
Mt
M∞
= kP t
n (2.6)
where Mt and M∞ represent the amounts of drug released at time t and the total
amount of drug contained in the DDS, respectively, kP is an experimentally determined
parameter and n is an exponent that depends on the system geometry and the mass
transport mechanisms, (as represented in Figure (2.1)). It can be seen from Table 2.1 that
if the exponent n, for the case of spherical geometries for instance, has a value of 0.43,
Fickian diffusion is the leading transport process, while a value of 0.85 refers to zero-order
release, i.e. concentration independent drug release. Values larger than 0.85 indicate the
erosion controlled (also referred to as Case II ) transport, (Kosmidis et al., 2003b).
The Peppas generalisation is used to describe the drug release mechanism and provides
guidance on which model to use, with many authors using the power-law form as the basic
equation. For example, Kosmidis et al. (2003b) used this generalisation to analyse radial
and axial release from cylinder geometries, while Casas et al. (2010) analysed the effect of
shape on drug release. It became the standard method of analysis of any pharmaceutical
device. In recent work, swellable systems were modelled using a probabilistic CA approach,
(Laaksonen et al., 2009a) and Peppas equation was used to estimate the linearity of the
release for drug fractions. Even though the equation cannot fully explain all swellable
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systems of interest, it has proved very useful in the investigation of complex formulations,
where adequate experimental data are not available. In this way, the Peppas exponent n
has been used to explain the trends in different release curve phases, i.e. whether these are
of zero-order or anomalous, (typical for swellable systems), Laaksonen et al. (2009a).
2.5 Probabilistic models
With the development of high-performance computers, a new approach to modelling DDS
was introduced, namely probabilistic models. While these can be both mechanistic and
empirical in nature, they have the advantage of using a bottom-up approach, simplifying
representation of the system and looking at microscopic rather than macroscopic behaviour.
Probabilistic models use statistical techniques such as Monte Carlo (MC) and Cellular
Automata (CA) to describe drug release properties. Moreover, these approaches are flexible,
since differential equations may also be used to define specific elements of release phenomena,
but with stochastic features incorporated, (Siepmann et al., 2002).
The basic premise of probabilistic models is the assumption that we cannot always
determine the precise parameter values when modelling complex systems, and that the
outcomes of individual system reactions can follow stochastic, as well as deterministic rules.
Such models are thus applicable to systems where: (i) the complexity of the modelled device
prohibits usage of differential equations due to the inherent unknowns of many-element
interactions; (ii) where the design formulation of the complex device is undetermined
(most importantly, during the wet-lab experimental stage) making derivation of analytical
solutions prohibitively costly in terms of time. In addition to this, probabilistic methods
were shown not to lack both precision and correctness in prediction, (Zygourakis, 1990),
(Barat et al., 2006a), (Laaksonen et al., 2009a) and thus form a promising alternative to
traditional DDS modelling.
We cover the current state of probabilistic modelling of DDS based on MC and CA
approaches in detail in Chapter 3.
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Designing the parameters in DDS using Weibull function
It is useful also to mention a class of probabilistic dissolution models, which are not based
on discrete space simulations using MC and CA algorithms. One interesting group in
particular are those which utilise the Weibull function, since this function can be applied to
almost all kinds of dissolution and related release curves, (Costa and Lobo, 2001), (Martínez
et al., 2009). In investigating drug release for which diffusion is the dominant mechanisms,
Kosmidis et al. (2003a) used the form:
Mt
M∞
= 1− e(−atb) (2.7)
where Mt/M∞ is defined as for Equation 2.6 and a, b are Weibull parameters.
Starting from the Higuchi equation, the authors linked the Weibull parameters to
physical properties of the drug device, showing that the scale parameter, a, defines the time
scale of the process and depends on the diffusion coefficient, while the shape parameter, b
has a constant value and characterises the curve, (Kosmidis and Macheras, 2007, 2008),
(Villalobos et al., 2009). Furthermore, coefficient b acts as an indicator of the transport
mechanism, such that its value b < 1, b = 1 or b > 1 implies diffusional release, (parabolic
curve), first order release, (exponential curve), or complex release, (sigmoidal curve),
respectively, (Papadopoulou et al., 2006).
2.6 Modelling polymer behaviour in DDS
The primary objective of controlled release devices is to achieve drug release at a desired
and sustained rate. These are the most common type of systems with targeted delivery
being the main benefit, (e.g. in targeting the gastrointestinal tract, we usually do not
want the drug to be released too soon after the oral intake, but only at the target site).
Controlled drug dissolution is maintained by using polymers with different structures. In
Peppas and Langer (1994), the basic principles underlying the usage of biomaterials (such
as polymers) in pharmaceutical preparation are outlined.
One of the most important problems to solve in order to achieve controlled drug release,
therefore, is that of polymer dissolution. In large part, modelling drug dissolution aims to
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understand and predict the physics of drug release from a dissolving polymer, where these
are commonly-used materials, due to their biodegradability.
A first step to understanding controlled drug delivery is to review the most important
phenomena driving release, (previously defined in the Section 2.1), and their influence
on polymers of varied complexity. The main modelling approaches for these fundamental
phenomena are outlined. The connections between models of different types (i.e. top-down
and bottom-up) are also important as the underlying physical phenomena share similar
features, and knowledge obtained using models of one type can be used to derive rules for
another. For example, for the simple probabilistic model of diffusion we use Fick’s law,
which also defines the interaction between individual elements in Monte Carlo models.
The rate of drug release from the polymeric carrier is important as it must be kept in
the therapeutic range, (Sackett and Narasimhan, 2011).
Glassy and rubbery polymers
A useful division of polymers identifies two types based on their dissolution behaviour:
glassy and rubbery (Crank, 1975), (Lee and Peppas, 1987). The former have complex, non-
Fickian, “anomalous” behaviour where dissolution is time-dependent and swelling occurs as a
consequence of penetrant ingress into the drug device. The latter, “rubbery” polymers, have
Fickian behaviour, with diffusion as the main transport process. These rapidly respond
to changes in the environment, such as a change of temperature, (Narasimhan, 2001).
Classification of a given system is needed for the choice of an appropriate value for Peppas
exponent n.
2.6.1 Polymer dissolution
Purely diffusion-controlled systems are the simplest to understand and therefore can be
modelled by direct application of Fick’s laws, Equation 2.1, Equation 2.2, (Siepmann and
Siepmann, 2008). These can be applied to different DDS types, including both matrix
(monolithic) and coated (reservoir) systems.
In general, there are two main differences between dissolution from polymers and non-
polymeric materials: (i) Polymers require an induction time before dissolution can occur,
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while with a non-polymer this can occur instantly; (ii) Polymer dissolution is controlled by its
disentanglement threshold, a function of polymer chain length. An extremely high threshold
leads to a large amount of water intake while low values imply immediate dissolution.
Non-polymeric materials are in general controlled by external mass-transfer resistance
through a liquid layer adjacent to the solid-liquid interface, (Narasimhan, 2001).
In controlled release devices, under assumptions that the coating does not swell or
dissolve, drug permeability is constant and perfect sink conditions are maintained, with
release dependant on the ratio between concentrations of solute and drug. For the case where
drug concentration is higher, zero order kinetics can be used, otherwise first order kinetics
apply, (Heller and Baker, 1980). However, with the need to take into account coating effects
such as swelling and/or cracking due to polymer expansion, these simplifications are not
realistic, and mechanistic models, which can appropriately describe this level of composite
behaviour, are still lacking, (Siepmann and Siepmann, 2008).
2.6.2 Polymer erosion
In early empirical models, Hopfenberg (1976) derived an equation for the analysis of
surface-eroding polymers. The author assumed that the drug release rate was proportional
to the surface area of the device and, as such, can be calculated for any geometry. One
conclusion that can be derived from this model was that only “slabs” have zero-order kinetics.
Additional analysis of the geometry influence on erodible devices was due to Cooney (1972),
who defined two phases of dissolution. One in which molecules detach from the surface
and the other where diffusion into the fluid occurs. The release is described as dependent,
in the case of cylinders, on an “initial length to initial diameter” ratio, where the value
of this ratio defines the rate of release, (zero-order or otherwise). The Hopfenberg model
allowed initial predictions for drug release kinetics and improved understanding of erodible
systems, such as that described, (Zygourakis and Markenscoff, 1996). This led to looking at
the dissolution of polymers as transport processes controlled by two phases, (Narasimhan,
2001), as described earlier, i.e.
• diffusion of the chains through a boundary layer at the solvent-polymer interface
• disentanglement of the polymer chains
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Using the Higuchi equation as a starting point, Heller and Baker (1980) developed a
mathematical model for combining erosion with diffusion while taking into consideration
particular physiochemical phenomena. The authors assumed that degradation in polymeric
matrices with bulk erosion follows first order kinetics. Typical examples of those are
PLA and PLGA matrices. In addition to the purely diffusion-controlled Higuchi here,
permeability in biodegradable polymeric systems is not constant but increases with erosion.
As a consequence drug release initially decreases, (similar to Higuchi), but then increases,
(due to increased permeability), (Siepmann and Göpferich, 2001).
Additional molecular phenomena and their effects on drug dissolution were taken
into account in some studies, e.g. (Narasimhan and Peppas, 1997). These included
chain disentanglement from an amorphous polymer, water diffusion into the polymer and
hydrophilic drug release from spherical PLGA bulk-eroding microspheres. Furthermore,
Batycky et al. (1997) described the phenomena of microsphere hydration and polymer
erosion. Polymer degradation was represented as a combination of two processes - random
and end-polymer scission and the conclusion was drawn that models, based on only one of
these, cannot explain experimentally observed kinetics of particle mass loss and molecular
weight change, so that a combined model was necessary. Finally, a model for predicting
controlled release from both erosion and bulk matrices was developed, (Rothstein et al.,
2009). Drug release was shown to depend on even more mechanisms, such as hydration of
the system, formation of pores, and drug and polymer dissolution.
All these models have improved the understanding of the role of erosion, and its
variations to some extent. Nevertheless, they are still limited and fail to include other
important features such as: interaction between monomer-pore formation, protein-protein
interaction, the influence of pH on polymer chain scission, and the role of polymer swelling
among others, (Batycky et al., 1997).
2.6.3 Polymer erosion and diffusion
Importantly, for investigation of moving boundary problems for surface polymers, two
dissolution fronts, namely the erosion and diffusion front were introduced, (Figure (2.3)),
(Lee, 1980). Here, R refers to the time-dependent position of the moving diffusion front and S
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Figure 2.3: General schematic representation of concentration profile for surface-eroding
polymers. Two key boundary layers are visible: R(t), the time-dependent position of the
moving diffusion front and S(t), the time-dependent position of the eroding front, (Lee,
1980).
to the time-dependent position of the eroding front; A is the initial drug concentration within
the polymer, Cs, drug solubility, (as defined previously), and Cb is the drug concentration
of the well-stirred solution. Different ratios of A/Cs were investigated and led to the
conclusion that increasing this ratio causes decrease in relative drug release rate. The
release reaches zero-order for cases when the initial drug loading is much higher than the
solubility. This concept of multiple fronts, including also one for swelling, have been in use
in later models of dissolution dynamics, for example, Colombo et al. (2000).
2.6.4 Polymer swelling and polymer and drug dissolution
The term swelling-controlled DDS usually refers to systems where the swelling step is the
only release rate-controlling phenomenon or, in the broader sense, to systems where other
phenomena outlined above can play a role, (Siepmann and Siepmann, 2012b). The main
idea of using swellable systems is to control release, particularly for the case of drugs with
low diffusivity, (Arifin et al., 2006). These systems are often based on hydrophilic polymers,
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which can adsorb large amounts of water and cause polymer disentanglement, for instance
hydroxypropyl methylcellulose (HPMC) (Colombo et al., 2000), (Siepmann and Peppas,
2001), (Chirico et al., 2007), (Kimber et al., 2012).
The key features in polymer swelling are: the dry, non-swollen state (with a dense
polymeric network, and restricted molecule mobility) and relaxation of polymeric chains,
or swollen state (where molecule mobility and volume increase), (Figure (2.4)). These are
fundamentally different states and should be modelled as such, (Siepmann and Siepmann,
2012b).
Following earlier matrix models, (Lee and Peppas, 1987), (Harland et al., 1988) of
two phase release consisting of swelling and dissolution, Ju et al. (1995a) developed a
mathematical model for drug and polymer release from HPCS matrices. The model gave a
quantitative relationship between the polymer disentanglement concentration, pp,dis, and
equivalent molecular weight of polymer HPCS matrix,Meq where, below the critical polymer
concentration, polymer chains are detached from the matrix gel and display simultaneous
swelling-dissolution behaviour. Also, a diffusion layer separating the matrix from the bulk
solution was incorporated into the transport regime. The model predicts that overall tablet
size and characteristic swelling time correlate qualitatively with pp,dis. For determining
the relation between pp,dis and molecular weight, a power-law was used and its advantages
and limitations in this case were discussed. The results showed that drug release is more
affected by polymer release than by polymer molecular weight, (Ju et al., 1995a,b).
Subsequently, a model describing the drug release from drug delivery systems consisting
of an ensemble of drug-loaded crosslinked polymer particles was presented, (Grassi et al.,
2000). As main factors affecting drug release, the following were accounted for: the particle
size distribution, the physical state and the concentration profile of the drug inside the
polymeric particles, the viscoelastic properties of the polymer-penetrant system and the
dissolution-diffusion properties of the loaded drug. Two drugs, completely different in
terms of dissolution behaviour, namely, MAP (medroxyprogesterone acetate) and TEM
(Temazepam), were used to be crosslinked with polyvinylpyrrolidone (PVP) particles.
Interesting use of the Weibull distribution was made to model particle size distribution,
in the dry state (corresponding to initial powder conditions). The main novelty of the
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Figure 2.4: (Top) - Detailed schematic of polymer entanglement from non-swollen to swollen
state. Within the dry glassy core, polymers exist in an unhydrated regime with dense
network structure and low molecule mobility, (left). In the swollen glassy layer, solvent
diffusion promotes water concentrations leading to a more mobile network, and very strong
chain entanglement, (middle). As a result of significant swelling, fewer polymers are present
in the gel layer, inducing less though still strong entanglement. Finally, in the water-rich
diffusion layer, the chain entanglement becomes weak. At the gel-diffusion layer interface,
chain entanglement can no longer hold polymers together causing polymer dissolution to
take place, (right). Black dots represent drug particles diffusing from non-dissolved to
highly dissolved state. (Bottom) - Polymer concentration profile equivalent to the top
scheme. The space defined by the double lines represents the undissolved matrix. Adapted
from (Ju et al., 1995a).
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proposed model was in its versatility, as different situations were modelled, and the particle
size distribution analysed. However, its main restriction lies in the fact that it is destined
only for (chemically or physically) crosslinked polymer particles that do not undergo any
kind of erosion.
Lee and Chakraborty (2002) used kinetic Monte Carlo simulation to study the dynamics
of polymer chains as a consequence of random disordered media of monomer obstacles.
The polymer was modelled as a chain of spherical beads within a 3D lattice divided into
cells. The cell can be either occupied by a bead or not. At each MC step the algorithm is
performed to check the chain formation and location of the beads. If a chosen bead is found
to be at the end of a chain, the bond which connects it to its nearest first neighbour will be
rotated to a new position through a randomly chosen angle. Otherwise, the bond will be
rotated in a circular motion by rotating the bonds formed with the two neighbouring beads.
Each movement can be accepted or rejected according to the Metropolis criterion with a
probability ∆U which represents the difference in energy between the old and new chain.
Authors looked at several classes of homo- and hetero-polymers and noted that, above
a threshold temperature, polymers bearing monomers attracted to sites in a disordered
medium and are more mobile than those with neutral or repulsive interactions. This study
improved the understanding of polymer dynamics in disordered media.
In delayed release systems, as a consequence of water ingress, a polymeric coating can
develop cracks due to the hydrostatic pressure build-up. This phenomenon, together with
osmotic pumping, has been investigated in several studies, (Marucci et al., 2010), (Kaunisto
et al., 2011) and is investigated in detail in Chapter 4.
Recently, an interesting novel algorithm was presented for simulating the radial swelling
and dissolution of cylindrical tablets using the Discrete Element Method. Each particle
was allowed to absorb water and swell, pushing against its neighbours and causing an
overall expansion up to the disentanglement threshold. When that threshold is reached,
the polymer dissolves and the particle decreases in size. Detailed parametric studies were
performed to ascertain the main factors influencing polymer dissolution, such as the water
diffusion coefficient, the dissolution rate constant and the disentanglement ratio. The model
was validated against an exact numerical solution for simpler geometries but the additional
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introduction of drug particles is not discussed, (Kimber et al., 2011a, 2012).
2.7 Models for simulation of drug release in gastro-intestinal
(GI) tract
Our research focuses on developing stochastic models for simulating drug dissolution
processes for controlled release formulations, predominantly those which target the GI tract.
Consequently, we now discuss example models used in this context.
2.7.1 Effect of coating on the dissolution
For drugs, specifically targeting transit and dissolution in the gastro-intestinal tract, a
planar tablet geometry in the form of coated drug pellets is often used, as it provides
reliable results, compared to tablet or capsule forms.
Ethylcellulose(EC) is a frequently-used material for coating, as it represents a generally
non-invasive polymer with good film-forming capabilities. It is both inert and hydrophobic,
although able to expand as a consequence of water ingress when maintained under high
humidity, (Geraghty, 2004). Its viscosity depends on its molecular weight during processing,
while mechanical properties such as flexibility, elongation and tensile strength depend on
the degree of polymerisation, (polymer molecular weight). Ethylcellulose is also stable up
to 50 ◦C and, its properties, in general, make it ideal for use in matrix agents, both for
prolonged release or as a coating material.
The influence of different drug types on the release profiles of EC-coated pellets was
analysed, Sadeghi et al. (2003), while a model which considered constant and non-constant
diffusivities using ethylcellulose-based mini-matrices was reported, Verhoeven et al. (2009).
Further, to facilitate the prediction of drug release from coated tablets, (Muschert et al.,
2009) formulated an analytical solution of the behaviour of ethylcellulose-coated thin-film
drugs, using chemical and mathematical analysis. This could be used to speed up the
development of DDS for the treatment of diseases of the GI tract by “minimising” the in
vitro effort needed in laboratory trials. The authors showed that diffusion through the
polymeric film coatings represents the sole uniform drug release mechanism, and fitted the
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results of experimental trials to Fick’s law equations. Furthermore, they managed to show
that the mathematical solution is essentially one-dimensional, due to the dispersion of drug
molecules within polymeric networks and the fact that the surface of the coating is very
large, compared to the thickness of the tablet.
For other types of coatings, Ensslin et al. (2009) demonstrated the direct influence of
film coating thickness and polymer blend ratio on drug release rates. They also gave a
simple mathematical model that provides a way to calculate release rates from initially
known coating parameters, although applicable to a certain type of drug pellets only. Other
drug parameters that affect drug release, specifically in the GI tract, have been studied by
authors such as Ahmed (2005) who investigated the effect of pH of gastric fluid on polymer
swelling and hydration, and Leopold (1999) who gave an overview of the effect of different
types of colon-specific polymers on the rates of swelling, dissolution and erosion. In Liu
et al. (2007) the authors also provided a review for drug delivery mechanisms of the use of
pectin, a polymer well-suited to the gastrointestinal tract due to its reaction with colonic
bacteria.
Most recently, Loney and Susarla (2009) presented a mathematical model for diffusional
release of spherical drug particles which incorporated the innovation of physiological
characteristics in the simulation of the GI tract. These authors highlighted the need for
justification of the assumptions of earlier models, in particular that of perfect sink conditions
in a constantly changing environment, such as the GI tract. The developed model also
accounts for the important role of adsorption.
2.8 Summary
To date many different theories have been performed to tackle different aspects of dissolution.
The choice of adequate models for developing a particular DDS strongly depends on required
accuracy and predictability. Most theories take into account only the most important
properties of the system and are still not oriented toward routine usage by pharmaceutical
scientists, (i.e. empirical models). Therefore, there is a need for optimisation of existing
approaches and research on new ones.
Starting from this viewpoint, but with application to novel formulations in mind and in
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an effort to improve realism, we describe additional molecular phenomena for inclusion in
the models, described in Chapter 4.
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Chapter 3
Probabilistic modelling:
Methodology
This chapter reviews the main methodologies used in the thesis, namely Cellular Automata
and Monte Carlo methods. It discusses the difference between Direct and Inverse Monte
Carlo and reviews in more detail their use in the context of DDS modelling. As building
blocks for controlled release in GI tract are reviewed, at the end of the chapter we present
an overview and motivation for the work presented in the thesis.
3.1 Cellular Automata
In computation theory, cellular automata (CA) are important type of discrete model used
in a number of scientific fields that consist of a regular n-dimensional grid of cells, each
having one of a finite number of states. The state of each cell evolves over discrete time,
starting from an initial state and then progressing through a series of generations, according
to a fixed set of rules that take into account the state of the cell itself and the states of
cells in its neighbourhood.
As a type of modelling tool, cellular automata were first discovered and described by
Ulam and von Neumann in the 1940s, while working on models to describe the growth of
crystals and calculate liquid motion, (von Neumann, 1966). The concept was to describe
the liquid as a group of small, discrete units and derive the motion of each unit in the flow,
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Figure 3.1: An example of Conway’s “Game of life”. Each cell can have one of two states,
alive or dead, i.e. black or white, respectively. As an example of dynamics: If a cell has
two live neighbours, its state remains unchanged, (green case). If a live cell has less than
two live neighbours it dies, “starves” (red, case 1). If a dead cell has exactly three live
neighbours it becomes live, (reproduction occurs), (red, case 2).
according to the behaviour of the neighbouring units.
Perhaps the best known example, frequently used is a two-dimensional, two-state cellular
automaton created by Conway in the 1970s and named “Game of life”, (Gardner, 1970). It
consists of a 2D matrix of cells which can be either alive (black) or dead (white). If a cell
has two living neighbours, its state does not change. If it has three living neighbours it is
revised. In other situations, such as four or more living neighbours (overcrowding) or a
single or no neighbours (starvation) it dies. Thus the set of states includes being alive or
dead, and the set of rules includes various cell transition probabilities changing from one
state to another, Figure (3.1). The initial state of the “Game of life” can be set arbitrarily,
with certain initial configurations receiving wide coverage in scientific literature (Ninagawa
et al., 1998), (Bosch, 2000), (Adachi et al., 2008), (Burguillo, 2013).
Due to the “bottom up” nature of the system description, CA make suitable and powerful
tools for simulating the influence of the microscopic scale on macroscopic behaviour of
complex systems (Hoekstra et al., 2008), (Désérable et al., 2011). Thus, they have a wide
application in scientific fields including traffic modelling (Burstedde et al., 2001; Korcek
et al., 2011; Vasic and Ruskin, 2012), bacteria growth (Margenstern, 2011), fluid dynamics
(Leon et al., 2011; Désérable et al., 2011), modelling of tumours (Patanarapeelert et al.,
2011), gas lattice dynamics and many others.
Cellular Automata can be divided into categories based on a number of properties, with
fundamental distinctions being made by the type of neighbourhood and nature of the rule
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set itself. There are two classical neighbourhood types of interest in multi-dimensional
CA (Figure (3.2)): von Neumann, which considers the orthogonally adjacent cells only
(4 in the case of two-dimensional automata, and 6 the in case of three dimensions), and
Moore, which considers the entire adjacency lattice (so both orthogonal and diagonal
neighbours - 8 for two-dimensional automata, and 26 for three dimensions). While the
Moore neighbourhood potentially offers more realistic interactions (the CA applied to
physical systems for example) it requires more computations to evaluate the target state
of the cell. Before the era of high performance computing, this posed a disadvantage in
applications to complex systems, so von Neumann was generally preferred. However, with
today’s HPC clusters this is no longer crucial to the decision of which to use, with choice
governed instead by the physical realism of the problem space to be modelled.
In terms of other possible multi-dimensional neighbourhoods that could be used to
describe the space of a physical system, it is worth noting the Margolus neighbourhood
which considers the cells of a 2D or 3D lattice divided into 22 or 23 cell blocks, (Toffoli and
Margolus, 1987). Rules are applied locally, and the dynamics of the system are achieved by
shifting the partitioned grid itself (i.e. “cells” contain different “blocks” in each time step),
(Figure 3.2) (bottom).
Another useful division of CA concerns the nature of the state transition rules. Deter-
ministic CA employ rules which are fixed and do not change over time (as in the “Game of
life” for example). In contrast probabilistic Cellular Automata rules may or may not be
applied, depending on random number generation, and relevant for example, to situations
where knowledge of the real system is incomplete. Stochastic CA properties are particularly
useful for drug dissolution modelling and will be extensively covered in later chapters.
A final categorisation of CA type is based on the order and nature of cell state updates.
Synchronous Cellular Automata (SCA) apply transitions in an atomic way by calculating
for the current iteration and applying changes in the next. Thus the state of the system is
not dependent on the order of updates. In contrast, asynchronous Cellular Automata (ACA)
apply updates in the current iteration, so that other cells are aware of the neighbour state
change immediately. A detailed analysis of asynchronous automata and discussion of their
advantages and disadvantages compared to their synchronous counterparts is presented in
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Figure 3.2: Different variations of CA neighbourhoods for 2D matrix. (Top left) Extended
von Neumann neighbourhood, (Top right) Moore neighbourhood, (Bottom) Margolus
neighbourhood, illustrating cell repartitioning to contain different blocks.
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Chapter 4.
3.2 Agent-Based Modelling
Agent-Based Models (ABM, also referred to as multi-agent systems) present a natural
extension of the cellular automata approach. CA can be viewed as a way to model physical
system dynamics by “passively” propagating a change through the modelled system by
influencing a neighbouring cell state. Agents provide “active” dynamism, representing
independent physical entities that are able to move from cell to cell in a single iteration
and are thus better suited for describing active processes, such as drug diffusion. Including
a new feature to an existing CA model, however, introduces additional computational
requirements, and requires good code optimisation and, usually, parallel re-implementation
of the model (Perrin, 2008). The gains, however, are significant. The resulting models
permit large scale simulations and inclusion of various localised effects, such as those found
in the gastro-intestinal tract.
ABM is a model in which the key unit of abstraction is an independent entity (an agent)
that has both spatial and temporal positioning. The generally-accepted properties for an
intelligent agent, (there being no unique definition), are given by Wooldridge and Jennings
(1995):
• Autonomy : acting without intervention with some control over its actions and the
internal state.
• Social behaviour : interacting with other agents through a specific language.
• Reactivity : ability to see part of its environment and change its behaviour according
to the environment state.
• Proactivity : not only reactive to the environment changes but capable of acting itself
and taking the initiative, in order to satisfy identified goals.
ABMs, like CA, provide a generic enough paradigm to be used in a wide variety of
fields. Notable examples include economics modelling (Holland and Miller, 1991), traffic
congestion (Wen, 2008), biomedical systems such as the human immune system (Kim, 2009),
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social and other networks (Ojanen et al., 2010), organisational structures (An, 2012) and
social behaviour (Hughes et al., 2012), as well as medical diagnostics (Rodríguez-González
et al., 2012).
The agent-based approach requires explicit reference to agent-like entities in the system.
Advantages of ABMs include modelling efficiency, robustness, interoperability between
existing systems, and reasonably intuitive solving of problems for which data, expertise
and control are distributed (Jennings and Sycara, 1998). The approach is thus particularly
useful in the context of natural sciences, and permits reciprocity between agents and
biological entities and between real-system interactions and exchanges between agents types.
Agent-based models implementing several agents are referred to as multi-agent systems.
These systems provide a generic framework for model development, as noted by Perrin
(2008).
Although suitable for modelling molecular diffusion processes and naturally compatible
with stochastic models, ABMs have not so far made significant impact on DDS modelling
although an example of their use is given in a seminal paper by Barat et al. (2008). In
this thesis, we use a subset of agent behaviours (namely the autonomy and reactivity) for
describing certain active processes within the modelled device. It would be of interest,
however, to further examine their full potential in DDS system modelling.
3.3 Monte Carlo methods
Monte Carlo methods represent a large class of computational algorithms that utilise
random sampling as a means of optimisation, numerical integration, and generation of
probability samples (important in our case). Initial MC simulations were also done by Ulam
and von Neumann in the 1940s, while working for the Los Alamos National Laboratory.
MC methods have numerous applications, ranging from the physical sciences e.g. fluid
dynamics and astrophysics through traffic modelling, statistical physics to financial analysis
and business, (Sopasakis, 2004), (Tezuka et al., 2005), (Li et al., 2007). The essence of each
MC method lies in generating a set of inputs over a certain domain by sampling from a
probability distribution to define a starting state. A set of deterministic computations is
then performed and aggregated to obtain the “system” result.
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There are two broad method groups for Monte Carlo modelling. The direct methods
use probabilistic distribution sampling for setting initial spatial properties of the model as
well the state of the modelled entities (cells, flows, agents, etc.). Direct, deterministic or
stochastic computations, are then utilised for describing the evolution of such entities over
time to produce the aggregated end result for the system. Conversely, inverse MC methods
utilise the sampling process to try to derive the unknown but feasible distributions for
model parameters, from which the known aggregated result was obtained. In other words,
direct models start from a known initial state and attempt to derive the end result, while
inverse methods start with a known set of one or more end results and try to determine
the possible, but unknown, initial states.
3.3.1 Application of Direct Monte Carlo methods in DDS
When applied to drug dissolution modelling, MC methods bring several advantages. They
allow simulation of dissolution problems at increased resolutions by generating natural
structural variations, and using parameters that can only be estimated using probabilistic
distributions. They describe the system behaviour over time as a stochastic process and
enable observation of certain properties of the system at individual time steps. As an
example, an MC model might describe the internal location of pores within the polymer
structure as random with certain distribution characteristics. Those pores can be allowed
to evolve over time using random transitions to increase in size say, taking in polymer or
drug particles and similarly. A snapshot of the system state can then be obtained at any
time point to determine evolved behaviour.
MC methods have been variously used to take into account mechanisms underlying the
rate-limiting steps in DDS such as diffusion, swelling and erosion. One of the first models,
developed in 1993, (Göpferich and Langer, 1993) simulated microstructural changes in
bioerodible polymers and still remains a basis for all subsequent MC simulation models.
In this model, the polymer matrix was represented by a 2D computational grid, divided
into individual cells. Each cell/pixel corresponded to one of two possible polymer states:
amorphous, (with a higher likelihood of erosion) and crystalline, (with a slower erosion
rate). In the polymer matrix, erosion from one particular cell occurs only if that cell was in
34
contact with a previously-eroded neighbour, where MC was used to represent this erosion
as a random phenomenon. The probability of erosion of an individual cell was assumed to
follow a Poisson distribution with the characteristic value for the erosion rate being greater
for amorphous than for crystalline polymers. Each cell was assigned an expectation of life,
(distributed as a first order Erlang distribution).
Improvements on the original model investigated additional factors influencing erosion,
such as porosity and pH changes, (Göpferich and Langer, 1995a). Both mechanistic and
empirical methods were used to describe release of monomers, using Fick’s second law,
(Equation 2.2) and given by:
∂
∂t
c(x, t)(x, t) =
∂
∂x
Deffc(x, t)(x, t)
∂c(x, t)
∂x
(3.1)
where c is the concentration of the diffusant as a function of the effective diffusivity
Deff and  is the porosity along the diffusion pathway.
The porosity distribution was interpreted as a network of pores, modelled using a 2D
grid and MC. Degradation was considered as a spontaneous process of transformation from
polymer into monomer with monomer dissolution affected by pH changes and following
Fick’s first law. The innovation lay in the tracking of changes in the molecular weight of
the polymer. The model also enabled determination of the constant rate of erosion, but
not of release predictions for the incorporated drug.
Further improvements led to investigation of surface and bulk erosion from polymers,
(Göpferich and Langer, 1995b), programmable release from several layers of cylindrical
eroding polymers, (Göpferich, 1997a), and erosion from slow and fast-eroding polymers,
(Göpferich, 1997b). Starting from these models, many additional MC-based models for bio-
erodible microparticles were generated and will be discussed further, for example Siepmann
et al. (2002).
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3.3.2 Monte Carlo in modelling DDS for the GI tract
At a relatively early stage, Kalampokis et al. (1999a) presented an interesting “heterogeneous
tube” model for simulating the villi1 of the gastro-intestinal tract by using direct MC for
describing the dissolution and adsorption processes. Transit flow in the tract was simulated
using two diffusion models referring to two types of random walk: the blind ant and myopic
ant, (Kalampokis et al., 1999b). For simulation of the GI tube, an empty cylinder geometry
was used, where the drug, inserted at one end of the cylinder, was allowed to the other end
following the rules of a biased random walk.
3.3.3 Cellular Automata (CA) in Direct Monte Carlo methods
The first use of probabilistic CA models was described for drug release from bioerodible
pellets. Pellets can be as systems, composed of several components of arbitrary geometry and
with different dissolution rates: system behaviour was defined according to local relations,
(Zygourakis, 1990). Subsequently, CA and parallel iterations were used, (Zygourakis and
Markenscoff, 1996), for the design of bioerodible devices, where the transient behaviour
of the surface erosion system was described. As with MC models, (Göpferich and Langer,
1993, 1995a), there are two possible states of polymer cells in the computational grid for
CA: amorphous (highly erodible) and crystalline (poorly erodible). However, Zygourakis
and co-worker’s models were not based on differential equations. Instead, simulations
were used to determine the effects of intrinsic dissolution rate, drug loading and porosity.
Improvements on early models include assumptions on cell-dissolution neighbourhood,
where dissolution of each solid cell depends on the number of solvent-filled neighbours.
Increased solvent around the cell leads to more rapid dissolution. The authors suggested
that simulations could be used for rapid screening of newer formulations and for speeding
up the design process. They pointed out the advantage of the CA approach in terms of its
ability to handle multicomponent systems with arbitrary geometry.
MC, together with CA, was subsequently used for setting initial conditions to investigate
the behaviour of a binary device system, (Barat et al., 2006a,b). The novelty of these models
1The villi are small projections which cover the surface of intestinal wall, and serve for absorption of
fluids and nutrients. The surface area of the wall in this way is increased and it enlarges the area available
for absorption.
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was that they enabled creation of pores “inside” the device, not only on the surface, and
also emphasised the importance of the surrounding medium, not defined in earlier MC/CA
models. The theory on USP II apparatus medium influence was due to Ramtoola and
Corrigan (1987) and Healy and Corrigan (1996), who examined the influence of particle size
and discovered that, in general, higher dissolution rate occurs for increased excipient particle
size. Consequently, two boundary layers were defined in the apparatus: the concentration
layer where advection governs mass transport and the velocity boundary layer, (a small
region around the compact) where diffusion is the main mass transport, (McMahon et al.,
2003), (Crane et al., 2004a), (Crane et al., 2004b). In parallel work, (Barat et al., 2006b),
diffusion was modelled as the sum of the set of particles that can move to a new position.
Particles that pass beyond the concentration boundary layer were considered to be dissolved.
Advection was modelled using the Pohlhausen equation (Crane et al., 2004a) such that if
the particle concentration in the cell is higher than a defined maximum, the particles are
removed by advection. Possible states of the system were defined, according to Göpferich
et al. (1995), Göpferich and Langer (1995b), but with additional update rules.
Pure Cellular Automata application in DDS modelling
In investigating the erosion and swelling behaviour from binary matrix systems, CA without
MC randomisation has been used as well, (Laaksonen et al., 2009a), (Laaksonen et al.,
2009b). The main differences include dispensing with arbitrary lifetimes for the drug and
polymer and assuming that diffusion was based on the pure random walk, thus eliminating
the need for Fick’s first law. There is no specified expectation of life, rather the diffusion
coefficient and rate of disintegration are calculated. These models were developed for several
types of release mechanisms: erodible matrices, diffusion through channels/pores, membrane
controlled release and the investigation of swelling-controlled drug release. Although the
models provided a new perspective, a major limitation was the restriction to 2D cylindrical
geometries due to relatively small simulation space.
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3.3.4 Direct Monte Carlo vs. Inverse Monte Carlo
The Inverse Monte Carlo approach is used for problems, for which we do not have complete
knowledge of the relationship between model parameters and observed data, (Mosegaard
and Sambridge, 2002). One of the main reasons for using this MC variant is thus to avoid
stringent assumptions of linearity between the two, (Socco and Boiero, 2008). Instead, it is
assumed that initial parameters follow a probability distribution, as described in Voutilainen
et al. (2001).
In this context, MC methods can be divided into two groups, (i) sampling methods
and (ii) optimisation methods, (Mosegaard and Sambridge, 2002). The latter are used to
find a globally optimal solution from a number of local optima. Sampling methods are
useful when it is necessary to examine reliability of solutions in order to narrow down the
feasible solution space. One technique, often used for sampling, is the Bayesian paradigm,
where the principle is to take all unknown variables to be random. In general, the Bayesian
framework for posterior distribution evaluation can be represented, (Mitchell, 1997), by:
P (h|E) = P (E|h)P (h)
P (E)
(3.2)
where P (h) and P (E) are prior probabilities of the hypothesis h and observed data E,
respectively. P (h|E) is the posterior probability2 of h given E and P (E|h) is the likelihood
of obtaining the actual data E, for the specific h.
The Bayesian paradigm for inverse problems is widely used, with examples ranging from
noise reduction, (Davies, 1998), and environmental modelling (Dowd and Meyer, 2003) to
geophysical inverse problems, (Mosegaard and Sambridge, 2002).
IMC methods have been used across many scientific disciplines, also, to solve a set of
related, inverse model problems. As an example, they may be used to find a near-optimal
solution in terms of data fit and adherence to constraints for a posed problem. In another,
IMC methods may be used to search for solutions fitting the data within a certain tolerance.
IMC is a general method of co-called “structural” modelling based on experimental data and
was first described, (McGreevy and Pusztai, 1988), and applied to condensed matter science.
2The posterior probability is the conditional probability determined after additional information is used
to modify the initial, a priori, probability assigned.
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The authors developed and applied the methodology to understand how physical properties
of materials were determined by their atomic structure. Despite origins in condensed matter
physics and solid state chemistry, IMC has also proved applicable to many other different
data, as follows.
In geophysics, a large amount of work has been done on investigation and improvement
of inverse methods, with generally applicable results (Mosegaard and Sambridge, 2002).
Keilis-Borok and Yanovskaja (1967) applied inverse MC methods to determine if “Earth”
models were consistent with seismological data. Geman and Geman (1984) applied simulated
annealing, a technique for finding approximate global optima of a function that cannot
be evaluated directly, to Bayesian image restoration. The authors suggested using the
Metropolis algorithm to sample the posterior distribution and to determine its maximum
estimate.
One of the first algorithms for inverse MC problems was simulated annealing (SA),
(Geman and Geman, 1984), a heuristic algorithm used for finding the global optimum of a
given function in large, discrete search space. The SA algorithm is based on the idea of a
global reduction in the probability of accepting worse case solutions as the solution space is
explored. Each point of the search space (s), analogous to a state of the physical system,
together with the function to be minimised, is considered.
Another algorithm, used to draw samples from a desired probability distribution of
possible parameter values, as long as the function proportional to density is calculable,
is the Metropolis-Hastings algorithm (MH) (Metropolis et al., 1953). Here, the aim is to
generate a series of Markov Chain samples for which the distribution matches that of the
target distribution over an extended period of time. In Bayesian sampling models, the
density proportionality constant, also known as the normalisation factor needs to be known,
so that the MH category of algorithms offers a significant advantage.
An improvement on Metropolis-Hastings is Gibbs sampler, first introduced by Geman
and Geman (1984), which represents a special case of the MH algorithm. It can be
extended to a general framework for sampling from a large set of variables in turn, and can
incorporate the steps of Metropolis-Hastings as part of the algorithm. It is applicable when
the conditional distribution of each variable is known and can be sampled.
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It is worth mentioning that not all inverse methods apply Bayesian techniques. Early
work was based on simple searches of the parameter space for “best fit” models, (Keilis-Borok
and Yanovskaja, 1967), while a related set of methodologies, namely genetic algorithms
and the neighbourhood algorithm, have more sophisticated evolution characteristics and a
reduction-based approach.
3.3.5 Inverse Monte Carlo in investigating the effect of particle size
distribution
The main difficulty when modelling novel formulations for drug devices lies in unreliable
and inconsistent in vitro data. Data obtained from the pharmaceutical partner have
been extremely noisy and relatively sparse; thus extensive model assumptions have proved
necessary and their validation has been far from straightforward. Determining correct
dependencies is a highly complex process, exacerbated by the inability to measure certain
critical parameters of the system in vitro (notably the diffusion coefficients for drugs and
all polymers involved) and it is often difficult to utilise direct MC techniques because of
this.
In Barat (2006), the authors created a model, based on Inverse Monte Carlo (IMC)
simulations in a Bayesian context, which was capable of extracting knowledge from exper-
imental data, (time series of dissolved quantities). The work leverages de Almeida et al.
(1997), by applying a Bayesian framework and inverse techniques to a powder dissolution
system to reconstruct the set of initial particle size distributions from a large number of
possible states, in order to provide the best fit to the experimental data. Fitting is done by
empirically updating key parameters through repeated comparisons with the experimental
release curves. This approach provides substantial flexibility in determining the important
parameters of the DDS, based solely on available “drug release vs. time from administration”
curves.
The model of Barat (2006) thus took the observable dissolution data as the starting point
and tried to discover a set of key parameters that describe the total number of particles. The
observable dissolution process was decomposed into two components: a deterministic part,
defined by relationships between the state parameters at a given time, and a random noise
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Figure 3.3: Simplified design of the modelled device: yellow cells represent the gelatine
carrier with dispersed drug packets (grey). The device is coated with EC/Pectin layer
(green).
component, assumed to have a Normal (Gaussian) distribution. The size distributions were
updated, according to the de Almeida et al. (1997) algorithm, simulating the deterministic
part of the dissolution process, with the likelihood then calculated for each distribution,
(to determine the most probable values of key parameters together with their confidence
intervals). In the next iteration time step, these probabilities were reused as the starting
point for the next prediction. This cyclic process enables algorithm values to be updated,
while values of parameters are simultaneously measured for each time step.
The main novelty of this earlier work by DCU group was applying IMC techniques to
the field of drug dissolution, showing (importantly) that crucial parameter values could
be determined through analysing a number of release curves under different conditions.
However, since it was done as a proof of concept study only and was not applied to real
data many questions remain to be fully investigated, not least in terms of the practical
application value and potential for adaptation to different types of formulation, release or
similarly.
3.4 Project motivation and overview
In summary, the main goal of this project is to develop novel stochastic Cellular Automata
models for simulation of drug delivery systems and apply these in an industrial context to
predict drug release behaviour from coated beads, targeting the gastro-intestinal tract. The
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Figure 3.4: X-ray Tomography of modelled device. (left) A single bead with one layer of
coating; (right) variant of the bead with two coatings.
project was carried out in collaboration with the pharmaceutical partner, Sigmoid Pharma
Ltd., which has acknowledged expertise in developing controlled release formulations,
specifically for treatment of GI tract diseases such as Crohn’s disease and ulcerative colitis.
One of the objectives here is the incorporation of experimental features, characterising
the drug device and collected by the pharmaceutical partner, into a probabilistic model
by mapping these to a set of independent, simple CA rules. The “device” consists of a
capsule, containing hundreds of coated spherical beads, which carry the active substance,
Cyclosporine A (CyA). Due to the complex nature of the device, the underlying release
mechanisms cannot be precisely determined, prompting the need for probabilistic modelling
methods, in order to understand the device behaviour.
A simple cross-section view of the drug design of interest is shown in Figure (3.3)
and X-ray tomography images of actual device (provided by Sigmoid Pharma) in Figure
(3.4). A mixture of ethylcellulose and pectin is used as coating materials. As discussed in
Chapter 2, considerable work has been done by chemists to investigate the pharmaceutical
potential of this type of coating, (specifically its influence on release profiles of different
drug types encapsulated within EC-coated pellets, and on gastric fluid enzymes). All such
features must be taken into account when developing a suitable model. Encapsulated
by the coating, the active substance, Cyclosporine (poorly soluble), is dispersed within a
swellable/hydrophilic gelatine carrier, (Coulter, 2010). While the coated formulation is pH
independent and hydrophobic, the capsule content is highly hydrophilic and dependent
on temperature. To our knowledge, no previous model exists for this type of complex
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formulation and this project comprises original work in the area.
The work to date has included the definition, building and application of a modelling
framework, which provides a foundation for the simulation of physical properties for specific
designs and their effect on drug release kinetics. So far, the framework has been used to build
several models describing specific types of drug behaviour. Details on this implementation
are presented in Chapter 4 of the thesis. Further, the framework has also been applied
to the investigation of other device design parameters and drug release patterns. IMC
methods were used in the context of extracting the unknown parameters, (such as solubilities
and diffusion coefficients), from noisy in vitro data using reverse engineering methods,
(Chapter 7).
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Chapter 4
Models for Controlled DDS
In this chapter a novel, integrative CA framework for drug dissolution is presented with
several subsequent models derived from it. In the context of achieving realistic dynamics,
comparisons are drawn between synchronous and asynchronous Cellular Automata and
their relative merits are discussed. Such analysis is lacking in the literature but can lead to
real improvements in simulation.
4.1 The Meta-Model
In this section, we describe the fundamental basis and initialisation of the computational
framework used for simulations, together with the meta-model1 which includes the CA
modelling features, (such as representation of diffusion), common to all subsequent derived
models. Several models, describing drug release driven by different dissolution phenomena,
(such as erosion and swelling moderated by one or more coating layers for the active compo-
nent), are extensions of the meta-model and are presented in detail in Sections 4.2, 4.3, 4.4,
respectively, while the influence of these specific features on release behaviour is discussed.
Additionally, a model which looks into the influence of in vitro media on the drug device is
also developed, and is described in Section 4.5.
1In this context, we consider “metamodelling” as a practice of construction of a collection of basic
“concepts”. These concepts are used as a mechanism for derivation of different sub-models of interest.
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4.1.1 Fundamentals of developed models
The basis of all probabilistic models developed to date can be described in terms of a
discrete CA framework, satisfying the following conditions:
• Initial cell states are assigned randomly, according to a specified probability distri-
bution, within the structural constraints of the device. (This is because the local
distributions of device features, e.g. drug density or polymer composition at a given
site, are unknown);
• The different dissolution phenomena are modelled independently. (We can separately
investigate the influence of polymer swelling while ignoring coating erosion and
vice-versa);
• The three-dimensional discrete space allows for models of various geometries and
device compositions;
• An efficient large scale simulation. (This, in order to explore molecular level effects).
Recalling Chapter 3, the general formulation is given by Figure (3.3) where a number
of drug beads are contained within a quickly erodible capsule. The models themselves
simulate the dissolution of a single, idealised, drug bead represented in a three-dimensional
space, assuming its release profile to be representative of the cumulative release from all
beads present in the capsule. The simulation space itself is represented by a lattice, divided
into discrete cells, with each being described by a state Ψ(i,j,k,t) defining the aggregate
condition of the bead structure at discrete space coordinates (i, j, k) and at a discrete point
in time (t). The meta-model defines the Cellular Automata rules:
Φ(σ) : Ψ(i,j,k,t) → Ψ(i,j,k,t+∆t) (4.1)
for each cell which are applied to cell state (Ψ) in order to re-evaluate it after each
time increment (∆t) of the simulation. When a particular rule is applied to the cell state,
this is in the context of the states of all neighbouring cells (σ) in the 3D space, (26 in all,
corresponding to a Moore neighbourhood), which also determines the effect of the rule for
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the given cell. The rules, as applied, can thus model any distinct process that causes a
change in the bead state, including drug diffusion, chain-scission of ethylcellulose polymers,
erosion or swelling of the device core.
The bead itself is represented as an “idealised sphere”, consisting of a number of layers
containing the drug molecules. The possible states of each cell represent different structural
forms of the bead that affect the behaviour of these molecules as they diffuse out of the
sphere. The Meta-model defines several common cell types unique to the modelled device,
and re-used by all the derived models:
1. Gelatine cells (designated |P , as of polymer form) which represent the internal
structure of the bead that serves as initial carrier of the drug (Cyclosporine).
2. EC/pectin cells (designated |C), comprise the coating and are used jointly to model
the coating layer of the sphere.
3. Wall cells (designated |W ) mark the boundary of the simulation space and block
any cellular transition occurring outside this.
4. Buffer cells (designated |B) which model the dissolution space around the cell.
5. Solvent cells (designated |S) which represent the internal solution inside the bead
coating that is created as a consequence of dissolution of gelatine material.
Each cell, under certain circumstances, (with the exception of those in the wall layer),
can hold a certain concentration of drug (Cd) represented as discrete “packets” that can
model an arbitrary precision of drug volume loading (v/v)2 within the cell dimensions.
Between subsequent time points in the simulation (∆t), a packet can move (diffuse) to a
neighbouring cell. Thus, the size of the packets and the time step of the simulations are
primary factors in controlling the simulation speed, and we can choose either to simulate
large, bulk diffusion processes or very finely-grained ones, as required.
The models themselves have been developed in several stages, designed to facilitate
our understanding of key behaviour at increasing levels of internal complexity and inter-
dependency, and starting with simple erosion-based transitions. Additional rules were
2In chemistry, volume-in-volume ratio (denoted as v/v) represents the volume of the substance relative
to the total volume of the solution.
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developed to consider specific variants and to represent more realistic, composite interactions
between processes such as diffusion, erosion and swelling.
Meta-model initialisation
At the beginning each cell is initialised to a start state, depending on its location.
1. The coordinates of cells that satisfy the spherical equation:
(i− o)2 + (j − o)2 + (k − o)2 − (r − d)2 ≤ 0 (4.2)
r is the sphere radius with o the centre of the sphere, and d the thickness of the
coating layer are initialised with starting gelatine state (Ψ(i,j,k,0) = |P ), (representing
the polymer inside the bead). For each of these cells, a random number (R) between
0 and 1 is generated and compared to the drug volume (v/v) loading ratio of the
sphere:
Vd =
mdrug · ρsphere
msphere · ρdrug (4.3)
where m and ρ are, respectively, the mass and the average density of the sphere and
the drug itself.
If R ≤ Vd, the cell is initialised with a number of drug packets, where this number
depends on the desired resolution of the simulation. This ensures that the desired
percentage of cells corresponding to (v/v) ratio will contain drug packets. Drug
diffusion is not permitted through |P cells.
2. Cells which are contained outside the gelatine sphere, but within boundaries defined
by the larger, coating sphere, satisfy the equation:
(r − d)2 ≤ (i− o)2 + (j − o)2 + (k − o)2 ≤ r2 (4.4)
and belong to the coating layer (Ψ(i,j,k,0) = |C). Coating layer cells cannot contain
drug packets.
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3. Cells which satisfy the boundary property (i = 0 ∨ n, j = 0 ∨ n, k = 0 ∨ n) are
initialised as walls: Ψ(i,j,k,0) = |W .
4. All other cells are initialised to represent the buffer solution: Ψ(i,j,k,0) = |B.
5. Solvent (Ψ(i,j,k,t) = |S) cell types do not occur during model initialisation, but only
during cell transitions in the course of model execution.
Transition rules between cell states are represented using dimensionless ratios, (one of
the main advantages of CA models, as this allows comparison of processes occurring at
different velocities).
Modelling diffusion
As described in Section 2.1, the diffusion of a drug in a governed environment is given
by Fick’s laws, which gives the change in concentration gradient over time. Although,
at macroscopic level a given drug formulation may follow either Fickian or non-Fickian
(anomalous) behaviour, we assume that Fick’s laws always hold on smaller scale. Movement
can occur in any one of the directions in three dimensional space, so we assume that there
exists probability of movement in any direction where there is a concentration gradient.
We model the influence of Fick’s laws by allowing each drug packet to have a probability
(Pl) of movement to a given neighbouring cell (l) with lower drug concentration. This
probability is directly proportional to the concentration gradient between two neighbouring
cells, i.e.
∆Cl = C(i, j, k, t)− C(i∗, j∗, k∗, t), (4.5)
where C(i, j, k, t), C(i*, j*, k*, t) represent dimensionless drug concentrations in the
current and adjacent cell, respectively. The sum of all movement probabilities to permitted
neighbouring cells, (i.e. to those for which CA rules do not prohibit movement, non |C
cells), has to satisfy the law governing the sum of probabilities:
n∑
i=0
Pl = 1. Therefore, the
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influence of concentration differences is normalised, giving:
Pl =

∆Ci
k∑
j=0,∆Cj>0
∆Cj
, if ∆Ci ≥ 0
0, if ∆Ci < 0
(4.6)
where i ∈ {0, k} and k is the number of neighbours to the given cell. For certain types
of cells (|W , |C and cells where ∆Ci ≤ 0), Pi is assumed to be 0 by default. To summarise:
according to this rule, if there exists a non-zero concentration gradient between the cell and
any of its valid neighbours, there is a non-zero probability that a drug packet will move to
that cell.
The speed of diffusion itself (i.e. the frequency of drug packets moving from one cell
to another) is calculated using the formula defined by Laaksonen et al. (2009a), which
relates the simulation time step (∆t) with diffusion coefficient (D), and the resolution of
the cellular grid (a):
∆t =
a2
4D
(4.7)
Key release indicators
In order to categorise the release curves obtained from the models (as anomalous, Fickian or
case-2 relaxation) we use Peppas Equation (2.6) (Chapter 2) to classify the drug dissolution,
based on the parameter n and the resulting curve behaviour in achieving zero-order release
rate. The parameters M and M∞ represent the amount of drug released at time t and total
amount of drug respectively, while kp is the kinetic constant. Values of the parameter n
are obtained from resulting release curves, using linear regression methods, where n is the
slope of the log-log line, of cumulative release against elapsed time, for the period during
which the majority of the drug dissolution occurs.
A dimensionless Deborah number (Vrentas et al., 1975) can be used as an additional
descriptor of the release, indicating Fickian or anomalous transport. The Deborah number
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is defined as:
De =
λe
τe
=
λeDw
δ2
(4.8)
where λe represents the characteristic relaxation time of the polymer, τe the characteristic
water diffusion time and δ is gel layer thickness. Changes in Deborah number can be
estimated directly from the water diffusion and polymer swelling probabilities using the
derived version of the equation, where Dw is estimated from the water diffusion probabilities,
while λe and δ are read from the resulting simulation measurements.
4.2 Modelling erodible coated drug devices (ECDD)
The first model specifically developed to address project aims (as stated in Section 3.4) is
designated the ECDD and considers the case for polymeric chain erosion in the coating and
subsequent drug diffusion, where these were assumed to be the primary factors influencing
release3. The main rationale for taking this initial, simplified approach was the availability
of experimental data that showed significant sensitivity of drug release to changes in the
coating thickness, implying erosion due to water intake rate as a primary contributor to
release. There is a long list of possible effects that can influence rates of degradation
and erosion (e.g. pH changes, water diffusivity, composition of polymers, polymer chain
length, (Göpferich and Langer, 1993, 1995a) and so on) and it is of particular importance
to determine the most influential and to establish the dominant release kinetics.
In the theoretical introduction, (Section 2.1), we noted that erosion represents the
scission of polymeric chains, allowing solvent penetration into the coating layer and, further,
into the sphere. On the microscopic scale, we can essentially look at this as a stochastic
process, where the probability of chain breakage is a value following a known distribution.
Such events occur independently of each other and at a specified rate within an interval
of time. Following (Göpferich, 1997b), bulk erosion effects are represented by the Erlang
3This work has been published in (Bezbradica et al., 2011).
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distribution:
e(t) = λe−λt (4.9)
where parameter lambda (λ) in the CA model, describes the rate of polymer breakage,
i.e. porosity formation. This parameter is characteristic of the material and can be changed
if a different coating material is used. In our case, a coating cell is considered to consist of
the mixture of ethylcellulose and pectin. The individual characteristics of each of these
components influence erosion, but we focus on their combined role. The lifetime (τc) of a
coating cell can be determined as inverse by proportion to λ given by:
τc =
1
λ
ln(U), U ∈ Unif [0, 1] (4.10)
where Unif [0, 1] is an Uniform distribution taking values between 0 and 1.
Further, we introduce a new cell type (type 6), namely a coating channel cell (|CH), to
model cracks and pores in the polymer structure caused by erosion of the coating material
or partial chain disentanglement. Unlike |C cells which act as a barrier to drug diffusion,
|CH cells permit drug movement, thus allowing for diffusion through the coating layer.
At the beginning of the simulation, (t=0 ), each |C cell is assigned an individual value of
τc, based on Equation (4.10). In every iteration, this value is decreased by the time step of
the simulation (∆t). When τc falls to zero, the coating cell is considered to be fully eroded
and is thus transformed into a channel cell:
Φ(τc = 0) : |C(i,j,k,t) → |CH(i,j,k,t+∆t) (4.11)
The drug matrix is held together by gelatine, another polymer inside the coating, which
is considered to undergo surface erosion. At t=0, each |P cell is assigned a fixed lifetime
(τp). A process, of progressive solvent penetration through the coating layer, eventually
allows |P cells to come into contact with the solvent cells (|S), hence providing a trigger
for their erosion. As with |C cells, the speed of erosion of a |P cell is determined by the
change in the gelatine lifetime, where this lifetime starts to decrease as soon as the gelatine
cell comes into contact with a |CH or |S cell. Additionally, the decrease in lifetime is
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Figure 4.1: Schematic representation of CA rules for ECDD model. The main transition
rules given in Table 4.1 are visible. Arrows are showing drug and water diffusion (straight)
and polymer erosion (circular).
proportional to the number of those cells in the direct neighbourhood. Thus,
τp(t+ ∆t) = τp(t)− ks∆t (4.12)
where ks is the number of all surrounding |CH or |S cells. When a |P cell is eroded it
becomes a solvent cell, |S. Table 4.1 summarises the CA rules of model ECDD and Figure
(4.1) shows a schematic example of transitions between two model iterations.
4.3 Modelling swellable coated drug devices (SCDD)
Building on the basis of the previous ECDD model, which laid the foundation for investiga-
tion of some release phenomena of the target device, as well as accessing the efficiency of
the model framework, proposed in Chapter 5, a more complex set of release mechanisms
could then be formulated. It was anticipated that these would improve the simulation
model description of the device behaviour observed by experiment.
The principal addition made was incorporation of polymer swelling phenomena into
the CA system, as gelatine (and related substances) are known to swell under hydration,
(Klepko and Mel’nichenko, 1995). Hydration causes a general increase in the polymer
volume, as water penetrates deeper into the device core, creating a hydrogel layer. The
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Cell type Behaviour description
Buffer (|B) Drug is considered released when it reaches buffer
zone. Cell type acts as a perfect sink.
Ethylcellulose (|C)
Drug-free coating layer. Assigned lifetime, (τc),
based on λ (degradation rate) parameter. Forms
a |CH cell upon complete erosion.
EC channel (|CH) Drug can diffuse through |CH cells.
Gelatine (|P )
Assigned fixed initial lifetime (τp). As it erodes
into |S cells, it facilitates movement of drug “pack-
ets”.
Solvent (|S) Occurs as result of gelatine erosion. Drug can
diffuse through the solvent.
Drug packet
Drug, initially dispersed in gelatine cells. Each
cell can hold a maximum (saturation) amount of
drug “packets”.
Table 4.1: Cell types and rules of behaviour for ECDD model.
thickness and permeability of this layer control the rate of drug release. It should be noted
at this point, that such gelatine swelling phenomena categorise the system as true, non-
porous and swelling-controlled DDS, in contrast to the swelling matrix systems, where drug
diffusion occurs though the porous matrix structure even if there is no solvent penetration.
Characterising the difference is the fact that the drug particles are immobile while a polymer
is in its glassy state, and can diffuse out only after a phase transition to the rubbery state
takes place, (Colombo et al., 2000).
The modelling of such swelling systems is a non-trivial task. Unlike the other major
release mechanisms of polymer erosion and drug diffusion, which can be modelled in relative
isolation, swelling acts in conjunction with these mechanisms to create a complex set of
state transition fronts inside the device. Two of the most important fronts are: (i) erosion,
taking place at the outside water/gel interface, where the disentangled polymer chains
erode, and (ii) diffusion, occurring at the internal solid/dissolved drug interface where
polymer transition from glassy to rubbery state occurs. The difference in radii of those two
fronts, i.e. the gel layer thickness, acts as a major controller of the drug release rate, so
describing its behaviour is crucial (see Figure (4.2)).
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Figure 4.2: Photograph of an HPMC matrix tablet loaded with buflomedil pyridoxalphos-
phate, after one hour of swelling release. Three dissolution fronts are presented allowing for
visualisation of gel-layer thickness, (Colombo et al., 2000).
Swelling has attracted significant attention relatively recently, mostly in mechanistic
and empirical models, ranging from a simple power-law equation, proposed by (Korsmeyer
et al., 1986), to more complex cases, which have used a mechanistic approach linked to
the particular hydration properties of a given device. Examples describing swelling as the
essential parameter in probabilistic models of CA type, are few, with only one major model
described recently, (Laaksonen et al., 2009a). Of course, existing models have limitations,
both in terms of the amount of initial knowledge needed to “feed” the model and also in
terms of limited applicability to complex formulations for targeted delivery, (such as the
one we are investigating).
We thus investigate two related models, one assuming a constant rate of swelling and the
other assuming a varying rate related to the physical behaviour described in the literature
(Singh and Weber, 1996). Both the uncoated and coated drug formulations are modelled,
with the former used mostly for validation of the modelling assumptions. A schematic
representation of CA rules and behavioural transition is presented in Figure (4.3) and
Figure (4.4). The colours represent different cell types, the arrows the direction of transfer
and dots within a cell the concentration. An example of both self state change and lifetime
transfer is apparent from the right hand panel.
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Figure 4.3: Schematic representation of CA rules for uncoated devices. Saturation loading
is 4 drug packets per cell. Initial cell can be under or over saturated.
Figure 4.4: Schematic representation of CA rules for coated devices. The initial cell can be
under- or over-saturated.
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4.3.1 Effect of swelling kinetics - “constant-rate” (SCDDa)
To model swelling, we introduce additional states and cell transition rules to the existing
CA model:
1. Similar to (Laaksonen et al., 2009a), we describe the swelling process by two proba-
bilities - namely the probability, PW , of water diffusing into the polymer cell (core or
coating), and PS , the probability of core polymer chains diffusing out of the initial
core volume, proportional to the swelling rate of the polymer.
2. Each |P cell is assigned a swelling potential (Sp) representing the effect of the stress
field4 formed between the glassy/rubbery interface on one side and rubbery/solvent
interface on the other. This potential allows the cell to swell a certain number of times,
and is linked to the amount of polymer left within the |P cell, which is represented by
the lifetime (τp) (i.e. |P cells with higher lifetime have a higher swelling potential).
This rule combines the swelling and erosion processes into one common parameter,
allowing for a simplified description in the event of difficulty in comparing with
unreliable experimental observations for individual processes.
3. A new cell state representing the rubbery polymer stage, (|WP , as “wet polymer”),
was introduced. This state enables the diffusion of drug cells through the wetted
environment, as well as erosion and swelling of the gel polymer chains themselves. A
separate glassy to rubbery polymer cell transition rule is defined:
Φ(p ≤ kwPW ) : |P(i,j,k,t) → |WP(i,j,k,t+∆t) (4.13)
where kw represents the number of neighbouring water cells, (either |B or |S), PW
the water intake probability, and p, a uniformly distributed random variable, selected
for each cell in every time step. We consider the |P sites (glassy polymer) to be
mechanically and chemically inert, with no swelling, erosion or drug diffusion taking
place.
4The stress field is formed as a consequence of the concentration gradient between two fronts.
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4. Diffusion through |WP cells occurs with probability based on the remaining lifetime
of the cell (τp):
PWG = 1− τp(t)
τp(0)
(4.14)
where PWG represents the probability that a drug packet present in the |WP cell will
move. The drug diffusion rate within the gelatine thus ranges from 0 (immobile) to 1
(rate of drug diffusion in water).
5. As in the ECDD model, |WP cells erode when their lifetime reaches zero, and are
converted into |S cells.
6. The behaviour of gelatine cells is further enhanced as an initial value for τp is set
using the Erlang distribution, Equation (4.10), which describes the nature of the
gelatine erosion more realistically, as this includes both surface and bulk (Ulubayram
et al., 2002).
7. The process of swelling causes the |WP cell to transfer part of its material to a
neighbouring |B or another |WP cell, simulating chain disentanglement in a random
direction:
τp(i
∗, j∗, k∗, t+ ∆t) = τp(i∗, j∗, k∗, t) + Lc, (4.15)
and
τp(i, j, k, t+ ∆t) = τp(i, j, k, t+ ∆t)− Lc (4.16)
where Lc is a simulation constant representing the lifetime of polymer chains trans-
ferred during individual cell swelling. This value is determined by calculating the
average lifetime of gelatine cells at the beginning of the simulation and dividing this
quantity by Sp.
The lifetime transfer only occurs between cells where there is a “lifetime gradient”.
Swelling is thus represented as the diffusion of polymer from higher “concentration” to
57
lower. Further, we choose the target neighbour in the same way as for drug diffusion
- the sum of all probabilities of swelling affecting neighbouring cells must satisfy the
probability sum rule and the movement is proportional to the difference in lifetime.
The formula is the same as in Equation 4.6, with ∆C replaced by ∆τp. Moreover,
there are types of cells (|W , |C, |P or cells where the lifetime difference is negative)
for which the probability is set to zero.
8. The mechanism of drug diffusion through the coating layer is changed. Instead of the
bulk porosity used in the ECDD model, we now assume a more realistic sequence of
events, where the coating layer first takes in water through the ethylcellulose chains
with a probability PW , allowing it to reach the core layer after a certain period of
time. The core layer then begins swelling, according to the rules 1-7 described above,
creating a hydrostatic pressure difference, which has the potential to cause polymer
chain breakage (“cracking”) in the coating, resulting in expansion of gelatine out of
the coated sphere.
9. Finally, we consider the phenomena of polymer blocking and core fragmentation which
are specific to the Cyclosporine formulation modelled. Polymer blocking occurs when
the undissolved Cyclosporine chains attempt to diffuse through the ethylcellulose
membrane. This can lead to significant chain entanglement. This, in turn, causes
micro-pores within the coating to become congested and drug diffusion through
the outer membrane to be reduced significantly. Core fragmentation is the process
whereby large chunks of core gelatin tend to clump together, which results in larger
clumps with reduced solubility that trap the drug inside the bead, causing release
rates to plateau after a certain percentage. We introduce an additional modelling
parameter, PC , representing the probability of a |P cell going into the non-dissolvable
state in each iteration. Such a cell does not loose polymeric material over time and
remains in the same state throughout the simulation.
4.3.2 Effect of swelling kinetics - “varying-rate” (SCDDb)
For various pharmaceutical applications, it is of interest to know the actual swelling kinetics
of the hydrogel which will be used as the drug carrier, as this may have a significant impact
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on drug release itself, (Martínez-Ruvalcaba et al., 2009). There are several theories to date
that deal with hydrogel swelling kinetics. The physics of this process was studied initially
in isolation by Tanaka and Fillmore (1979), Li and Tanaka (1990) and Singh and Weber
(1996). These papers documented two characteristic swelling curves, differentiated by the
ratio (F ) of gelatine volume in equilibrium (maximum swelling point) and its initial volume.
If this is less than a characteristic value of 2.5, (based on the inflection point of the swelling
curve for spherical geometries, Singh and Weber (1996)) then swelling can be considered as
a Fickian process, with the change in sphere radius given by:
ae − a(t)
ae − a0 =
6
pi2
∞∑
k=1
exp(−k
2t
τT
) (4.17)
where ae, a0 and a(t) represent the distance from equilibrium radius at the initial,
last and interim swelling times, and τT is the characteristic swelling time of the polymer.
However, as pointed out, (Singh and Weber, 1996), this law holds only for small swelling
rates, and does not give a good prediction for polymer swelling where F is larger than
2.5. In this case, the dissolution process becomes non-Fickian, with swelling predominantly
controlling release, resulting in a slightly different, sigmoidal curve.
We observe the influence of swelling probability changing with time, (as in Tanaka and
Fillmore (1979) and Singh and Weber (1996)). We assume that the probability of polymer
swelling (PS) is linked to the change in radius between two time points, with the exact
mechanism depending on the total ratio of volume change:
PS = e
−C1 tτT , F < 2.5, (4.18)
PS = C2 [s(t) (1− s(t))] , F > 2.5 (4.19)
where F represents the ratio of the device volumes at equilibrium and initial states
respectively; C1 and C2 are empirical constants that link the swelling kinetics to model
probabilities, (limited by factors such as lifetime and swelling potential), and must be
determined, (a non-trivial task). Finally s(t) represents a logistic curve, used to describe
the sigmoidal nature of the process.
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4.4 Modelling multiple coatings (MCES)
While single coated beads permit the fundamental controlled release scenario (based
on the properties of a single polymer or of a polymer mixed with additives (such as a
Surelease R©/Pectin combination), there are often undesirable side effects that occur as a
consequence of interaction between the core polymer and the coating polymer or between
the coating polymer and the drug. Adding extra layers of different polymers can help
alleviate this issue. Also, these additional coatings can provide other benefits by augmenting
behaviour, such as boosting the dissolution of the drug or by modifying action of the coating.
As an example, a common multi-layer device design includes a core surrounded by two
layers - the inner one is a swellable polymeric layer and the outer one made up of a non
water-soluble polymer. Upon water penetration, the inner coating will swell, causing the
outer one to rupture. Another possible use of multiple coatings is to trap several stages
of a drug between each of these, causing a multi-stage release at different moments of GI
tract transition.
In our specific case, the use of a second coating on the target device was to remove the
negative effects of polymer blocking and core fragmentation, discussed in previous Section,
which were shown to be the major causes of incomplete Cyclosporine release from the beads.
To negate these effects, a second coat of Opadry R© film coating system was added to the
modelled device. The Opadry layer dissolves quickly after the water penetrates the bead
and enhances the gelatin and cyclosporine dissolution within the internal solvent, allowing
the chains to diffuse more quickly and preventing clustering of gelatin within the bead
(Colorcon Inc, 2009).
The multiple coating model (MCES) thus builds on the previous erosion and swelling
models (EC- and SCDD), and we present the additional model characteristics as incremental
delta terms only. It is assumed that those features not explicitly revisited here remain the
same as defined in the general swelling model presented above, (SCDD). The dominant
release control process in MCES is assumed to be either erosion or swelling, with the same
control mechanisms (including the λ factor and water diffusion probability (PWG) for the
gelatin erosion, and swelling potential and swelling probability for gelatin swelling).
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4.4.1 Geometry parameterisation
While the MCES model retains the geometrical characteristics of the previous models (3D
space, variable geometry), the method of specifying the thickness of the coating layers
is simplified somewhat by defining each layer thickness directly. Previous calculations,
based on weight gains (wg), required a knowledge of average polymer density (d), which is
generally unknown as beads undergo a thermal process after layering, (d ∼ f(ρ, wg), where
ρ is unknown). The thickness of the beads under various coating configurations, (none,
single or multiple), can be easily measured under lab conditions and the thickness of the
coatings derived from the difference.
4.4.2 Influx of water into EC/P layer
The coating cracking mechanism, caused by gelatin expansion and noted in reference to the
single coated swelling model (SCDDa), is augmented by allowing the diffusion of active
substance through micro-pores caused by EC polymer separation. The transition is defined
as cell state change from EC cell to a wet EC cell. The change occurs with water diffusion
probability PW , if there is at least one neighbouring solvent, buffer or another wetted EC
cells. The diffusion probability PW can be estimated by the following equation:
PW =
√
Dwater/EC
DCyA/water
(4.20)
i.e. the square root of the ratio of speed of diffusion of water molecules through
ethylcellulose relative to the overall speed of drug diffusion in water, for the given simulation
setup.
4.4.3 Opadry R© layer erosion
As noted earlier, incorporating a further coating requires an additional cell state and
associated rule to model the coating behaviour. The behaviour of Opadry R© polymer is
controlled through erosion only. The role of Opadry was discussed in Section 4.4. Each
Opadry cell is assigned a lifetime, similar to that of gelatin cells. However as the primary
effect of Opadry is to act as a buffer between the outer coating and the inner core, it dissolves
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quickly and a change to the properties of the selected solute parametric distribution is not
needed. Instead, a simplified uniform probability range (lifelower, lifeupper) is sampled to
assign a lifetime to each Opadry cell. A transition rule “Opadry cell” → “wet Opadry cell” is
defined and controlled via an associated probability POP . This parameter is used to delay
the start of layer erosion only. A mean lifetime is assigned, based on in vitro observations
from experiments carried out with the industrial partner.
4.4.4 Diffusion through EC coating permeated with solvent
The two approaches to modelling diffusion of drug through the wetted ethylcellulose chains
used by the ECDD and SCDD models showed qualitatively good results but parameters are
not straightforward to derive from experimental data. Thus, in the MCES model we chose
to describe the process by a similar paradigm to that of Equation (4.20). In order to move
to a neighbouring cell in the EC layer, drug packets have to overcome the PP probability.
They can only move through wetted EC cells. The same rule in selecting direction of
movement, based on concentration difference, still applies (i.e. first we determine if the
drug packet can move while inside a wet EC/P area and then select in which direction).
The PP parameter is critical in order to get the correct range of drug release rates between
different coating thicknesses.
The additional model rules are summarised as a schematic in Figure (4.5).
4.5 Influence of dissolution environment in MCES models
Of utmost importance for drug devices which have to transition between different dissolution
media is the distinction between how each environment influences drug behaviour. In
augmentation of the MCES model, (and indeed any of the presented models so far, as the
changes are orthogonal to the specific model rules), we can also mimic the influence of the
different environment (e.g. in the case of the Sigmoid Pharma project, this includes acidic,
(pH = 1.2) and enteric, (pH = 6.8) environments). Two parameters are proposed. The first
is the relative ratio of drug diffusion coefficients between the two environments, (effectively
allowing for slow-down or speed-up of the dissolution). The second is related to the presence
of chemical additives in the environment, which increase the relative capability of the
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Figure 4.5: A schematic representation of the CA rules for MCES model. The additional
rules of drug diffusion and Opadry erosion are displayed. Arrows show drug and water
diffusion (straight), polymer erosion (semi-circular) and polymer transfer (swelling, circular).
current environment to dissolve the target drug. As an example, Cyclosporine solubility is
low in acidic environments, but dissolution is fast with the addition of surfactants, such as
sodium dodecyl sulfate (SDS).
We have modelled the following properties of the dissolution environment:
• Dissolution rate - i.e. the speed of dissolution. The parameter defines the probability
of a CyA packet dissolving in given time step and it is directly proportional to the
dissolution rate which can be determined empirically using a variation of the Noyes-
Whitney Equation (2.4.1), given by:
DR =
AD
h
(
Cs − Xd
V
)
(4.21)
where DR is the dissolution rate, A is the surface area of drug, h the thickness of
boundary layer, Cs the saturation concentration of drug in different media, Xd the
amount of dissolved drug and V the volume of the active dissolution media.
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• Solubility - the maximum amount of drug that can dissolve in a defined volume of
solvent. It is defined and parametrised as the dissolved drug percentage after which
no more dissolution occurs due to saturation of the media. The solubility is estimated
using the formula:
Stot = km(CSURF − CMC) (4.22)
where CSURF is the concentration of surfactant, CMC the critical micelle5 concen-
tration of the solubiliser used, (for example SDS surfactant used in the Sigmoid
experiments has CMC of 0.008M/l) and km is the molar solubilisation capacity of
drug.
• Changes in diffusivity with temperature: Temperature changes directly influ-
ence the diffusion coefficient, so this can be partially modelled if we understand the
connection between the temperature (T ) and the drug diffusivity of the environment
(D). For that purpose, we can use Stokes-Einstein formula to estimate D for different
T :
D =
kbT
6piηr
(4.23)
where η is the viscosity of the medium, kb is the Boltzmann constant, T is the
temperature of the environment and r is the radius of the spherical particle.
4.6 A comparison of SCA and ACA in probabilistic pharma-
ceutical modelling
In the literature, both synchronous (CA) and asynchronous (ACA) types of automata have
been used so far, (Section 3.1), without analysing their comparative impact on resulting
model outputs. Choosing the appropriate update mechanism, besides having an impact
on the perceived realism of the simulation, also has practical benefits for the applicability
5Aggregation of molecules in a colloidal solution.
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of different model parallelisation algorithms and their performance when used in large-
scale simulation context. High-fidelity models described in the previous sections have
further stressed the need for analysing differences between the two. In this section, we
compare several variants of probabilistic CA and ACA update algorithms for building
models of complex systems used in controlled drug delivery. Advantages and disadvantages,
related to different synchronous and asynchronous modelling scenarios, are outlined and
the performance obtained reported.
In research papers on application of CA to the DDS field, synchronous and asynchronous
update methods have been used, (Göpferich, 1997a; Siepmann and Siepmann, 2008; Barat
et al., 2008; Laaksonen et al., 2009a), but their effectiveness has not been analysed.
Choosing, the algorithm of cellular matrix iteration and the order of application of the
local rules, affects how temporal realism of the physical process is represented. As a
DDS is physicochemical in nature, chaotic or random updates might represent the system
dynamics better than synchronous, “all-at-once”, changes. On the other hand, as the size
and complexity of the models grows, scalability and the need for efficient parallelisation
of model space restricts use of the asynchronous methods due to performance, (Bandman,
2006b). Understanding the effects of synchronicity and asynchronicity on model outputs,
can enable optimal choices to be made during model development. It is also worthwhile to
examine the equivalence of substituting one iteration rule for another while maintaining
model outputs such as drug release rates and device geometry changes within acceptable
ranges. The transition of CA to ACA has been investigated in the literature in other
modelling contexts (Kalgin, 2008; Alba et al., 2002; Bandman, 2006b).
In this part of the chapter we compare behavioural characteristics, model outputs and
performance for different synchronous and asynchronous CA update mechanisms in the
context of probabilistic models used in controlled drug delivery and their parallel implemen-
tation, (where differential equations are not applicable due to the inherent unknowns in the
parameter space). We introduce the mechanisms as components of a wider meta-model
presented and describe how their logic fits into the CA system.
Section 4.6.1 presents the design methodology used for developing the CA rule sets,
together with comparison of different CA and ACA update mechanisms when used in the
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context of the meta-model and a theoretical analysis of their properties and variations in
parallel and sequential implementations. We summarise findings in the final section and
consider directions for future improvement.
4.6.1 CA and ACA modelling
Design methodology
As for any model build, the first stage involves transfer of the domain knowledge of the
structural and behavioural characteristics of the DDS to the CA model. Figure (4.6)
outlines the main modelling classes of interest, where the DDS consists typically of different
polymeric coatings, carriers or matrices, (Bezbradica et al., 2011). There are several distinct
DDS characteristic categories to be considered:
• the shape and geometry of the system (slab, cylindrical or spherical) - this is captured
in the shape and size of the model cellular matrix;
• the polymer composition of the device defined by states of the matrix cells;
• the polymer physico-chemical interaction mechanisms (laws) - described by character-
istic behaviours that occur inside the DDS;
• the drug loading and initial dispersion within the device;
• the influence of the dissolution environment on polymer behaviour.
The models, with above characteristics, are classified as kinetic CA or ACA models
(Bandini et al., 2010). Based on the way we choose to represent the physical phenomena
modelled, we can adopt rules, which are either deterministic or probabilistic, (or a combi-
nation of both) affecting the individual cell behaviour and the surrounding neighbourhood.
Both classical CA neighbourhood mechanisms (Von Neumann and Moore) can be used for
either model type.
Another important aspect of the meta-model in context of the CA or ACA used is the
establishment of the initial configuration and dispersion of elements within the modelled
device as well as the existence of boundary conditions. Although it is common for various
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Figure 4.6: Meta-model diagram with detailed components.
families of CA update mechanisms to operate under periodic boundary conditions (Xiao
et al., 2005; Voorhees, 1990; Burstedde et al., 2001), pharmaceutical models benefit from
using the fixed equivalent, as drug movement across the matrix boundaries is used as a
direct method for calculating release rates. To satisfy the condition that the models need
to mimic the inhomogeneous nature of the physical device, with exact distributions not
available from experimental data, the meta-model establishes the initial cell states using
stochastic distributions within the known device geometry. The stochastic aspect usually
has a lower and upper limit which is deduced from in vitro experiments, and the distribution
of values within the limits follows a probabilistic distribution, chosen to mimic known
chemical properties of the material, (for example its diffusion coefficients or degradation
rate). Therefore, various direct Monte Carlo algorithms can provide a natural solution to
the initial condition problem, by establishing a random starting state for each simulation
run. The stability of the obtained models can thus be tested, by validating that variation
in model outputs is not statistically significant for multiple runs using the same parameter
set.
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4.6.2 Update methods
Crucially, a good description of the model dynamics, i.e. the closest qualitative match to
the behaviour of the pharmaceutical system modelled, relies on choosing the appropriate
update method of the cellular automaton itself. While both synchronous and asynchronous
modelling have been used for this type of systems, an evaluation of the influence on model
performance and correctness is lacking. This is addressed here, with particular emphasis
on the correctness of the update rules as we consider several standard synchronous and
asynchronous CA update methods (Schönfisch and de Roos, 1999; Bandini et al., 2010;
Baetens et al., 2012).
Mathematically, the principal features of the 3-dimensional DDS models can be repre-
sented as a cellular automaton using a tuple representation, given by:
ACA = {G,A,U,Θ, F} (4.24)
where G denotes a set of cell coordinates (the model matrix in our meta model). In the
case of a three-dimensional system:
G = Z3 = {(i, j, k)|1 ≤ i ≤ Nx, 1 ≤ j ≤ Ny, 1 ≤ k ≤ Nz} (4.25)
A is the model alphabet - a finite set of possible cell states (the aggregate polymer
states in the conceptual model) and U denotes the cell neighbourhood (including the cell
itself). Then A (U(x), t) denotes the state of a neighbourhood of cells U around a given cell
x at a moment in time t. The behaviour of the system is described by a set of elementary
transition rules for the conceptual model, F, where these are applied to the states of a
neighbourhood of cells U. For the sequential case of synchronous updates, we can
write the following:
Fs = {f(x) : A(U(x), t)→ A(U(x), t+ 1)|x ∈ G} (4.26)
Finally, Θ denotes the CA/ACA update order function, applied to G and A in order
to advance the global model state. As a basis for Θ we investigated the application of
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several random and ordered asynchronous update methods, (see e.g. (Cornforth et al., 2005;
Valsecchi et al., 2010)) and compared these to the well-used synchronous method.
For a clearer description of the implementation of the different forms of Θ, we move
from the mathematical to the algorithmic description:
• We implement the different update forms as modifications of the basic synchronous
CA two-phase update algorithm of the main matrix G (Table 4.3a);
• The first ACA update method investigated is the random order algorithm which
involves updating cells of G in a random order which is changed every time a full
cell sweep is finished. All cells are updated in each time step of the simulation
(Table 4.3b);
• The random cyclic algorithm is a variation of the random order algorithm, with
the difference that a single random permutation of G is always used (a cycle). Random
permutation of G is chosen at the beginning of the simulation (Table 4.3c);
• In the random independent method (Table 4.3d), one cell is chosen at random
for updating at each time step. In the overall simulation, each cell should thus be
updated approximately the same number of times. However, over shorter time periods
a given cell may be updated significantly more often. To achieve uniform selection,
the algorithm thus depends heavily on the size of the cycle of the random number
generator implementation. The Mersenne Twister algorithm has been used in this
case, to reduce bias (Matsumoto and Nishimura, 1998);
• Finally, the fixed cyclic sequential algorithm (Table 4.3e and 4.3f) was used
in two forms: in the first one, cells of G are visited in sequential order of their
coordinates, (first width, then depth, then height in 3D). In the second form, cells are
sorted based on their state (A), so that polymers of certain types are given simulation
priority over polymers of other types (outer coating, then the inner coating, then
the core). The order of cell simulation within the same polymer type is sorted by its
coordinates.
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(a) Synchronous algorithm:
for each time step t
S ← random permutation of cells in G
Sd ← temporary copy of S
for each cell x in matrix S
for each rule f in F
A(U(x), t+ 1)|Sd = f(U(x), t)|S
for each cell x in matrix Sd
A(U(x), t+ 1)|S = A(U(x), t+ 1)|Sd
(b) Random order algorithm:
S ← random permutation of cells in G
for each time step t
x ← next cell from S
for each rule f in F
A(U(x), t+ 1)|S = f(U(x), t)|S
if x = last cell from S
S ← random permutation of cells in M
(c) Random cyclic algorithm:
S ← random permutation of cells in G
for each time step t
x ← next cyclic cell from S
for each rule f in F
A(U(x), t+ 1)|S = f(A(U(x), t))|S
(d) Random independent algorithm:
for each time step t
x ← random cell from G
for each rule f in F
A(U(x), t+ 1)|S = f(A(U(x), t))|S
(e) Fixed cyclic sequential algorithm (1):
for each time step t
x ← next cyclic cell from G
for each rule f in F
A(U(x), t+ 1)|S = f(A(U(x), t))|S
(f) Fixed cyclic sequential algorithm (2):
S ← type-sorted set of cells from G
for each time step t
x ← next cyclic cell from S
for each rule f in F
A(U(x), t+ 1)|S = f(A(U(x), t))|S
Table 4.2: Synchronous/asynchronous Cellular Automata update algorithms.
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Equivalence of Sequential and Parallel Implementations
In a concrete, model execution context, the mechanisms presented above only apply as
long as the simulation is sequential. Once the algorithm has to scale up to be applicable to
large data sets, the inclusion of parallelisation will have fundamental impact on the update
logic. It can be shown that in our case synchronous matrix updates are more suitable for
parallelisation, as the effect of parallel updates on the resulting state should be equivalent.
Consider a parallel version of the fundamental rule set given in (Equation 4.26):
Fp = {f(x1, ...xn) :
k⋃
i=1
A(U(x), t)→
k⋃
i=1
A(U(x), t+ 1)|x1, ...xn ∈ G} (4.27)
Essentially, parallelising the update mechanism by splitting the CA space into disjoint
domains, each having a set of boundary cells, introduces a simultaneous update of k cells
at a time, where n represents the degree of parallelisation. The exact selection of cells x1,
... xn depends on the particular parallel algorithm being used. In the synchronous case,
the state of a neighbourhood of cells U(x) at moment t depends only on the same state
for the previous instant t− 1, and not on any currently updated state of any of the other
neighbourhoods. Therefore, for synchronous updates, it holds that FS ⇔ FP , which is in
line with Bandman (2006a).
For asynchronous updates, the equivalence of sequential and parallel implementation
breaks down. As the parallel version of the rule set presents a set of functions applied
simultaneously, the order of their application can result in a different overall state of the
matrix. This is always true if any of the chosen neighbourhoods U(xi) overlap.
Therefore, in the case of random order and random cyclic updates, we expect the
parallelisation to always result in a slightly different model output. The same holds for
different variations of fixed cyclic rules, presented in Table 4.3, where the idea of the
underlying algorithm essentially breaks down. The only exception to this rule is the
random independent order of updates, which might produce equivalent results, but only
if, in each individual iteration, cells xi are chosen from each parallel domain so that their
neighbourhoods U(xi) are non-overlapping.
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From an implementation point of view, for parallelisation of pharmaceutical models
using some of the industry standard parallel APIs, such as Message Passing Interface
(MPI), synchronous updates are preferable from the execution speed point of view, as
simulations have a practical wall-clock time limit of 24hrs, (the amount of time it would
take to run a single in vitro experiment). Synchronous updates are extremely efficient in
terms of execution speed, especially as they can utilise two-sided communication using MPI
to send and receive primitives. Asynchronous parallelisation schemes require one-sided
communication primitives such as MPI “put” and “get”, utilising the remote memory access
mechanism (RMA), which, although slower, allows for the cell state to be asked for or
provided on demand, without the need to wait on some eventual update (Thakur et al.,
2004).
Finally, it is important to note, according to Toffoli and Margolus (1987) that, for
relatively slow changing stochastic CA models, the expected variance in outputs between
synchronous and asynchronous update methods would be small. This results from the fact
that large-scale, low-probability models do not have too many cell state updates in each
iteration, which in turn limits the number of cases where overlapping neighbourhoods are
updated.
4.6.3 Model properties
Table 4.3 revisits the main CA rules used, in the meta-model described, with respect to
their impact on neighbouring cells and the type of update performed (probabilistic or
deterministic). Following the notation from Section 4.6.2, each of the transition functions
is applied to an alphabet of CA states:
A = {PCOAT , PCORE , S,D} (4.28)
where PCOAT and PCORE denote the coating and core polymers respectively, S represents
solvent cells and D drug molecules. The rules can also be described using a more formal
notation:
• erosion: polymer lifetime of a given cell x (l(x)) decreases linearly with time according
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Phenomenon Rule behaviour Type
Erosion Applies to all polymer cells.
Amount of polymer present
represented through randomly
distributed cell lifetime.
Polymer degradation directly
mapped to lifetime decrease.
Initial state - probabilistic;
Subsequent updates - determinis-
tic;
Neighbour-independent.
Diffusion Applies to drug carrying cells.
Drug moves from cells with higher
concentrations to cells with lower
concentration.
Destination cell chosen with pro-
portional probability.
Initial drug dispersion set using
probabilistic distribution.
Initial state - probabilistic;
Subsequent updates - probabilis-
tic;
Neighbour-dependent.
Swelling Applies to core polymeric cells.
Amount of polymer present in cell
is transferred to a neighbouring
cell according to concentration gra-
dient.
Destination cell chosen with pro-
portional probability.
Initial state - derived from erosion;
Subsequent updates - probabilis-
tic;
Neighbour-dependent.
Dissolution Applies to cells outside of drug
device boundaries.
Drug is removed after it crosses
the boundary.
Amount of drug removed depends
on set probability.
Initial state - derived from diffu-
sion;
Subsequent updates - probabilis-
tic;
Neighbour-independent.
Table 4.3: Elementary CA rule matrix for the meta-model together with descriptions and
type quantifiers.
73
to the following function: fe(x) : {l(x)→ l(x)− t|∀x ∈ {PCOAT , PCORE}}
• diffusion: the amount of drug present in cell xa (d(xa)) partially transitions to a
neighbouring cell xb with probability pdiff : fdiff (xa, xb) : {d(xa, xb)
pdiff−−−→ d(xa) −
∆d, d(xb) + ∆d|∀xa ∈ {D}, xb ∈ U(xa),∆d > 0}
• swelling: the amount of polymer present in a cell is distributed in a similar fash-
ion, using probability ps: fs(xa, xb) : {l(xa, xb) ps−→ l(xa) − ∆l, l(xb) + ∆l|∀xa ∈
{PCOAT , PCORE}, xb ∈ U(xa), xb ∈ {PCOAT , PCORE , S},∆l > 0}
• dissolution: finally, the process of partial or total drug dissolution is described as
the reduction in drug molecule count of a given cell once it transitions to solvent
state: fdiss(x) : {d(x) pd−→ d(x)− n|∀x ∈ {S}, n ≤ d(x)}
Multiple rule combinations can be superimposed (e.g.f(x) = fe(fdiff (fs(x)))) to fully
define a cell behaviour during a single iteration if the given cell state satisfies all the
alphabet preconditions of the rules given in Equation (4.28).
4.6.4 ACA to CA transition
The initial model developed, ECDD (Section 4.2), used a random order ACA update scheme,
(Bezbradica et al., 2011). This was used for two reasons, (i) to more faithfully represent
the nature of chemical processes occurring inside the device (ii) for performance reasons,
with the initial model using thread-level parallelism, deemed more suitable for ACA update
types as cell state exchange is not as expensive as in process-level implementations.
However, since further model extensions and increasing complexity required a transition
to synchronous updates in order to achieve faster running times, certain compositions of
elementary rules were found to be no longer applicable (Bezbradica et al., 2012). As rule
applications in ACA lead to an immediate change in the matrix state, readily visible to all
other rules, the possibility of having “undefined” states, where two consecutive state changes
lead to an invalid cell neighbourhood in the next iteration, cease to apply. With synchronous
models, on the other hand the possibility exists that an elementary rule changes the state
of the cell in the next iteration, such that subsequent executions of other elementary rules
on the same cell no longer apply. For the case of the erosion rule, the complete loss of
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polymer now has to block further swelling updates originating from the cell, even though
the swelling rule would be applicable to the cell state in the current iteration. Accordingly,
diffusion has to adapt to its valid neighbours changing to the polymer state due to swelling
in the next iteration, which would then make any drug movements invalid.
4.7 Summary
In the first part of this chapter we incorporated all main dissolution phenomena, (defined in
Chapter 2, Section 2.1), into our meta-model. As such, we created a novel comprehensive
and complex modelling framework which allows easy extrapolation of a base model to
different desired geometries, dissolution scenarios or device structures used in complex drug
design, (and with capability well beyond that required by the Sigmoid Pharma project).
Within these models, we have been able to combine stochastic prediction of outcomes, with
empirical information, from observation of in vitro experiments, in order to access the
impact of parameter changes.
The rationale for taking this approach was to address certain limitations of earlier
model applicability to complex structures, (such as coated swellable formulations) and to
supplement sparse a priori experimental data needed for calibration.
In the second part of this chapter we presented an overview of methodological considera-
tions, important to modelling drug delivery systems using CA and ACA, and have analysed
the advantages and disadvantages of each update method. While some flexibility is possible
in choosing between asynchronous and synchronous methods for approximate solutions in
this context, this is governed by structural requirements.
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Chapter 5
Model Implementation and Analysis
Currently, a “hot-topic” in computing, Data Analytics typically refers to the use of large
scale computing to solve problems involving “big data”. The use of Data Analytics in
drug design and discovery was of limited use historically, as the process of in vitro drug
release was considered akin to a black box, where different inputs were varied in order to
tailor desired outputs1. In this sense, the internal dynamics of the pharmaceutical device
could not be deduced solely by observation as this presents a superimposed picture of the
phenomena involved.
As described in Chapter 1 pharmacokinetic modelling of drug release from a DDS,
from the drug discovery phase through to development and manufacturing, provides both
support for the decision-making process as well as an improved and effective usage of drug
development time together with reduction of design parameter space. The basis for analyses
both within and between input data sets is also covered. This has the potential to reduce
the amount of in vitro/in vivo testing required, important to cost-effective and flexible
solutions. Hence, in silico modelling and analysis could enable extensive offline testing and
evaluation of parameter sensitivity, (Bader, 2012).
In our case, in vitro and in silico data analysis and development of the current models
were performed based on the workflow presented in Figure (5.1). This continuous feedback
loop is composed of several distinct stages, separated into two main parts (enterprise partner
and modeller).
1This work has been published in (Perrin et al., 2012).
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The initial drug design and in vitro testing in the USP II apparata (The United States
Pharmacopeial Convention, 2007), has been performed by the enterprise partner. The data
are filtered to determine the variables of interest, intrinsic to the drug device design process,
(input parameters such as geometry, size, drug loadings, and coating thicknesses), and
relevant to the modeller (e.g. the types of physical processes/chemical reactions present,
release curves for different parameter sets, etc.). The data obtained were used in the
construction of the CA models presented here and shed light on different assumptions about
the dissolution processes.
The models are then optimised for parallel execution and simulated on high performance
computing clusters for various input data sets, in order to maximise the gain from running
many simulations at once. As the laboratory testing is performed for periods of up to 24
hours, in order for in silico simulations to be cost-effective, the workflow and the underlying
framework must be able to support large numbers of simulations over a relatively short
time period.
Two main sets of simulation results are generated: (i) a control set, which validates
results against the known experimental data points and is used to assess model usability
for predictive purposes. For controlled release, a sigmoidal (“S” Shaped) release curve is
expected, demonstrating properties of zero-order release kinetics during a period when the
device passes through a region of maximum adsorption; (ii) a generic data set showing
variations of release profiles, dependent on parameter changes, which can then be used to
feed back into the drug design process.
If the model validation shows promising results, extensive optimisation can also be
performed in order to ensure model robustness and reusability for similar drug device
analysis. An insight on system evolution is also provided by graphical representation of the
model, which captures successive stages of the dissolution.
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Figure 5.1: Data analysis and modelling workflow. The workflow starts at initial design of
the pharmaceutical device and preliminary in vitro testing. The resulting data are filtered
for the experiments that include relevant experimental variables, and are used to construct
the CA models. High Performance in silico simulations and data visualisation are then
used to investigate the influence of parameter change to the release profiles. If the control
results accurately describe the experimentally observed data, the simulated scenarios can
be used to reduce the space of further experimental designs.
5.1 Parallelisation strategies for large scale Cellular Automata
frameworks in pharmaceutical modelling
Here, we focus further on the implementation aspects of the simulation stage, with re-
sulting data analysis and visualisation covered in subsequent chapters2. One of the main
challenges in pharmaceutical data analytics is that uncovering structures and patterns in
complex, heterogeneous datasets is a computer-intensive task, requiring significant com-
putational resources. Recent advances in high-performance computing provide part of
the solution. Multicore systems are now more affordable and more accessible. Advances
2This work has been published in (Bezbradica et al., 2012).
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in high-performance computing (HPC) have resulted not only in improved performance
but also in greater availability of such resources. The cost per GFLOPS3 dropped below
$1000 for the first time in 2000, below $42 in 2009, (Nakasato, 2009), and below $2 in
2011, (Stevenson et al., 2011). Ongoing development of cloud-based solutions is likely to
further increase availability and affordability of HPC resources. HPC solutions are already
having significant impact on Data Analytics in a range of disciplines. This served us the
motivated for providing an overview of the challenges and present a detailed case study for
pharmaceutical R&D, since practical applications are lacking in the context of optimisation
and parallelisation of large-scale, high-precision, high-fidelity DDS CA simulations. The
key obstacle to parallelisation of pharmaceutical models is not only the amount of data
involved, but also the fact that many of these models incorporate agent-like behaviour
within the CA framework in order to describe pharmaceutical components. This makes
communication across process boundaries expensive.
In this chapter, we investigate how to develop more advanced methods for data analytics
and focus on a specific case of model-driven analysis. We apply two parallel-computing
application programming interfaces (APIs), namely OpenMP and MPI, to partition the
simulation space and analyse the applicability of each API to the problem individually, as
well as in the hybrid solution. We examine the speedup potential and overhead for local
and global communication for simulation speed and solution scalability.
5.1.1 Advantages of High Performance Computing
If we are speaking in Data Analytics terms, there are two sources of “big data” in general in
pharmaceutical analysis. The first is due to novel drug formulations generating considerable
experimental data from the design stage (Coulter, 2010), which require processing in order
to deduce relations between design parameters. Synthetic sources depend on the device,
where fine resolution is needed for micro- and nano- scale simulations, requiring high
performance, large scale infrastructure to execute. Even though such resources today are
readily available, either from local scientific computing clusters or commodity public cloud
infrastructure, the algorithmic solutions are less well-reported in the scientific literature,
3109 floating point (i.e. real number) operations per second.
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(Bader, 2012).
A second source of data comes from the problem of implementing parallelisation of CA
systems themselves, where the key challenge is that of the efficient transfer of large amount
of cell state information, which contain high-precision data, across process boundaries
where communication is expensive, (Bezbradica et al., 2012). This problem becomes more
complex for multiple scales as we switch from classical CA models, to ones incorporating
agent-like behaviour, (such as those of particle diffusion within the drug device).
Depending on the available infrastructure and on the need for granularity, the general
model framework, described in Chapter 4, can be adapted for different parallelisation
strategies, (Bezbradica et al., 2012). On one level, process level parallelism, which requires
more extensive computing resources, can be used at the development and analysis stages,
for processing of large data sets of experimental data, in order to reduce input requirements
from wet-lab experiments. Lighter, thread4 level parallelism can be utilised even under
laboratory conditions and is adequate for further analysis of single parameter ranges. Finally,
there is a possibility of adopting a hybrid approach, allowing selection between the two
strategies, which maximises the utilisation of available high performance infrastructure by
applying both thread and process level parallelism, (Silberschatz et al., 2012).
Inter-thread and inter-process communication overhead occurs as a consequence of the
cell state being exchanged during an execution rule and is solved by introducing boundary
cell layers, where communication is either sequentialised, (i.e. uses locking5), for the case of
threads, or delegated to one of the two neighbouring processes for process level parallelism.
5.1.2 Parallelisation Schemes
In order to develop the most efficient parallelisation algorithm for the CA model presented,
we need to understand the fundamental types of cell communications and cell transfers
occurring. Traditional synchronous CA models usually follow a standard pattern where
a cell state is passively dependent on its neighbours and, based on their state values, is
4In a programming context, threads represent a lower level parallelisation abstraction than processes. A
process would represent a general sequence of execution (i.e. an application) while a thread would represent
a sequence of execution within the process itself. Each process can have multiple threads.
5Locking is a general thread programming concept, where given thread blocks waiting for another thread
to perform a dependent action.
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Figure 5.2: Elementary Types of CA Rules present in the Model.
updated itself in the following iteration. These kinds of models should fit into the category
of so called “embarrassingly parallel” problems, where parallelisation of the problem space
is straightforward, (Massaioli et al., 2005). However, differences in the rule types in our
case mean that certain types of shared state and synchronisation between different parallel
processes is necessary.
Rule Types
In the models presented in the earlier chapters, each cell has a state describing the current
status of several different physico-chemical phenomena:
• The amount of degradation of polymer chains;
• The extent of expansion potential of polymer chains;
• The number of drug particles present in the cell.
These sub-states are mutually independent and can be updated separately from each
other. Thus, we cannot treat whole cell state updates as “atomic”6, only sub-state ones.
Therefore, every single cell has the potential to be updated several times during a single
simulation iteration.
The model rules that affect those sub-states can generally be classified into three
fundamental types (Figure (5.2)):
• Temporal rules which change the state of a single cell without neighbour influence.
This type of rule is always deterministic (e.g. polymer degradation over time)
6The atomic instruction is “indivisible”. It cannot be interrupted before its completion. For example, if
the CPU attempts to read from the memory it can only see operation as completed or not and will not be
able to read its inner state.
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• Neighbourhood-dependent rules which change the state of a single cell, based on
the combination of states from neighbouring cells. This type of rule can either be
deterministic (polymer erosion) or probabilistic (polymer wetting)
• Neighbourhood-dependent rules which change both the state of the cell and the state
of one of its neighbours. This type of rule is always probabilistic (e.g. drug diffusion,
polymer swelling).
It is also important to note, that conflicts can occur in shared cell updates of different
types (i.e. swelling and diffusion or erosion and swelling). In this case, we define a permitted
order of cell updates, where a state change will block further updates of certain kinds. For
example, erosion of a cell which degrades all the remaining polymer will further block any
swelling rules which can be executed from that cell.
The particular obstacle to overcome for parallelisation of the model to be efficient is
effective communication of the third type of rule across parallelisation boundaries. Recall
that these rules were introduced to realistically simulate the physico-chemical processes
which have an active spatial span, as opposed to being passively affected by the neighbour
state. However, the ability of the cell to affect the neighbour state in a probabilistic manner
leads to the possible occurrence of multiple updates of a single cell from two or more of its
neighbours (Figure (5.2)). To resolve possible conflicts several approaches may be used:
• The neighbouring cell can be marked as updated for all sub-states and no further
state changes permitted;
• The neighbouring cell can be marked as updated for a single type of sub-state change
(e.g. polymer swelling), but other types of state changes (e.g. drug diffusion) may be
permitted;
• The neighbouring cell state can be updated multiple times and all types of state
changes may be permitted. In this case, changes are considered to be additive.
In order to preserve the realism of the physical process, all models generally assume the
third approach; however there can be cases where the neighbouring cell is precluded from a
certain type of update (e.g. due to change of state). To illustrate the point let us consider
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Algorithm 1 Update(Matrix M)
1: Secondary = M
2: shuffled_cell_vector = Shuffle(M)
3: for each c in shuffled_cell_vector do
4: for each rule in rule_list do
5: Apply(c, rule) ⇒ Secondary
6: M = Secondary
7: ComputeRelease(M)
Table 5.1: The pseudo code for the basic model algorithm.
two examples. Example 1: the drug diffusion algorithm selects the same target cell for
drug packet movement from two different neighbours. In order to correctly describe the
resulting movement, the destination cell will contain packets from both sources. Example
2: polymer expansion into the coating layer has caused a neighbour state change which
prevents any further updates to the destination cell. In general, for the latter updates, we
assume a “priority approach” based on which cell caused the first change to the destination
cell state. Any subsequent attempts to change the state are ignored. However, from the
parallel implementation perspective, this implies both the need for cells to communicate
their state across to that of the destination cell, as well as some kind of “locking access” to
the destination cell during the update process, in order not to cause partial or incorrect
updates and thus loss of data.
5.1.3 Model Parallelisation Algorithms
The main model algorithm uses two 3D matrices, primary and secondary, to hold the state
of the dissolution space in the current and next iterations respectively. The algorithm
performs multiple pass visits of each cell in the primary matrix. The cells are visited in
random order, using a shuffle approach, to avoid any potential bias or rule cycle. In the
first pass, when a cell is visited, all possible behaviours defined for the particular cell type
are evaluated, and applied based on calculated probabilities. The resulting state is then
updated in the secondary matrix. When the first pass is finished, the matrices are swapped,
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Figure 5.3: Parallelisation Strategies - OpenMP. (Left) Primary matrix is divided into equal
regions with boundary (thread-shared) layers, each simulated by a dedicated thread (Centre)
Non-boundary updates are applied directly to the secondary matrix, while the boundary
updates are exchanged between the threads. (Right) The updated state is gathered back to
the primary matrix.
and a second pass is performed to calculate the resulting global state of interest to the
modellers, such as new dissolution boundary fronts, and overall amount of drug dissolved.
Since only one pass occurs at any one time, there are no conflicts in cell updates. The
algorithm pseudo-code is described in Table 5.1.
Thread-level Parallelism (TLP)
The first approach we consider, for solution of the efficiency problem, involves thread-level
parallelisation on a symmetric multi-processing (SMP) architecture. The main matrix is
kept as is, and the secondary matrix is divided into logical regions of equal size, where
updates in each region are controlled by a separate execution thread (Figure (5.3)). Since
the matrix state is shared in memory and visible to all threads, we now have the potential
for conflicts in cell state updates. In order to minimise the negative effects of explicit thread
synchronisation, cell state locking is considered only at region boundaries. Namely, two
boundary layers on each side of the region, except in the case of the first and last region,
are considered to be “shared” and locking is enforced for any state changes in that region
during the single update period.
However, other threads are permitted to make any updates that are considered legal
by the rule set, after the lock is lifted. The pseudo-code for the algorithm modification is
given in Table 5.2. The standard OpenMP API primitives have been used as a means of
implementing the parallelisation of the for loops in the main algorithm.
Although the approach provides a straightforward algorithmic solution to the problem,
SMP architectures are generally limited by the number of available execution cores, and
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Algorithm 2 UpdateByThreads(Matrix M)
1: Secondary = M
2: parallel for each region in M.Regions
3: shuffled_cell_vector = Shuffle(region)
4: for each c in shuffled_cell_vector do
5: if(IsShared(c) == true) then lock(Secondary(c))
6: for each rule in rule_list do
7: Apply(c, rule) ⇒ Secondary(region)
8: if (IsShared(c) == true) then unlock(Secondary(c))
9: #end parallel
10: M = Secondary
11: ComputeRelease(M)
Table 5.2: The pseudo code for the thread-level algorithm.
performance gain, i.e. speedup, from this type of parallelisation has a “hard ceiling” set by
the underlying architecture. Hence, in order to improve the execution times further, we
have to cross the process and machine boundaries.
Process-level Parallelism (PLP)
In order to split the algorithm execution across the different execution nodes, the focus shifts
to solving the communication problem instead of the synchronisation one. In distributed
computing platforms, such as MPI, a state has to be explicitly shared by sending and
receiving over the communication network. This network now introduces an additional
variable in the model performance, and necessitates the definition of a communication
pattern between different model regions.
Generally, the CA model space can be efficiently sent to separate execution nodes
using the explicit MPI commands MPI_Scatter and MPI_Gather, i.e. “scatter-gather”
algorithm, (Kandalla et al., 2010). Regions of equal size are sent (scattered) from a “master”
process, responsible for overall state management, to two or more “slave” processes, which
are solely responsible for the simulation of a single region. After the regions have been
simulated, their state is returned (gathered) back by the master process, which is responsible
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Algorithm 3 CrossProcessUpdate(Matrix M, int rank)
1: Secondary = M
2: n = Secondary.Regions.Count
3: Matrix region
4: if (rank == MASTER) then
5: Scatter(M.Regions) ⇒ region
6: for each c in Shuffle(region) do
7: if(IsBoundary(c) == true) then skip
8: ApplyRules(c, rule_list) ⇒ Secondary(region)
9: ExchangeBoundary(rank, rank + 1)
10: for each c in Shuffle(region.boundary) do
11: ApplyRules(c, rule_list) ⇒
12: Secondary(region.boundary)
13: if (rank == MASTER) then begin
14: Gather(M.Regions) ⇐ Secondary(region)
15: ComputeRelease(M)
16: end
Table 5.3: The pseudo code for the process-level algorithm.
86
Figure 5.4: Parallelisation Strategies - MPI. (Left) The simulation space is divided into
separate processes (master and a number of slaves), with boundary layers shared between
them (Centre) After internal cell state updates, neighbouring processes exchange boundary
layer information (Right) After the boundary calculations are completed, the state of the
simulation space is gathered back by the master process.
for assembling them back together and calculating the resulting output. It is interesting to
note that, due to the fact that the master process is idle during the period between the
scatter and gather phases, it also assumes the role of the slave, by assigning itself as owner
of one of the regions to update.
In our particular case, the scattering of the regions is not enough, because regions
share logical space of the CA framework, so that a mechanism to send boundary cell states
across this logical space needs to be present. Although MPI allows for asynchronous data
communication that can be used on a per cell basis (i.e. a cell sends out updated state
information as soon as it is changed), this places a prohibitive performance strain, both
in terms of the amount of micro-communications that need to occur and due to the fact
that any boundary cell update would need to wait on neighbour boundary state updates in
order to continue with the execution. To avoid this, we choose to serialise the boundary
layer updates to the end of the region update cycle. As with the concept of thread-level
shared layers, we introduce process-level shared layers. These are constructed of boundary
layers in each region. As illustrated in Figure (5.4), the update of the boundary layers is
now the sole ownership of just one of the neighbouring process regions that share those
layers. Upon completion of region updates, which can be done without the need for data
from neighbouring processes, boundary layer information is sent to the “owner” process
which completes the region update cycle, and returns the updated state back to the initial
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process. The main cycle then completes with the slave processes sending back the resulting
state to the master. The resulting pseudo-code is presented in Table 5.3: for brevity, the
function ApplyRules replaces the behavioural “for loop” from previous code examples, which
was responsible for rule applications.
Although this approach allows a much larger parallelisation ceiling, the fact that it
involves cross-process communications, usually made across a physical network, means
that the bandwidth speed is the main bottleneck that impacts performance. Even when
executing on the same node, using inter-process communication, the overhead can be
particularly large, especially considering the amount of data present in the model.
Hybrid Parallelism (HP)
The advantages and disadvantages of the proposed parallelisation strategies naturally lead
to the solution where both are combined in order to minimise the negative impacts of each
(Jin et al., 2011). On the one hand, we want to avoid the “hard ceiling” present in the
SMP solution by leveraging cross-process communication, while on the other, we want to
minimise the communication overhead present in the message-passing paradigm. In order to
achieve this, we execute one process per node via MPI, but implement the threading within
each region by using OpenMP. As a result, the process-level communication is reduced to
an absolute minimum, while the limit to the amount of cores that can be used is drastically
increased. Of course, communication overhead and non-parallelisable elements of the model
will result in diminishing returns as the number of cores increase. Also the model geometry
will be the ultimate limit, as the number of cores approaches the number of layers present.
The resulting hybrid pseudo-code algorithm is shown in Table 5.4 and its schematics are
given in Figure (5.5).
The central part of Figure (5.6) shows the CA rule type executions described in the
context of the hybrid model. The top panel of the central diagram represents the diffusion
process through three distinct update scenarios. In scenario 1, we have the normal case,
isolated (i.e. independent of shared space) rule execution, where a set of drug molecules
can choose to move to a suitable neighbour. Scenarios 2 and 3 display rule updates which
occur inside the shared layer. In this case state locking is performed, and cell access is
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Figure 5.5: Parallelisation Strategies - Hybrid. (Left) The simulation space is divided across
master/slave process with each process further dividing the space over multiple threads
(Centre) Internal state calculations are performed by each thread in each process with the
boundary threads exchanging the state information. (Left) The resulting state is gathered
by the master process.
Figure 5.6: Hybrid parallel model incorporating main rule types. Each of the processes
computes the internal cell transitions, divided into three core types.
sequentialised on a first-come first-served basis. In scenario 2, there is no additional contest
from the other thread, so regular cell state update occurs. However, in scenario 3, as the
synchronous CA update mechanism is used, a second update will not be aware of the
changes made by the first, resulting in a need to “resolve the update conflict”. In this case,
we assume the resulting state will be cumulative and both diffusions are permitted, unless
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a super-saturation7 of the cell occurs.
The middle panel in the central diagram in Figure (5.6) shows similar update scenarios
in the context of erosion rules. As rules in this case are passive and affect the self-state
only, there is a “smaller” potential for conflicts. In case of shared layer access, however, it is
still necessary to lock the cell, in order to prevent other rule types from affecting it.
Finally, the last central panel of Figure (5.6) represents the scenarios for simulation,
which incorporates swelling effects. These are fairly similar to the diffusion updates, with
added complexity that polymer transfer to neighbouring cell occurs, influencing erosion
cycle in the subsequent iteration.
5.2 Performance Metrics
5.2.1 Development and execution environment
The code for the models was written in the C++ programming language. It consists of
approximately 11000 lines of code divided across 20 classes. The build environment is a
combination of g++ compiler with Eclipse used as an IDE, on Ubuntu Linux, running on
VMWare Player within a Windows 7 environment. The compilers used on the compute
clusters included Intel and GNU C++. Standard outputs of the simulation program are
drug release and structural data (e.g. diffusion and swelling fronts, porosity) at desired time
points. In addition to this, there is a need to visually observe the evolution of models for
two main reasons: firstly, visualisation enables the interfacing with different subject matter
experts, e.g. pharmaceutical scientists and biotechnologists. Secondly, it allows a basic
verification during different stages of model development. Visualisation was performed
using OpenGL and displays a model cross-section as it evolves over time, to facilitate an
in-depth observation of processes occurring within the different layers, Figure (6.1). It is
implemented as an optional, separate component of the program, allowing two types of
data processing, numerical and graphical.
The parallelised algorithms are based on GNU OpenMP (GOMP) and Open MPI
7Super-saturation of the cells allows a larger concentration of the drug within the cell volume than
that which would result as a consequence of an ordinary diffusion flow. It usually occurs during the drug
formulation phase.
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libraries. Real simulation runs were performed on SMP architecture cluster provided by
ICHEC (The Irish Centre for High End Computing) (Stokes) and DCU (Ampato), with 12
and 8 cores per node, respectively. For each set of parameters, ten runs were performed to
assess simulation robustness, showing negligible differences in outputs, (much as expected)
as all models are both large-scale and high-resolution.
Model runs were performed using ICHEC Stokes supercomputer. Stokes is an SGI Altix
ICE 8200EX cluster with 320 compute nodes. Each compute node has two Intel (Westmere)
Xeon E5650 processors and 24GB of RAM. The nodes are interconnected via two planes
of ConnectX Infiniband. Our model was implemented in C++ (using the gcc 4.3.0 64bit
compiler), OpenMPI version 1.4.3 and GNU OpenMP (GOMP) version 3.1. In all cases,
1440 iterations of the simulation were run, with one iteration configured to represent one
minute of real time. This choice was based on the need to correlate the data obtained
to the in vitro experiments which usually run for 24 hours. The bounding volume of the
simulation space was 300 x 300 x 300 cells, resulting in around 2.7 GB of in-memory model
data.
5.2.2 Performance for TLP
The focus of the first set of runs was on performance gain achievable using OpenMP
parallelisation only. Simulations were run for 1-8 cores, in addition to the execution times,
we observed the speedup of different code segments and their relative participation in
overall program execution. Figure (5.7) (top) shows the improvement in execution times,
which is significant and near-linear. At the lower end of the tested spectrum, the initial
execution time for non-parallelised code is almost 11 hours, while at the opposite end (8
cores) we gain a 6-fold improvement in wall-time in execution speeds. From the other two
measurements, we can see that the potential for speedup in parallel sections of the code
can bring further time reductions, as parallel code still represents a larger fraction of the
total executed code8. However, we are bound by the limitation of the SMP architecture,
which prevents further expansion of the thread-parallel approach.
8Parallel speedup indicates the reduction in speed achieved in part of the code which is parallelised.
In contrast, total speedup refers to reduction in speed of the overall code, including both parallel and
sequential part.
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Algorithm 4 HybridUpdate(Matrix M, int rank)
1: Secondary = M
2: n = Secondary.Regions.Count
3: Matrix region
4: if (rank == MASTER) then
5: Scatter(M.Regions) ⇒ region
6: parallel for each slice in region.slices
7: for each c in Shuffle(slice) do
8: if(IsBoundary(c) == true) then skip
9: if(IsShared(c) == true) then lock(c)
10: ApplyRules(c, rule_list) ⇒ Secondary(region)
11: if(IsShared(c == true) then unlock(c)
12: #end parallel
13: ExchangeBoundary(rank, rank + 1)
14: for each c in Shuffle(region.boundary) do
15: ApplyRules(c, rule_list) ⇒
16: Secondary(region.boundary)
17: if (rank == MASTER) then begin
18: Gather(M.Regions) ⇐ Secondary(region)
19: ComputeRelease(M)
20: end
Table 5.4: The pseudo code for the hybrid algorithm.
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5.2.3 Performance for PLP
Dividing the algorithm across compute nodes allows us to lift the restrictions imposed by
the thread-level paradigm, using the MPI framework. We investigated the performance of a
pure-MPI (i.e. no threading) solution over 2-32 cores, with the goals both of comparing the
performance to OpenMP as well as examining the potential for speedup and the overhead
for local and global communication on simulation speed and solution scalability. Results
obtained (see Figure (5.7) (middle)) show that, for this model size, communication overhead
has a significant impact on simulation times, although the potential of the MPI solution is
ultimately greater as it does not suffer from “ceiling” limitations.
Interestingly, due to expensive communication, the MPI solution is not as efficient as a
comparable OpenMP one. Since the “scatter and gather” operations incur a certain overhead
(from 1-2 seconds wall-clock time per iteration in our experiments), the sequential portion
of the simulation (S-time) is increased, relative to the parallel component (P-time). For the
case of 8 cores, the relative performance is almost 40% improved for thread-level parallelism.
However, the real benefit occurs for a larger number of cores, where the MPI solution
benefits from practically unlimited infrastructure. This holds for all models described in
Chapter 4 regardless of the overhead caused by each model complexity.
5.2.4 Performance for HP
Combining the two approaches presented above was the ultimate objective of this experiment.
By using the fine-grained parallelism within a compute node, and thus avoiding the
communication price, we expected to gain some advantage over the coarser-grained approach
that MPI provides (Pope et al., 2011). Figure (5.7) (bottom) presents the comparison of
the two. From Figure 5.7 (middle), even with MPI for increasing number of cores, there is
an increase in the relative sequential execution time. This is in agreement with findings
presented in Figure 5.7 (bottom), where the total improvement in execution speeds reaches
a plateau after a certain number of cores. Above a certain point, (at around 64 cores), the
performance of both MPI and hybrid approach reaches the limit for the model.
Finally, we investigated the average time taken to simulate each of the parallel slices
and conclude that further optimisation is possible by applying an appropriate dynamic load
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(Left) Execution Times (OpenMP); (Centre) Parallel vs. Total Speedup (OpenMP); (Right) Sequential
vs. Parallel Execution (OpenMP)
(Left) Execution Times (MPI vs. OpenMP); (Centre) Parallel vs. Total Speedup (MPI); (Right)
Sequential vs. Parallel Execution (MPI)
(Left) Execution Times (Hybrid vs. MPI); (Centre) Parallel vs. Total Speedup (Hybrid); (Right)
Per-Slice Simulation Times (1x8)
Figure 5.7: Performance Results: OpenMP (top), MPI (middle) and Hybrid (bottom).
As complexity of parallelisation and number of cores increase, the hybrid approach shows
better performance gains over the other two.
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balancing solution. For future work, some refinement of the approach is indicated enabling
current benchmarks to be re-evaluated for different model-space division strategies.
5.3 Conclusions
We have presented several parallelisation strategies, aimed at improving performance of the
CA frameworks, used as a modelling basis for pharmaceutical investigations performed in
previous chapters. Each strategy is viable, depending on the speedup requirements and
available infrastructure. In general, cluster computing permits the in-depth simulation of
complex drug formulations, as well as the evaluation of a wide parameter range through
reduction of in silico experiment time.
The results show that the hybrid approach offers the best performance, followed closely
by the pure MPI based solution (i.e. no threading) over 8-32 cores. With the promised
advances in MPI implementation, this gap may reduce further. Further improvements
may be possible and can be attempted by experimenting with different load balancing
methods, in order to close the gap observed in individual thread/process execution times.
Finally, it would be interesting to see the applicability of the proposed solutions when run
as part of commodity cloud computing infrastructures, which already promise a flexible
and cost-effective solution platform, (Schatz et al., 2010) for the types of research questions
of core importance to the pharmaceutical industry.
We also showed the implementation and benefits of a complete cycle of in silico data
analysis in the stages of drug development, starting from a workflow towards comparison
and parameter investigation stage. We have demonstrated both the feasibility and the
advantages of combining this process with the in vitro development. The amount of possible
analysis that can be done by the modelling framework in terms of the investigation of
parameter influence on drug release is practically unlimited, allowing the analysis of model
data from a variety of different perspectives. The HPC extension to the framework makes it
more applicable for a wider set of problems, allowing for a fast and cost-effective modelling
solution. Depending on the size of the device simulated (on milli-, micro- or nano-scale),
an appropriate parallelisation strategy can be chosen to maximise the processing power
available.
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Chapter 6
Simulation and Results
In this chapter we discuss results for all of models developed in Chapter 4. For each of
these, a detailed sensitivity analysis was performed, demonstrating a key advantage of using
the stochastic modelling approach, i.e. the potential to predict the influence of various
parameter values and ratios. This allowed for the possibility of “stress testing” the extreme
scenarios and combinations, as theoretical model verification is clearly important. All models
developed in this thesis were validated against experimental data and showed good matching.
Furthermore, as models progress in complexity, (starting from the relatively simple, ’ECDD’,
to the more complex ’SCDD’ and ’MCES’), the difference between simulation and experiment
are seen to decrease, demonstrating that this incremental approach, to incorporation of
increasing complexity, yielded satisfactory results.
6.1 Simulations for model for erodible coated drug devices
(ECDD), Section (4.2)
The initial values for the ECDD model, (Section 4.2), were chosen according to the available
in vitro data and, unless otherwise stated, the erosion rates of gelatine and ethylcellulose
are taken to be 90 minutes and 2 days, respectively. The sphere was set at 1.43 mm in
diameter, and to contain 5% of EC coating. The drug loading is kept constant for all
simulations at 10.8% of the mass. Visualisation of the erosion model shows the bulk erosion
of the coating layer and the delayed erosion process of the gelatine core as the main drivers
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Figure 6.1: Simplified internal morphology of one 3D sphere simulating drug dissolution
through coating layer (ethylcellulose). Enlarged: part of the sphere with definition of model
cell types.
of drug release, (Figure (6.1)).
The physical size distribution of spheres determines the actual mean and variance of
the release rate, (Figure (6.2)). This feature suggests a refinement of initial parameters
is necessary, (e.g. coating thickness or drug loading), as these are directly dependent on
the size of the sphere. Increasing the sphere size mostly slows down the drug release due
both to the capability of the device to hold more drug and the fact that larger spheres have
heavier and thus less permeable coatings.
The first step in the modelling was to determine the most appropriate time interval in
which cell states should be updated, as this correlates directly with the diffusion coefficient
used. This essential parameter directly determines the diffusion process speed (from
Equation 4.7) and has order of magnitude of seconds, (from Fick’s first law and dimensional
analysis). Simulations were then performed for intervals between 5 seconds and 1 minute,
(Figure (6.3)). By comparing results against experimental data, (Figure (6.7)), a time
interval of 30 seconds was chosen for all subsequent simulations.
The effect of porosity in the coating layer was investigated by varying the lifetime of EC
cells, (i.e. varying τc, Equation (4.10)), to obtain different release behaviour for different
lifetimes of EC chains, (Figure (6.4)). The slower release rate of the drug is due to decreased
porosity, i.e. slower channel formation occurring in the coating.
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Figure 6.2: Release profiles as a function of the bead size [in mm].
Weight gain of the coating thickness is also one of the primary factors influencing drug
formulation and performance. Here, we varied the coating levels from 4% - 8%, (Figure
(6.5)). The release curves qualitatively reproduce a reduction in diffusion rate, but the
impact of adjusting the weight gain is somewhat smaller than observed in vitro. This is
expected, to some extent, as perfect sink conditions are modelled in our case. In reality,
the concentration of EC in the boundary layer inhibits movement of drug packets and some
local saturation occurs. This phenomenon must be taken into account in future model
extensions.
Since the gelatine represents a mixture of different substances (peptides and proteins)
and the total lifetime was not known precisely from experiment, different values were
investigated as parameters of our simulation. As can be seen, (Figure (6.6)), the lifetime of
the gelatine carrier can be considered to be negligible in terms of influence on final release
rate. However, gelatine is an important controller of the drug release in the initial stages,
as it influences the “burst effect” by accelerating drug transfer through EC channels.
This, simplified, model comparison showed good prediction potential. In analysing the
results, it should be remembered that measurements of the in vitro release rates using
different dissolution media in USP II may have certain limitations in terms of release
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Figure 6.3: Release profiles as a function of the simulation time interval.
detection depending on drug solubility. The insolubility of the Cyclosporine causes a
fragmented release, which requires adding surfactants to the dissolution media in order
to improve drug solubility. If suitable amount of surfactant is not present, the equipment
used is not able to detect exact release rates, (Maggi et al., 1996). As a result, the release
curve may reach a platform at 80% of total release, (although 100% is accounted for in the
experiment).
Although simulated results do not reproduce quantitative in vitro data precisely, (Figure
(6.7)), results obtained are promising. These show that the ECDD model predicts qualita-
tively similar behaviour compared to that seen for experimental release curves. Results
also show that the behaviour of the device cannot be modelled using erosion only, but that
other phenomena, such as swelling, have to be taken into account (Atyabi et al., 2004).
The next focus was thus incorporation of the swelling effect, caused by increased hydration
of the broken polymer chains. Additionally, the model should be augmented to include
the effect of different polymer coatings and different media surrounding the drug (biphasic
release) in order to simulate the different surroundings in the proximal and distal GI tract
environments. Nevertheless, the initial approach enables comparison of a set of simulated
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Figure 6.4: Release profiles as a function of the coating degradation rate lambda.
and experimental release curves, allowing us to determine key parameters and their values
for this novel formulation, and to reproduce qualitative behaviour. This allowed for the
comparisons with a large set of simulated and real release curves in order to estimate best
fit parameter values.
6.2 Simulations for model for swellable coated drug devices
(SCDD), Section (4.3)
6.2.1 Validation against experimental data
The first set of runs for the SCDDa model was performed against available experimental
batch data in order to validate the model prediction capabilities. The data used was
provided by Sigmoid Pharma and consisted of two batches of uncoated spheres with different
Cyclosporine A loadings (10% and 15% respectively) and three batches of Surelease/Pectin
coated spheres of different coating thickness (4.6%, 7.4% and 15% weight gain respectively).
Example visualisation of simulations is presented in Figure (6.8).
Due to a lack of experimental data for all bead sizes, the absolute coating thickness
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Figure 6.5: Release profiles as a function of the coating weight gain.
Figure 6.6: Release profiles as a function of the gelatine lifetime.
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Figure 6.7: Simulated release profiles against experimental release profiles. Experimental
data provided by Sigmoid Pharma Ltd.
Figure 6.8: Visualisation of the SCDD model with relevant cell types. The spheres show
progression from initial to the dissolved state. Green indicates the gel layer, and red the
solid gel state. We can observe the “ghost shell” of the coating remaining in the end after
core material has eroded completely.
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Figure 6.9: Linear regression curve used for estimating absolute thickness (in cm) from the
available weight gain data. Experimentally available measurements and X-ray images show
good linear correlation. This indicates that the approach is feasible for thicknesses > 21µm;
(note that the position of the intercept indicates that the relation is non-linear somewhere
below this point).
was derived from the relative weight gains by means of linear regression using known
measurements and X-ray tomography images showing actual coating regions after the
thermal processing. The regression curve used is plotted in Figure (6.9).
In order to analytically compare the level of correlation between simulation and the
experiments we chose to employ the widely used similarity factor (f2) equation as described
by Shah et al. (1998), which considers two profiles to be similar on the basis of (i) overall
profile similarity and (ii) similarity at every dissolution sampling point. Our measurements
satisfied the conditions described and the factor was employed to analyse the statistical
similarity between two given dissolution profiles. The results are accepted as similar if the
value falls within the 10th percentile range (corresponding to values of f2 between 50 -
100, with 50 indicating a 10% boundary and 100 a perfect match; correlated results fall
somewhere within the range). The similarity factor is calculated using the equation:
f2 = 50log
100
[
1 +
1
k
k∑
i=1
wi(yexp − ysim)2
]0.5 (6.1)
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where log indicates the base-10 logarithm, k indicates the number of sample points
taken, wi the weight factor that takes into account the variability of samples at each
timepoint, yexp and ysim the experimental and simulated release data at each timepoint
respectively. The weight factor was calculated using the equation given by Moore and
Flanner. (1996):
wi = log
{
100
[
1 + (yexp − ysim)2
]0.5} (6.2)
Simulation parameters were chosen based on direct experimental observations provided
by Sigmoid Pharma. In situations where those observations were not available (or possible
to obtain) we used available reference data from literature. Table 6.1 provides a summary
of the parameter values used for validation with experimental data.
The main rate limiting parameter, the diffusion coefficient of Cyclosporine A was set at
2 · 10−6 cm2/s, as indicated by the measurements made by Trammer et al. (2008), Park
et al. (2013), which put the CyA diffusion speed within the range of 0.96− 5 · 10−6cm2/s.
The base diameter of the sphere was derived by averaging bead size data available from
laboratory measurements, and gelatine lifetimes were chosen based on visual observations
made in the Sigmoid lab. Probability of core swelling was kept to the low swelling region
as observations showed that no significant expansion of the core occurred during the bead
dissolution. Relative speed of the diffusion of water into the Surelease layer, (PW ), was
derived using the measurements made by Ravindra et al. (2000) and Equation (4.20) and
set to 0.16. Similar investigation was performed for the speed of water diffusion into the
core layer (PWG) using available gelatine/water interface data from Domenek et al. (2008)
which reported the experimental value to be of the order of 108cm2/s, resulting in relative
speeds of order of 10−2 when compared with the main diffusion coefficient. The duration
of the experiment was 24 hours, with comparative measurements made at 1, 2, 3, 4, 6, 12,
16, 18, 20 and 24 hours respectively.
Two parameters, which could not be derived either from reference data or experiments,
were the coating diffusion probability (PP ) and the amount of entanglement (PC). The
entanglement rate could be estimated from available release data by looking at the “plateau”
the release curves would attain as the CyA would no longer dissolve. The coating diffusion
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Parameter Simulation value Experimental reference
Sphere diameter 1.65mm (1.5mm uncoated) 1.65mm (1.5mm uncoated)
Df 2 · 10−6 cm2/s 0.96 · 10−6 - 5 · 10−6 cm2/s
Gelatin λ 60 min 60 - 120 min
PS 0.3 0 - 0.5
PW 0.16 0.16
PWG 0.01 0.01
PP 0.3 N/A
PC 0.1 N/A
Duration 24 h 24h
Table 6.1: Key SCDDa model parameters used for comparison with experimental data.
Reference parameters were derived from batch data, experimental observations and literature.
The coating permeability and probability of entanglement was estimated based on simulated
model data ranges.
had to be estimated, using the comparison between available release, with sensitivity
analysis data. It would be of interest to investigate this value in vitro by performing
experiments on diffusion of CyA through Surelease films to further validate the estimated
value. In addition to parameter values represented, it is also important to indicate that in
the uncoated release scenario the dissolution media used was water instead of SDS, and
therefore the maximum solubility of CyA was capped, as indicated by the experimental
measurements.
The resulting simulation release curves for each batch are presented in Figures (6.10)
to (6.13) respectively. Table 6.1 summarises the main batch parameters, while Table 6.2
gives similarity factors obtained for each curve. We can conclude that a very good match
is obtained with the majority of the simulation points falling within the normative 10%
variability range (i.e. having similarity factor values within the range of 50 to 100) indicate
good agreement with the reference data. The only outlier is the FC021/09 batch, for witch
the release curve showed anomalous behaviour and this might have been influenced by noise
in the data (each batch had only two repeated data measurements). More measurements
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Modelled batch Achieved similarity factor
EXP11/085 (uncoated, 10% d.l.) 100 (<1%)
EXP12/111 (uncoated, 15% d.l.) 74 (<3%)
FC015/09 (15% Surelease, 10% d.l.) 61 (<6%)
FC008/09 (7.4% Surelease, 10% d.l.) 82.9 (<2%)
FC021/09 (4.6% Surelease, 10% d.l.) 40 (<15%)
Table 6.2: Values of the similarity factor (f2) for different experimental modelling scenarios
for SCDDa. Results show good match allowing for sample error. The only outlier was
batch FC021/09 which fell outside 10% variability acceptable.
might establish a better baseline for comparisons and allow for better normalisation or
identification of outliers, so that these could be allowed for in the comparison.
6.2.2 Sensitivity analysis
After obtaining satisfactory results for the SCDDa model (as described in the previous
section), we investigated the model’s ability to describe major phenomena influencing
release, as well as to predict parameter changes required to obtain zero-order release, a
desired quality of controlled release devices. For the purpose of classifying the results
based on dominant release phenomena, we used the Korsmeyer-Peppas model described by
Equation (2.6) to divide the results into specific release categories. The results obtained
are described in detail in the following sections. Changes for each of the parameters were
evaluated for three key release scenarios: (i) erosion dominant release; (ii) swelling dominant
release and (iii) the equilibrium between the two which should lead to a constant gel layer
driving the release profile. Each parameter change scenario, (except for the changes in
coating thickness), was performed for both the cases of uncoated and coated beads in
order to compare the two and help to understand the impact of coating on swellable beads.
Additionally, the dynamics of dissolution behaviour was examined through the positions of
two characteristic transition boundaries within the device (e.g. Figure (6.17): the swelling
front, (where polymer moves from being in a static to dynamic state), and the erosion front,
(where polymer starts dissolving). These are the best indicators of the spatial nature of the
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Figure 6.10: Experimental vs. simulated results for batches EXP11/180 (10% CyA loading)
and EXP12/111 (15% CyA loading). Obtained similarity factor shows less than 1%
difference in the obtained profiles. The maximum dissolution amount was capped as the
dissolution medium used for the experiments was water instead of SDS.
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Figure 6.11: Experimental vs. simulated results for batch FC008/09 (7.4% Surelease coating
and 10% CyA loading). Obtained similarity factor shows the results fall into the standard
variability range (<10%).
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Figure 6.12: Experimental vs. simulated results for batch FC015/09 (15% Surelease coating
and 10% CyA loading). Obtained similarity factor shows the results fall into the standard
variability range (<6%).
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Figure 6.13: Experimental vs. simulated results for batch FC021/09 (4.9% Surelease
coating and 10% CyA loading). Obtained similarity factor shows the results fall outside
the standard variability range (<15%). We believe this anomalous behaviour is due to
noisy data, and better results could be achieved by repeating experimental measurements
in order to obtain smoothed results.
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underlying phenomena, which cannot be observed directly or solely from release data.
Influence of ethylcellulose coating thickness
The first parameter investigated was the thickness of the ethylcellulose coating. The release
curves were simulated for thicknesses of 0.04mm, 0.08mm and 0.16mm respectively. The
results are presented in Figures (6.14) and (6.15). As expected the increase in thickness
causes both a decrease in release rates, as well as larger offset until the release begins, as
the surrounding buffer needs more time to penetrate the ethylcellulose matrix. Analysing
the Peppas n factor for the three scenarios, thinner coatings indicated, as expected, larger
diffusion influence, with the values of n decreasing correspondingly. Most n values were
within the anomalous region, indicating the influence of both erosion and swelling on the
release, however for thicker coatings n values indicated erosion controlled release. This
suggests that heavier coatings inhibit swelling behaviour within the sphere.
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Figure 6.14: Influence of ethylcellulose coating thickness on resulting drug release curves in
the equilibrium scenario. Thickness was varied from 0.04mm to 0.16mm and, as expected,
caused an overall decrease in swelling rate. Release curves mostly indicated anomalous
release with erosion and swelling equally controlling the release behaviour. Peppas n values
obtained ranged from 0.7 to 1.29 indicating a zero-order release (n = 0.85) is possible to
achieve.
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Figure 6.15: (top) Influence of ethylcellulose coating thickness on resulting drug release
curves in the fast erosion scenario. Thickness was varied from 0.04mm to 0.16mm and,
as expected, caused an overall decrease in swelling rate. Release curves mostly indicated
anomalous release with erosion and swelling equally controlling the release behaviour.
Peppas n values obtained ranged from 0.61 to 1.05. (bottom) Influence of ethylcellulose
coating thickness on resulting drug release curves in the fast swelling scenario. Thickness
was varied from 0.04mm to 0.16mm and led to overall decrease in swelling rate. The release
curves mostly indicated anomalous release with erosion and swelling equally controlling
the release behaviour and thinner coatings trending towards diffusion controlled, Fickian
release. The Peppas n values obtained ranged from 0.57 to 1.04.
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Influence of drug loading on release profiles
Another device design parameter that we considered was the amount of drug loading (in
volume terms). Figures (6.16) to (6.26) show the effect of changing drug fractions from
0.2 to 0.8 across the three scenarios modelled, (namely fast erosion, fast swelling and
equilibrium) and across coated and uncoated beads.
A major difference in how drug loading influences release is found for coated and
uncoated beads. In the first place, obtained profiles show diffusion to be dominant release
mechanism. Peppas n values range from 0.41 to 0.55 indicating Fickian influence at lower
loading levels, and anomalous ones (> 0.55) indicating higher influence of swelling at upper
drug loading levels. The results agree with those of (Laaksonen et al., 2009a) as higher
amounts of drug by volume of the device lead to a smaller amount of gel polymers, and lower
probability that a drug particle will be bound to the gel phase. This holds for both fast
erosion and equilibrium scenarios, but in the case of the fast swelling scenario represented
in Figure (6.25) we observe a behaviour which seems more consistent with that reported
by Siepmann and Peppas (2001). The increased swelling enlarges the rubbery gel state
trapping the drug particles for a longer time. The increased size of the gel front is visible
in Figure (6.25).
For coated formulations, the reduced release is consistent across all of the three scenarios.
As the presence of coating inhibits swelling, coated formulations are generally more erosion
controlled, thus preventing the drug particles getting entangled in the wet polymer and
thus diffusing out more quickly. Obtained Peppas numbers confirm this, with investigated
release ranges not varying much from n = 1.01 to 1.16, indicating erosion controlled, case
II release.
Effects of gelatine clustering and entanglement on release profiles
During the verification of the SCDDa model against experimental release data, one critical
factor which negatively influenced the experimental profiles was partial core dissolution and
entanglement of long, undissolved gelatine polymer chains with the ethylcellulose coating.
This appears to have led to partial blockage of the pores formed during buffer penetration
into the coating and large portions of drug ending up “encased” in the gel solid (glassy)
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Figure 6.16: Influence of drug loading on release profiles from coated beads displaying
combined erosion and swelling behaviour. The decrease in release rates with increase in
drug amounts is attributed to faster core erosion and a smaller gel layer due to the coating
inhibiting swelling.
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Figure 6.17: Influence of drug loading on swelling and erosion front changes for an equilibrium
release scenario (coated beads). A decrease in gel layer thickness is caused by lack of a core
material (due to a higher drug percentage). A constant gel layer thickness can be achieved
by balancing the erosion and swelling influence leading to more stable and predictable
release.
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Figure 6.18: Influence of drug loading on release profiles from coated beads - displaying fast
erosion behaviour. The decrease in release rates with increase in drug amounts is attributed
to faster core erosion and a smaller gel layer due to the coating inhibiting swelling.
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Figure 6.19: Influence of drug loading, on swelling and erosion front changes, for a fast
erosion release scenario (coated beads). The decrease in gel layer thickness is caused by
a lack of core material due to a higher drug percentage. A constant gel layer thickness is
achieved, but the collapse of the core does not allow it to be maintained for a prolonged
time due to lack of swelling.
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Figure 6.20: Influence of drug loading, on release profiles from coated beads, displaying fast
swelling behaviour. The decrease in release rates with increase in drug amount is attributed
to faster core erosion and smaller gel layer due to the coating inhibiting swelling.
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Figure 6.21: Influence of drug loading, on swelling and erosion front changes, for a fast
swelling release scenario (coated beads). Decrease in gel layer thickness is caused by lack of
core material, due to the higher drug percentage. The high variability in the wet gel phase,
as shown generally leads to an unstable release.
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Figure 6.22: Influence of drug loading, on release profiles from uncoated beads, displaying
fast erosion behaviour. The increase in release rates with increase in drug is attributed to
smaller gel layer due to increased amount of drug solids. At the lower end of the investigated
range (20% drug loading volume) the release tends more towards Fickian behaviour (n =
0.45).
phase. This phenomenon is difficult to observe in vitro and, mostly, it is the effects which
are measured empirically. It was of interest, therefore, to simulate the correlation between
the probability of its occurrence (PC) and the resulting decrease in release curves.
We again ran sensitivity analysis simulations across all three release scenarios and
Figures (6.27), (6.29) and (6.31) show release curve changes for each scenario, while Figures
(6.28) and (6.32) indicate the amount of drug trapped in the solid gel state. Note that the
released amount and the trapped drug amount are not mutually exclusive. There may be
free moving drug particles in the solvent area within the coating that are also unable to
diffuse out.
Comparing release curves, we can see that the apparent relationship is exponential
to some degree in all cases. Highly erodible cores are the least impacted as, although a
proportion of drug stays within the core, pore blocking is much reduced since the movement
of core polymers is also significantly inhibited. Varying the parameter above 20% in this case
produced almost linear reduction (roughly 10% per step), indicating that diffusion through
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Figure 6.23: Influence of drug loading, on swelling and erosion front, changes for fast erosion
release scenario (uncoated beads). The decrease in gel layer thickness is caused by the
lack of core material, due to the higher drug percentage. A constant gel layer thickness is
achieved, but the collapse of the core does not allow it to be maintained for a prolonged
time due to lack of swelling.
the coating was not impacted and the majority of trapped drug was in the core. Observing
scenarios where swelling of the core is a greater force driving the release, the inability of drug
to diffuse through the coating can be shown to exponentially increase as the entanglement
probability gets bigger. In the case of balanced dissolution, (Figure (6.27)), the difference
in release between 10% and 20% entanglement probabilities is more pronounced, while in
the case of highly swellable cores it is marked in the extreme. Therefore, the erodability of
the core plays a major role in preventing negative impact on release.
6.2.3 Results for Variable rate swelling models
As described in the section 4.3.2, SCDDb model is based on the experimentally observed
behaviour of gelatine to have a non-constant swelling rate, (decreasing either exponentially
or sigmoidally). As the non-linearity constants of the equations (4.18) and (4.19) cannot be
derived from the available experimental data, it is of interest to compare a set of simulated
profiles for three cases: (i) constant swelling probability (Laaksonen et al., 2009a); (ii)
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Figure 6.24: Influence of drug loading, on release and front changes, for an equal erosion
and swelling release scenario (uncoated beads). (top) The increase in release rates with
increase in drug is attributed to smaller gel layer due to increased amount of drug solids.
(bottom) The decrease in gel layer thickness is ascribed to the lack of core material due to
higher drug percentage. Equal influence of erosion and swelling results in constant gel layer
thickness leading to stable release.
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Figure 6.25: Influence of drug loading, on release profiles from uncoated beads, displaying
fast swelling behaviour. The initial increase and subsequent rapid decrease in release rates
with increased drug amounts is attributed to larger area of the gel layer due to larger
swelling.
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Figure 6.26: Influence of drug loading, on swelling and erosion front changes, for a fast
swelling release scenario (uncoated beads). The decrease in gel layer thickness is ascribed
to the lack of core material due to higher drug percentage. The high variability in the wet
gel phase, as shown, generally leads to unstable release.
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Figure 6.27: Influence of increasing entanglement probability (Pentanglement = PC) for
release curves in the equilibrium release scenario. These curves show an exponential decline
due to the presence of swelling, which blocks the drug diffusion channels throughout the
core.
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Figure 6.28: Influence of increasing entanglement probability (Pentanglement = PC) with
the amount of solid drug remaining in the core in the “equilibrium” release scenario. The
amount of remaining drug shows an exponential increase due to the presence of swelling,
which blocks the drug diffusion channels throughout the core.
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Figure 6.29: Influence of increasing entanglement probability (Pentanglement = PC) for
release curves in the fast erosion release scenario. The release curves show a linear decline
due to lack of swelling with little impact on existing drug diffusion channels throughout
the core.
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Figure 6.30: Influence of increasing entanglement probability (Pentanglement = PC) with
the amount of solid drug remaining in the core in the fast erosion release scenario. The
difference in the amount of drug remaining shows that entanglement effect is not significant
as the speed of erosion did not allow blocking or clustering phenomena to occur.
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Figure 6.31: Influence of increasing entanglement probability (Pentanglement = PC) with
the amount of solid drug remaining in the core in the fast swelling release scenario. The
amount of remaining drug shows an exponential increase due to the amount of swelling,
which blocks the drug diffusion channels throughout the core.
0 200 400 600 800 1000 1200 1400
0 .
0
0 .
1
0 .
2
0 .
3
0 .
4
Entanglement percentage (coated, fast swelling)
time(minutes)
E n
t a
n g
l e
d  
d r
u
g ( f
r a c
t i o
n )
Pentanglement = 0.0
Pentanglement = 0.2
Pentanglement = 0.4
Pentanglement = 0.6
Pentanglement = 0.8
Pentanglement = 1.0
Figure 6.32: Influence of increasing entanglement probability with amount of solid drug
remaining in the core in the fast swelling release scenario. The amount of remaining drug
shows high exponential increase due to presence of swelling, which blocks the drug diffusion
channels throughout the core.
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Figure 6.33: The effect of changing a swelling probability that is constant during the time
of the simulation. Resulting profiles show a constant decrease with increased swelling.
exponentially decreasing swelling probability (Tanaka and Fillmore, 1979), (Li and Tanaka,
1990) and (iii) sigmoidally decreasing swelling probability (Singh and Weber, 1996).
Figures (6.34) and (6.35) show the results obtained for the case of a highly swellable
scenario. Figure (6.30) shows the effect of varying a constant swelling probability (PS)
across the full value range [0, 1]. The resulting profiles show a uniform decrease with
increased swelling, which seems in relatively poor agreement to what would be expected in
vitro (Laaksonen et al., 2009a). This can be explained by the fact that swelling plays a
major role at the start of the dissolution process, while later it can be less relevant as the
amount of remaining material is low. In the case of exponential and sigmoidal probability
change, the initial swelling rate is always high, it is only the dropoff rate that changes. This
is apparent from Figures (6.34) and (6.35) where the difference is more pronounced at later
stages of the release curve.
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Figure 6.34: Effect of variable swelling probability on drug release curves in the case of
exponentially decreasing PS .
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Figure 6.35: Effect of variable swelling probability on drug release curves in the case of
sigmoidally decreasing PS .
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Figure 6.36: Visualisation of the MCES model with relevant cell types. The spheres show
progression from initial to the dissolved state through different dissolution environments
(HCl and SDS). Green indicates the gel layer, and red the solid gel state.
6.3 Simulations for model for multiple coated drug devices
(MCES), Section (4.4)
6.3.1 Validation against experimental data
First MCES model runs, (Section 4.3), were performed for the purpose of comparing
simulation results with available in vitro experimental data for Surelease/Opadry coated
devices provided by Sigmoid Pharma. A set of simulation parameters, corresponding either
to direct experimental observations or available literature, was chosen (Table 6.3). Then the
respective thicknesses of Surelease/Pectin and Opadry layers were varied to match those
values used in the lab experiments. Example visualisation of the performed simulations
through different environments (HCl and SDS) is given in Figure (6.36).
The average diameter (d) of the modelled sphere was set to 1.8mm (including both
coating layers of varied size). The diffusion coefficient (Df ) of Cyclosporine A was set at
2 · 10−6 cm2/s, placing it within the range of 0.96 · 10−6 − 5 · 10−6 cm2/s as measured by
Trammer et al. (2008), Park et al. (2013). Gelatin λ factor, (Equation (4.9)), and Opadry
lifetime were estimated from ranges observed during experiments. Based on improved
understanding of the main release control phenomena, (obtained during development of
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previous models), the swelling probability (PS) was estimated to be in the low range, as
swelling of the core, especially in double coated formulations was not observed to be marked.
Relative rate of diffusion of water into the Surelease layer (PW ) was estimated based on
measurements made by Ravindra et al. (2000) and the CyA diffusion coefficient (Equation
(4.20)) and found to be around 0.16. A similar derivation was performed for the case of
water diffusion into the core layer (PWG) using available gelatine/water interaction data
from Domenek et al. (2008) which gave an experimental value of approximately 10−8 cm2/s,
resulting in relative speeds of approximately 10−2 when compared with the main diffusion
coefficient. Probability of the clustering/blocking phenomenon was kept at zero, under the
assumption that presence of Opadry inhibits this process from occurring. Finally, as the
in vitro solution was changed after two hours from the acidic (HCl) to the enteric (SDS)
environment, we have kept the solubility of CyA low in HCl, (as reinforced by experimental
observations). The only parameter, where direct experimental values could not be obtained,
and where controlled, wet-lab investigation would be desirable was relative diffusion of
Cyclosporine A through the Surelease membrane. This had to be estimated by comparing
available release curves and sensitivity analysis data. The value chosen agreed with most of
the experimental curve profiles used, but it would be of interest to validate this in isolated
in vitro experiments on Surelease slabs. The duration of the simulation was 24 hours,
corresponding to experiment, with control values sampled at 1, 2, 4, 6, 12 and 24 hours
respectively. The values of the simulation parameters are summarised in Table 6.3.
For analytical comparison we used the similarity factor of Equation (6.1) with standard
weight factor as for Equation (6.2).
The obtained results are plotted in Figures (6.37) to (6.42) for each batch respectively,
and Table 6.4 summarises the similarity factors achieved. As shown, a very good match
was seen for different variations in thicknesses of both layers with similarity factors staying
in the range of 2% - 3% and not exceeding 8%. The only outlier was the batch using
relatively low amounts of Opadry (2.7%). As indicated from its graph (6.41) slower release
was observed, which seemed to be due to some clustering of gelatine occurring within the
bead, (even though in our models we assume this value to be zero), as the Opadry levels
used were not significant to inhibit this phenomenon fully. Overall, however, a majority of
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Parameter Simulation value Experimental reference
Sphere diameter 1.8 mm 1.8 mm
Df 2 · 10−6 cm2/s 0.96 · 10−6 - 5 · 10−6 cm2/s
Gelatin λ 60 min 60 - 120 min
Opadry(c) lifetime 120 min 30 - 120 min
PS 0.3 0 - 0.5
PW 0.16 0.16
PWG 0.01 0.01
PP 0.2 N/A
PC 0.0 0.0
HCl solubility 0.0 0.0
SDS solubility 1.0 1.0
Duration 24 h 24h
Table 6.3: MCES model parameters used for comparison with experimental data. The
reference parameters were derived from batch data, experimental observations and literature.
The coating permeability was estimated based on simulated model data ranges.
Modelled batch Achieved similarity factor
11-085 (10% Opadry, 11% Surelease, 10% d.l.) 73.46 ( 3%)
11-086 (10% Opadry, 17% Surelease, 10% d.l.) 86.01 ( 2%)
11-115 (10% Opadry, 23% Surelease, 10% d.l.) 72.01 ( 3%)
11-227 (6.3% Opadry, 10.3% Surelease, 10% d.l.) 82.9 ( 2%)
11-241 (2.7% Opadry, 12.1% Surelease, 10% d.l.) 46.17 ( 12%)
12-119 (10% Opadry, 11% Surelease, 15% d.l.) 54.96 ( 8%)
Table 6.4: Values of the similarity factor (f2) for different modelling scenarios. Results
show a good match within the limits of sample variability.
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Figure 6.37: Experimental vs. simulated results for batch 11-085 with 10% of Opadry and
11% of Surelease/Pectin layer weight gains respectively. The achieved similarity factor was
73.46 (indicating less than 3% difference in release profiles).
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Figure 6.38: Experimental vs. simulated results for batch 11-086 with 10% of Opadry and
17% of Surelease/Pectin layer weight gains respectively. The achieved similarity factor was
86.01 (indicating less than 2% difference in release profiles).
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Figure 6.39: Experimental vs. simulated results for batch 11-115 with 6.3% of Opadry and
12.1% of Surelease/Pectin layer weight gains respectively. The achieved similarity factor
was 72.01 (indicating less than 3% difference in release profiles).
simulation results were in good agreement with experiment, suggesting a large degree of
confidence in the models’ ability to react correctly to main design parameter changes.
6.3.2 Sensitivity analysis
Following validation of the MCES model as useful for modelling controlled release from
double coated spheres in Section 6.3.1, we investigated its ability to predict factors influ-
encing zero- or near zero-order release in several dissolution scenarios. We chose to analyse
the effect of the MCSE model parameters in three key cases: (i) where erosion/diffusion
is the dominant release phenomenon; (ii) where swelling of the polymer core is the main
phenomenon and (iii) where both phenomena are contributing equally. All three scenarios
are examined over a range of both design and internal parameters.
Influence of ethylcellulose/pectin coating thickness
The first parameter investigated was the thickness of the outer, ethylcellulose/pectin, layer
which is a major factor influencing release behaviour.
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Figure 6.40: Experimental vs. simulated results for batch 11-227 with 10% of Opadry and
23% of Surelease/Pectin layer weight gains respectively. The achieved similarity factor was
82.09 (indicating less than 2% difference in release profiles).
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Figure 6.41: Experimental vs. simulated results for batch 11-241 with 2.7% of Opadry and
23% of Surelease/Pectin layer weight gains respectively. The achieved similarity factor was
only 46.17 (12% match). We explain this by the fact that release was significantly slower
when compared to other experiments and reached the plateau at around 90% indicating
some clustering effects were occurring due to low concentrations of Opadry.
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Figure 6.42: Experimental vs. simulated results for batch 12-119 with 10% of Opadry and
11% of Surelease/Pectin layer weight gains respectively. The drug loading in this case was
15% of mass. Achieved similarity factor was 54.96 (less than 8% difference).
Figure (6.43) shows the influence of changing the thickness for the case of fast eroding
spheres. As expected, increase in thickness causes a decrease in release rate greater than
that observed in the SCDD model. It also increases the initial delay as water needs more
time to penetrate ethylcellulose polymeric chains, degrade the Opadry coat and only then
penetrate the gelatine core. Examining values of Peppas n factor, this decreases with
thickness increase and indicates strong Case II, erosion controlled release, consistent with
the expectations of the used parameter set. Best values (n = 0.86) were obtained for
small coating thicknesses indicating that thinner coatings produce curves consistent with
zero-order release (n = 0.85). The n factor further increases as the coating thickness
increases going further into the region of erosion controlled release.
Figure (6.44) represents corresponding dissolution radii change of the core sphere,
indicating that the core radii dynamics are not affected by thickness change. The delay
factor caused by the thicker coatings is visible as it also delays the start of the swelling
process. The results are consistent with the erodible device with constant gel layer thickness,
although, (as indicated by the Peppas factor), erosion forces do play a major role in release.
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Figure 6.43: Influence of outer coating (Surelease) thickness on resulting drug release
curves. The thickness was varied from 0.04 mm to 0.16 mm and causes a decrease in overall
release. The profiles closer to zero-order release were better correlated with smaller coating
thicknesses with 0.04 mm giving Peppas n values of approx 0.86.
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Figure 6.44: Influence of outer coating (Surelease) thickness on resulting core radii. The
delay in the start of the swelling process is visible from the picture. The gel layer thickness
was constant indicating good zero-order release potential. However a rapid erosion dynamic
in the model was the main driver of release.
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Figure 6.45: Influence of outer coating (Surelease) thickness on resulting drug release
curves. The thickness was varied from 0.04 mm to 0.16 mm and causes a decrease in overall
release. However, this shows better potential for zero-order release than the rapidly erodible
device. Profiles closer to zero-order release were again better correlated with smaller coating
thicknesses with 0.04 mm giving Peppas n values of 0.85, indicating zero order release was
achieved.
Figures (6.45) and (6.46) analyse the same coating variation, but this time for a scenario
where swelling and erosion forces are approximately equal. We observe similar effects for
drug release rates and for thinner coatings (due to more constant release in the desired
area), with good n values obtained (0.85) indicating zero-order release from the sphere.
Radii behaviour shows more stable core degradation, with larger but still not significant
swelling effect. The gel layer thickness was constant throughout the release, showing that
balancing erosion and swelling phenomena in the core material helps to achieve more stable
release, which is in agreement with results obtained in Laaksonen et al. (2009a).
Finally, we looked at the other end of the spectrum by simulating the coating influence
in a “fast swelling” scenario. It is important to note here that rapid swelling will also lead to
rapid subsequent erosion (as polymer chains will disentangle fast and thus undergo increased
exposure to the surrounding buffer much more quickly, leading to their degradation). This
is also reported by Laaksonen et al. (2009a) However, the initial swelling will influence the
release profile differently from erosion. Figures (6.47) and (6.48) present resulting release
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Figure 6.46: Influence of outer coating (Surelease) thickness on resulting core radii for the
“equilibrium” scenario. Gel layer thickness was constant, indicating good zero-order release
potential, with erosion and swelling dynamics balancing each other.
behaviour. The release is faster in general as the swelling polymer chains are carrying
the drug particles out of the sphere. Once the core material is spent, a similar residual
release profile is exhibited across all values of the parameter. The best n factor obtained is
0.87, slightly worse than for the equilibrium scenario in terms of obtaining constant release.
The resulting radii in Figure (6.48) show the expansion/collapse behaviour of the quickly
swellable polymer.
Influence of Opadry R© coating thickness
Figures (6.49) - (6.54) show release and dissolution radii profiles when varying the thickness
of the inner, Opadry coating, across all three dissolution scenarios. Although smaller, a
significant effect on release exists, with thinner coatings again achieving a better value of
Peppas n factor (0.92). It is worth pointing out that the variation in Opadry thickness
does not take into account the possible occurrence of the clustering/blocking effect and we
assume that the smallest coating thickness used is enough to allow complete dissolution of
the gelatine core. The results obtained show that the release is still in the erosion-dominated
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Figure 6.47: Influence of outer coating (Surelease) thickness on resulting drug release curves
for “fast swelling” cores. The thickness was varied from 0.04 mm to 0.16 mm and led to
decrease in overall release. Profiles closer to zero-order release were slightly worse than the
“equilibrium” scenario with the best Peppas n of 0.87.
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Figure 6.48: Influence of outer coating (Surelease) thickness on resulting core radii for the
fast swelling scenario. Profiles illustrate a quick expansion/collapse of the swelling polymer.
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Figure 6.49: Influence of inner coating (Opadry) thickness on the resulting drug release
curves for cores, where swelling and erosion are in equilibrium. The thickness was varied
from 0.08 mm to 0.24 mm and led to somewhat smaller decrease in overall release when
compared to effect of outer coating variations. All profiles show erosion-controlled behaviour
with the best Peppas n = 0.92.
zone.
Diffusion of drug through polymer coating
Here we look at the influence of the PP parameter which controls the relative diffusion speed
of drug packets through the outer coating. Figures (6.55) to (6.57) present simulation results
corresponding to varying PP in range from 0.2 to 0.8. Although the relative difference
between release curves is small, their categorisation according to the Peppas n factor
shows the increase in the contribution of diffusion to the release, moving the profiles from
erosion-controlled into the anomalous phase. The value of n ranges from 0.83 (for fast
erosion scenario) to 0.61 (for fast swelling scenario). The erosion and swelling radii are not
impacted by changes in diffusivity of the coating. Although previously reported work deals
with the same phenomena in the core, rather than coating, the underlying mechanism and
the results obtained are similar to those of Narasimhan (2001) which investigated the effect
of drug diffusion on the release profiles.
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Figure 6.50: Influence of inner coating (Opadry) thickness on resulting core radii for the
“equilibrium” scenario. The profiles illustrate a constant gel layer thickness throughout the
release.
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Figure 6.51: Influence of inner coating (Opadry) thickness on resulting drug release curves
for cores where erosion is the dominant force. The thickness was varied from 0.08 mm to
0.24 mm and all profiles show strong erosion-controlled behaviour with the best Peppas n
= 0.94.
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Figure 6.52: Influence of inner coating (Opadry) thickness on resulting core radii for the
“fast erosion” scenario. The profiles illustrate a constant gel layer thickness although the
core collapse is also rapid, resulting in a somewhat stronger erosion controlled behaviour.
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Figure 6.53: Influence of inner coating (Opadry) thickness on the resulting drug release
curves for cores where swelling is strong. Thickness was varied from 0.08 mm to 0.24 mm.
The profiles still show strong erosion-controlled behaviour with the best Peppas n = 0.93.
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Figure 6.54: Influence of inner coating (Opadry) thickness on the resulting core radii for
the “fast swelling” scenario. The profiles illustrate an expanding gel layer, causing fast core
collapse.
As the inner coating is not permeable to drug and collapses quickly during bead
dissolution it is not of particular importance.
Influence of drug loading to release profiles
Finally, we examine the effect of drug loading on the release profiles from double coated
devices. We varied the loading from 20% to 80% of the mass of the sphere for the three
distinct scenarios and the results are shown in Figures (6.58) to (6.63). The results agree
with observations reported by Siepmann and Peppas (2001), where increasing the drug
volume caused a decrease in release curves due to larger dominance of the drug solid phase.
The influence of drug volume has the biggest impact on the release of swellable devices,
but, for the purpose of achieving zero-order release, lower concentrations are desirable and
lead to the best results (values of n are 0.85, 0.82 and 0.87 for fast erosion, equilibrium
and fast swelling scenarios, respectively). Higher drug concentrations lead to less polymer
material in the core, and hence increased erosion, as evidenced by both the increase in
Peppas factor and the radii changes in Figures (6.59), (6.61) and (6.63).
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Figure 6.55: Influence of PP changes on the release profiles in the “fast erosion” scenario.
PP was varied from 0.2 - 0.8 with 0.2 step. Results show an increase in dissolution speed
with profiles moving through the anomalous region (0.66 ≤ n ≤ 0.83) towards a more
Fickian, diffusion controlled release.
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Figure 6.56: Influence of PP changes on the release profiles in the “equilibrium” scenario.
PP was varied from 0.2 - 0.8 with 0.2 step. Results show an increase in dissolution speed
with profiles moving through the anomalous region (0.69 ≤ n ≤ 0.78) towards a more
Fickian, diffusion controlled release.
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Figure 6.57: Influence of PP changes on the release profiles in the “fast swelling” scenario.
PP was varied from 0.2 - 0.8 with 0.2 step. Results show an increase in dissolution speed
with profiles moving through the anomalous region (0.61 ≤ n ≤ 0.82) towards a more
Fickian, diffusion controlled release.
The results of the analysis are summarised in Table (6.5). For the general case model
usage, in terms of understanding the parameter influence described here, it is important to
note the direction of change in n rather than its absolute value, as the Peppas factor is
influenced by many key parameters of the model (for example drug diffusion coefficient as
the main rate limiting factor).
Influence of dissolution environment on release profiles
Lastly, we investigated the influence of certain properties of the dissolution environment
itself in order to understand how factors such as drug solubility and temperature differences
can be modelled.
Figure (6.64) shows the effects of applying solubility and dissolution rate limitations
to drug release from the modelled device, (Equations (4.22) and (4.21)). We applied the
two together as they describe related phenomena. As shown, we can effectively model the
gradual drop in solubility as the drug approaches the fixed solubility rate. This enables
the “cap” value to be included in the model once the solubilisation effect of a particular
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Figure 6.58: Influence of drug loading levels on release curves for the “equilibrium” scenario.
The loading was varied from 20% to 80% with 20% steps. The Peppas factor ranges from
anomalous behaviour (0.82) for 20% to case II erosion-controlled behaviour (1.1) for 80%
consistent with the increase in solid drug state and decrease in polymeric material in the
core.
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Figure 6.59: Influence of drug loading levels on the main dissolution fronts for “equilibrium”
scenario for levels of loading ranging from 20% to 80%. The decrease in front size is directly
related to decrease in available polymeric material in the core.
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Figure 6.60: Influence of drug loading levels on the release curves for the “fast erosion”
scenario. The loading was varied from 20% to 80% with 20% steps. The Peppas factor
ranges from zero-order release (0.85) for 20% to case II erosion-controlled behaviour (1.16)
for 80% consistent with the increase in solid drug state and decrease in polymeric material
in the core.
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Figure 6.61: Influence of drug loading levels on main dissolution fronts for the “fast erosion”
scenario for levels of loading ranging from 20% to 80%. The decrease in front size is directly
related to decrease in available polymeric material in the core.
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Figure 6.62: Influence of drug loading levels on release curves for the “fast swelling” scenario.
The loading was varied from 20% to 80% with 20% steps. The Peppas factor ranges from
near constant release behaviour (0.87) for 20% to case II erosion-controlled behaviour (1.09)
for 80% consistent with the increase in solid drug state and decrease in polymeric material
in the core.
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Figure 6.63: Influence of drug loading levels on main dissolution fronts for “fast swelling”
scenario for levels of loading ranging from 20% to 80%. The decrease in front size is directly
related to decrease in available polymeric material in the core.
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Modelled scenario Peppas n range Release phenomena
Thickness of the outer coating 0.85 - 1.19 Erosion dominant over
swelling with increasing values
of the parameter.
Thickness of the inner coating 0.94 - 1.12 Erosion dominant with increas-
ing values of the parameter.
Smaller influence when com-
pared to outer coating.
Coating diffusivity 0.61 - 0.83 Diffusion becoming a domi-
nant process with increasing
values of the parameter. Ex-
treme values lead to Fickian
behaviour.
Drug loading 0.82 - 1.16 Erosion of the core driving the
release as core material is re-
placed by the drug. Swelling
more pronounced for lower val-
ues.
Table 6.5: Summary of the parameter sensitivity analysis presented in this section. Results
show that model is able to simulate a wide range of dominant release phenomena.
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Figure 6.64: Influence of various drug solubility levels on release curves. Drug release
reaches a plateau at expected levels, with a slow decline in drug dissolution rates.
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Figure 6.65: Examining the effect of changes of environmental temperature on drug diffusion
speeds shows negligible differences.
environment on the drug is known.
Additionally, Figure (6.65) shows the influence of environmental temperature on the
release curves, correctly predicting increased release due to increased diffusion rate. In the
case of the modelled drug (Cyclosporine A) the differences are small and have little effect,
but drugs with lower diffusion rates might be expected to have a larger shift.
6.4 ACA experimental results, Section (4.6)
For each of the described update mechanisms, simulations investigated the following:
• The shape of the release curve during a 24hr period, (characteristic of GI tract
transition time for the drug) (Figure (6.66) left)
• The radii of two main reaction fronts (Figure (6.66) right).
• The device composite structure changes during characteristic stages of the dissolution,
(visualisation of details) (Figure (6.67)).
In Figures (6.66a1), (6.66a2) and (6.67a) we show the results for synchronous updates,
(used as a basis for relative comparison with all subsequent ACA methods). Comparing with
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Figure 6.66: (left) Drug release curves during a 24hr simulation period for different update
methods (blue - release curve, grey - synchronous reference value); (right) Bead radii
changes over time (green - swelling front, blue - erosion front, black - core radius).
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random order updates, (Figures 6.66b1, 6.66b2, 6.67b), we find a good match, with negligible
release curve difference, (indicating that the methods are effectively interchangeable e.g.
where synchronous update is deemed more appropriate, (for specified structure for example
(Bezbradica et al., 2012)).
Figures (6.66c1/d1), (6.66c2/d2) and (6.67c/d) show possible alternatives to the asyn-
chronous random order method. It can be seen that the random independent selection
(Figure (6.66)d1) produces release curves, which are significantly shifted with respect to
expectation, although radii behaviour is similar, in the sense that polymer transitions occur
at the same rate. Features, which give rise to this discrepancy, can be observed in model
visualisations, where large drug clusters (black diamonds) occur as a consequence of some
cells being updated more often than others, (Figure (6.67d)). Random cyclic updating, on
the other hand, produces release curves which are qualitatively similar to those expected,
(Figures (6.66c1), (6.66c2) and (6.67c)), although radii decrease dynamics are much slower.
Finally, Figures (6.66e1), (6.66e2) and (6.67e), show results obtained using sequential
matrix sweeps. This approach is not recommended due to the significant bias, which can
be observed in the visualisation, leading to highly non-realistic radii dynamics.
It is also important to note that our results do not display the variance associated
with many CA models when switching from asynchronous to synchronous updates, (Fatès
et al., 2006; Sloot et al., 1999). As the stochastic model is both slow changing, with usual
probability values used «1, and highly symmetrical, due to the spherical device geometry,
results obtained do not show highly anomalous results. This is in line with theorems
presented in Toffoli and Margolus (1987) relating to equivalence between slow changing
synchronous and asynchronous update processes in CA models.
As a final assessment, we examined the overall performance in terms of simulation
length using different ACA mechanisms in thread-level execution context. As expected,
sequential algorithms were the fastest, as these could utilise the CPU memory cache better.
The random cyclic variants also perform well, which might make them an optimal choice for
the scenario where the simulation efficiency is needed, as opposed to state update realism.
The worst performers are the random order algorithms which are not able to leverage the
processor cache, due to constantly changing order of memory access. However, these offer
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Figure 6.67: Model visualisation for 10, 30, 150, 400 and 700 minute intervals, respectively:
(a) synchronous; (b) random order; (c) random cyclic; (d) random independent; (e) fixed
cyclic sequential.
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Figure 6.68: Comparison of parallel and total simulation times for different synchronous
and asynchronous update mechanisms. The examined mechanisms are, in order, FCS1 -
Fixed Cyclic Sequential (1st variant); FCS2 - Fixed Cyclic Sequential (2nd variant); RC -
Random Cyclic; RI - Random independent; RO - Random Order.
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the best simulation realism and precision when compared to the synchronous variant, so
the pros and cons of each should be weighed when making the decision. Figure (6.68)
shows the performance gains associated with switching between different asynchronous
update methods. We can observe that methods which utilise the CPU caching better due
to the inherent order of updates generally perform better. Figure (5.7) (middle) shows
the performance profile for synchronous updates when switching from a thread-level to
process-level parallelisation model (Bezbradica et al., 2012). Although synchronous updates
do not perform to the same level as asynchronous ones, they do not have a parallelisation
limit, and thus, ultimately, can be scaled to any number of nodes allowed by the model size.
6.5 Summary
In this chapter we presented the results and accompanying analysis of simulation runs
performed for each of the developed models (described in Chapter 4). For each model,
two kinds of simulations were run. First type were the ones intended to validate to what
degree the models were able to simulate in vitro dissolution of an actual pharmaceutical
device. The second type focused more on the model outputs for different kinds of erosion
and swelling scenarios.
Results obtained during the experimental validation stage are promising and show that
probabilistic approach is viable for pharmaceutical modelling methods. The results obtained
by the ECDD model represented an initial “gauge” which was used to further refine the
cellular automata rules and derive more complex models (SCDD and MCES) whose match
with the experimental data was more satisfactory.
Running sensitivity analysis on all models, on the other hand, demonstrated the
versatility of the underlying modelling mechanism. We are able to simulate different
intrinsic polymer behaviours with only a change in the parameter set and add incremental
components, such as additional coatings to the modelled device. Utilising standard release
curve classification methodologies we are able to profile our results and get an insight into
the in vitro behaviour based on the simulated data.
Both investigations also emphasised the need for other methods as means to optimise
values of the input parameters, further explored through application of Inverse Monte Carlo
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methods, Chapter 7.
Finally, at the end of the presented chapter we digressed a bit into the computational
problematic of the asynchronous vs. synchronous approach to iterating over the simulation
space. We showed that choosing the proper iteration algorithm has a significant impact
on the obtained results and the simulation realism, and has to be taken into account
during model development. The type of asynchronicity chosen was not only shown to have
an influence to the release curves and dissolution fronts, but also on the overall model
performance. Our findings show that one of the most appropriate solutions is random
order asynchronous, but a synchronous solution is viable as well. In this regard, model
visualisation provides valuable additional insight on structural behaviour and dissolution
mechanisms, which is not readily apparent from working with standard release curve data
alone, or which is inaccessible from supplementary experiment. These findings could be
useful for future modelling scenarios where it may be necessary to switch from one update
mechanism to another, e.g. for large-scale optimisation, or in response to the need to
describe component interactions in various tailored solutions.
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Chapter 7
Inverse Monte Carlo
We have so far covered development and usage aspects of probabilistic drug dissolution
models in two main stages: model development - in which fundamental physico-chemical
laws are translated into model behavioural rules and model prediction - in which a con-
structed model is used to understand the physical system behaviour under novel parameter
combinations. In between the two, however, there is an essential phase of model calibration,
where the initial base mapping is established between the experimental results and the
starting set of model parameters that will be tweaked in the prediction phase, (Figure
(7.1)). We now focus on this calibration phase, in which it is essential to understand how
the structure of the model relates to experimental data, as this forms the basis of the later
predictive analysis.
In our examination of the suitability and application of Monte Carlo (MC) techniques
to modelling of drug dissolution system phenomena we have so far mostly paid attention
to the “direct” question. That is to say, starting from a set of parameters as the basis for
generating different probability distributions applied in the model space, we have measured
the resulting drug release curves. However, the values of the constituent parameters of
those sets can only be estimated from available experimental data. Noise is often an issue
and some parameters values are difficult to obtain without costly experimental analysis.
Also, various models include parameters, the purpose of which is simplification of model
realisation rather than direct one-to-one mapping with the physical world.
In the calibration phase, we turn the initial problem around by asking the inverse
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Figure 7.1: Successive stages of the modelling process. (1) During model development
behavioural rules are established to represent the physical processes occurring within the
modelled drug device. (2) During the calibration phase, certain (non-design) parameters,
values for which cannot be obtained from experiment, are examined and indicative ranges
investigated. (3) Finally, when both the rule set and base parameter values are known, the
model can be used to predict drug release curve changes for changes in design parameters.
question: starting with the experimental data given and assuming certain error margins,
what is the optimal set of model parameters that would describe the experimentally observed
system behaviour. The inverse problem is always posed within a certain set of constraints,
(well-known experimental conditions), so that the problem space can be constrained, in
order not to end up answering an extremely general question.
7.1 Applications of inverse modelling
IMC methods are a variation on the standard Metropolis-Hastings algorithm (Metropolis
et al., 1953), a Markov Chain Monte Carlo (MCMC) method that calculates random
sequences from a probability distribution, where direct sampling is not applicable (i.e. the
exact probability distribution function is not known). The aim of the method is to produce
a structural model which is consistent with one or more sets of experimental data (within
acceptable errors), and subject to a set of constraints. Its purpose is not to answer the
question of model correctness, as that cannot be known in the general case, but rather to
gauge the usefulness of the model in understanding the relationship between the structure
and some physical property (McGreevy, 2001).
It is important to emphasise here, before reviewing the specific inverse modelling
methods of interest to finding our solution, the difference between Inverse Monte Carlo and
standard data fitting methods (Mosegaard and Sambridge, 2002). The idea is to start from
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a known experimental model and derive the possible values of unknown input parameters.
In doing this, we must explore the parameter space. The best parameter set will, of course,
give the best match to the experimental results, but that is of secondary importance to
some sense. The value of parameters found in this way is they can be used for future
prediction, rather than to evaluate the direct model in itself!
7.2 Application of inverse methods for elucidation of unknown
parameter values; Sampling from multi-variate distribu-
tions
In this chapter, we apply the inverse Monte Carlo (IMC) algorithms to the solution of the
inverse problem posed at the beginning of this chapter. We present an approach based on
Metropolis-Hastings and Gibbs algorithms for sampling from the model parameter space.
As a preliminary, we explore possible approaches that help illustrate issues that can arise
during inverse modelling.
7.2.1 Sampling from joint parameter distributions
Simulated Annealing
At the core of inverse algorithms, (incorporating a general Bayesian approach), is sampling
from an unknown joint distribution of the parameter space. For a single-dimensional Normal
distribution, methods such as adaptive rejection sampling can be used, (Robert and Casella,
2011), although MC methods in general could be considered to be too costly for single
dimensional applications, where more direct numerical methods can be applied (Mosegaard
and Sambridge, 2002).
However, for multi-variate parameter problems, MC numerical methods give a consider-
ably better convergence rate, (order of N−1/2 as opposed to N−1/M , where N is the number
of iterations and M the number of dimensions in the problem space).
We present here several viable approaches to solving the inverse sampling problem in
drug dissolution models and outline the advantages and disadvantages of each. The methods
generally build on elements of each other, so represent a natural evolution in application to
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problems of increasing complexity, and we present them in this corresponding sequence.
The first approach utilises simulated annealing for finding the global optimum of a
release function in large, discrete search space. Each point of the search space (s), analogous
to a state of the physical system is considered, together with the function E(s) to be
minimised.
At each step, the heuristic would consider a neighbouring state s′ of the current state,
and decide between moving the system or remaining in the current state depending on the
resulting change to E(s). The idea of the algorithm is to be able to accept a non-greedy
step for E(s) with a given probability, so that the algorithm does not get trapped in a local
optimum and is able to converge ultimately to a global optimum.
We mark the probability of a transition between neighbouring states using an acceptance
probability function P (e, e′, T ) that depends on the energies e = E(s) and e′ = E(s′) of
states s and s′. T represents the globally varying parameter, (typically called temperature
in early applications of the algorithm). The acceptance probability function must tend
to zero when T tends to zero. Therefore, for sufficiently small values of T the system
will increasingly favour moves that reduce energy values. The temperature T thus plays
a crucial role in controlling the evolution of the state s of the system depending on its
sensitivity to variation of system energies. For large T , the evolution of s is sensitive to
coarser energy variations, while it is sensitive to finer energy variations when T is small.
Also, in order for the algorithm to converge, T has to decrease at each step following an
annealing schedule which has to end with T = 0.
The Metropolis-Hastings algorithm (M-H)
We have already mentioned the Metropolis-Hastings algorithm as one way of performing
the sampling operation from multi-dimensional distributions. The algorithm can be used
to draw samples from a desired probability distribution P (X¯), where X¯ represents the
parameter vector, as long as the function proportional to density is known. The resulting
set of samples constitutes a Markov chain whose distribution, after sufficient length of time,
matches that of the target. In most Bayesian sampling models, the density proportionality
constant, also known as the normalisation factor needs to be known, thus this category
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of algorithms offers a significant advantage by allowing a sample to be generated without
needing to know the proportionality constant. The algorithm works as follows:
1. An arbitrary probability density Q(x′|xt) is chosen, also known as the proposal density
or jumping distribution. This is used to sample a proposal value x′, given a known
sample value xt. The proposal distribution must be a symmetric one, with the most
commonly used being the Normal and Uniform distributions. The proposal density is
used to explore the probability space using a random walk, thus generating a Markov
chain.
2. Once the proposed new sample is drawn, we calculate the acceptance ratio a =
P (x′)/P (xt). If a ≥ 1 we accept the proposed value and if a < 1 then we accept it
with probability a. That is, we generate a uniformly distributed random number
from r = U(0, 1) and accept the sample if r ≤ a. This is done in order to avoid the
problem of the search algorithm being trapped in local minima.
3. The algorithm should settle down after a certain number of iterations, after which
only small oscillations around the candidate value are performed.
However, the Metropolis-Hastings algorithm can suffer from a number of disadvantages
to which we need to pay attention when analysing the results:
1. The samples suffer from the so called correlation problem. In this, nearby samples will
be correlated with each other and will not correctly reflect the desired distribution. In
order to avoid this, we can take every nth sample. We can also increase the jumping
width (the variance of the proposal distribution) but we have to avoid the likelihood
of sample rejection.
2. It takes some time for the samples to converge to the desired distribution, especially
if the starting point is in the low density region. Thus, a burn-in period is necessary,
where a number of initial samples are discarded.
For problems with a larger number of dimensions, it can be difficult to properly set the
proposal density and define the jumping width. An alternative approach is to use Gibbs
sampling, a variant of the original Metropolis-Hastings algorithm.
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Gibbs Sampling
The Gibbs sampler generates an instance from the distribution of each variable in turn,
conditional on the current values of the other variables. This sequence of samples constitutes
a Markov chain converging to the desired joint distribution after a certain burn-in period,
making it ideal for Bayesian applications as they are typically specified as a collection of
conditional distributions.
The steps of a Gibbs sampling algorithm can be specified as follows:
• Suppose we want to generate samples from vector X¯ = {x1, x2, ..., xn} that follows
a joint distribution p(x1, x2, ..., xn), and denote such a sample in i-th iteration as
X¯(i) = {x(i)1 , x(i)2 , ...x(i)n }
• We assume (using e.g. known experimental data or system constraints) an initial
value of the parameter vector X¯(0)
• For each sample i = {1, 2, ...k} we sample each variable x(i)j from the distribution
conditional on the value of all other variables. The associated probability is thus:
p(x
(i)
j |x(i)1 , ..., x(i)j−1, x(i)j+1, ..., x(i)n )
The resulting samples approximate to the desired joint distribution of all the variables.
In addition, we can also approximate the marginal distribution of any subset of variables
by simply examining the samples for that subset and the expected value of any variable
can be approximated by averaging over all the samples.
The initial values for X¯(0) can either be assumed from experimental data, set randomly
(using a simple uniform distribution for example) or obtained from some other algorithm,
such as Expectation-Maximisation (Dempster et al., 1977).
As with Metropolis-Hastings, it may be necessary to apply burn-in periods and thinning1
to ensure good convergence and avoid correlation between the nearby samples.
1Thinning represents selecting every nth sample, where n is taken from the empirical observations of
the inverse process. This allows ignoring small oscillations in obtained acceptance results.
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7.3 Bayesian credibility intervals
In Bayesian inference, credibility intervals are the analogue of confidence intervals in
frequentist probability2. However, unlike the confidence interval, which is defined as an
estimated range of values which is likely to include an unknown population parameter,
credibility intervals tell us how likely it is for the parameter to reside within a given
contiguous interval [a, b]. The tightness of the interval (in both definitions) is denoted by
value α, such that (1-α)% of the probability mass is within the interval. One usual measure
is a 95% credibility interval, describing the 95% chance that the real value is within the
given boundaries.
There are two main conventions for determining interval boundaries:
• We choose the shortest possible interval which encloses (1-α)% of the posterior mass.
This is called a “highest posterior density” or HPD credibility interval.
• We choose the interval boundaries so that an equal amount of the probability mass
lies on either side of the interval. This is called a “symmetric” credibility interval.
7.4 IMC Algorithm Description
In combination with direct MC methods, our IMC algorithm depends on several key
properties. First, direct MC model inputs are structured into vectors of individual parameter
values:
X¯ = {X1, X2, ..., Xn} (7.1)
Where each Xi corresponds to one of the fundamental Direct MC model parameters,
(e.g. λ factor describing polymer lifetime or various diffusion probabilities).
Starting from these parameters there exists a measurable model output Y for the
given parameter vector X¯, (the simulated release curve) and there exists a corresponding
2Frequentist probability considers a definition of a random event as an absolute in terms of occurrences
during a controlled experiment. Bayesian methods on the other hand deal with probability of an event
relative to another that might have previously occurred.
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experimental measure to which the simulated output can be compared, within some margin
of error (usually experimental batch data with standard measurement error):
Y = F (X¯) + Θ(X¯) (7.2)
where F (X¯) denotes the deterministic part of the functional dependency between the
system input and output and Θ(X¯) is the stochastic part resulting from uncertainties and
noise in the physical model, (Barat, 2006)
A set of constraints is placed on the possible values of the input vectors to limit the
parameter space. These constraints are made based on understanding of the physical system.
A constraint can also, for example, discard input vectors which produce experimental data
outside of the acceptable error limits without performing the minimisation at all. In our
DDS case, the constraints come from experimental data that it is possible to measure: most
importantly this includes the major diffusion coefficient of the drug, coating thicknesses
and properties of constituent polymers.
An initial configuration of the model X¯init (selection of the initial parameter vector) is
made. This selection can be random, but it is useful to start with a reasonable estimate in
order to avoid long algorithm convergence rates or the isolated space problem. In principle,
IMC modelling is independent of the starting configuration, so this requirement is not a
strict one. However, in practice, the convergence time can be drastically shortened except
for the simplest of cases. Also, we make here an important assumption that any point
in our parameter space is reachable from any other point by repeatedly sampling from
posterior distributions of individual parameters.
For each parameter in the input vector, there exists a means of generating a new
sample based on the value of the previous one, thus creating a Markov chain. This can be
achieved by selecting an initial proposal density or jumping distribution, Q((X˘)|Xt), usually
a Gaussian, based on the value of the initial parameter Xt ∈ X¯init, and then modifying that
density if the new parameter value gives better agreement with the experimental data than
was previously available. The adjustment is achieved by use of an appropriate sampler,
e.g. with the Gibbs, (Geman and Geman, 1984) or a Particle filter method, (Doucet et al.,
2001).
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Figure 7.2: An illustration of bi-variate MVN for different values of µ and Σ. Adapted
from (Ng, 2013).
In our case, since the values of the model parameters have an expected value that can
be assumed to lie in a certain narrow range, using a Gaussian as a prior might present
itself as a natural choice. In context of the full parameter vector sampling however, this
translates into sampling from a multi-variate distribution, so we will use the Multi-Variate
Normal (MVN), and its truncated form as the source distribution.
The MVN distribution represents a generalisation of the Gaussian distribution to higher
dimensions and can be used to represent k -valued random vectors whose every linear
combination has a univariate normal distribution. It is often used to describe any set of
real-valued random variables centered around a mean value (Figure (7.2)). In our case this
would be any likely set of parameters which describes a system with the same or very similar
release behaviour compared to the experimental one. The spread of these “parameter points”
describes the stability of the system solution and is represented through the deviation of
the MVN. The MVN can be written using the following notation:
X ∼ Nk(µ,Σ) (7.3)
where X is the k -dimensional parameter vector taking values from Rn, µ is the k -
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dimensional mean vector:
µ = [E[X1], E[X2], ..., E[Xk]] (7.4)
and Σ is a k × k positive, semi-definite covariance matrix
Σ = [Cov[Xi, Xj ]], i = 1, 2, ..., k; j = 1, 2, ..., k (7.5)
It can be said that a variable X ∈ Rn is multivariate normal if any linear combination
of X is univariate normal, i.e. aX = Σni=1aiXi,∀a ∈ Rn is normally distributed.
We make an assumption here that the set of parameters in our model is independent
(and indeed, this is a consequence of the way in which the direct model has been constructed,
since each one of the constituent parameters describes an independent property of the
model - a single physico-chemical process), and we can generally assume that each of these
parameters follows a normal distribution centered on the theoretically precise value and
with a variation that represents the natural variation effects of the polymeric structure.
If we assume then that possible values for each of the model parameters Xi are normally
distributed with N(µ, σ2), the combined parameter vector of our model X is a multi-variate
normal distribution with N (µ,Σ), where µ = (µ1, µ2, ..., µn) and the covariance matrix is
given by:
Σ =

σ21 0
σ22
. . .
0 σ2n

(7.6)
where σ2i represents the variance of individual distribution components.
In addition, as each of the model parameters is bounded by some limit (a, b), representing
either a physical constraint, (for example the polymer degradation lifetime always larger
than zero), or a mathematical constraint, (probabilities always drawn from [0, 1] interval),
parameter sets are not from the MVN distribution itself, but rather from its truncated, uni-
and multivariate, version. Although more efficient methods for sampling from truncated
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distributions including specialised MCMC and Gibbs sampling have been proposed in the
literature (Kotecha and Djuric, 1999) we have chosen to use a simpler rejection sampling
method as the number of variable parameters is not too large. However, if better performance
is desired or the parameter set is large, specialised sampling methods are an option.
Finally, as we are using Gaussians to define priors of individual parameters, we need to
know their mean and standard deviations. As those are unknown (and essentially, explored
using the sampling algorithm itself), we assume an adaptive approach.
We start from a reasonable estimate of µ and σ for every parameter. As the sampling
algorithm should converge to the optimal values, the estimate can essentially be anything
with good coverage of the valid parameter range [a, b], but choosing estimates for µ based
on expected subranges of [a, b] would yield faster convergence. Based on the mean of the
prior distribution, the measure of difference to the experimental results and the spread of
the accepted parameter values, we can calculate the µ and σ of the posterior distribution.
Based on these, we can define the transition of the inverse algorithm from iteration i to
iteration i+ 1:
N (k) (µi,Σi)→ X(k)i → F
(
X
(k)
i
)
→ χ2i → A
(
χ2i
)→ N (k) (µi+1,Σi+1) (7.7)
Where A(χ2i ) is an acceptance function the result of which is used to accept or reject
a particular input vector and χ2 is the measure of fitness between the simulated and
experimental results:
χ2 =
Σ (yobs − F (X))2
σ2
(7.8)
With all of the above defined, we can run the IMC algorithm in several steps:
1. Define the initial input parameter vector - X¯init,
2. Pass the vector through a Gibbs sampler to obtain the next proposal sample,
3. Run the direct simulation with the proposed sample and quantify the simulation
output based on the indicator of χ2 value for the agreement between simulated and
experimental values at key measurement points,
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Figure 7.3: Graphical representation of the main stages of Inverse Monte Carlo algorithm,
used for deduction of unknown parameter sets. Arrows indicate the flow of information
between different steps.
4. Use an acceptance function A(X, χ2) that will set the next sample as the current
sample and modify the mean and standard deviation of the input parameters if the
χ2 is the best one obtained so far,
5. Repeat the procedure until the set of acceptable input values converges to a narrow
set that satisfies all the constraints. The resulting mean and standard deviation will
then describe the possible range of interest for the given parameter.
The main stages of the algorithm are illustrated in Figure (7.3).
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7.4.1 Algorithm optimisations
The Gibbs sampler usually requires from several hundred to several thousand iterations in
order to converge to the desired distribution. Also, a certain number of initial samples is
usually discarded as the burn in period. This number of forward simulations can place a
significant performance penalty that makes minimisation of running time of each iteration
of primary importance if convergence time is to be reduced.
As the runtime of forward simulation is a constant, there are two possible approaches
to optimisation of the total convergence time. One approach is to increase the number
of forward simulations run in each iteration of the algorithm and the other is to reduce
the sample space. We focus on the former optimisation and reduction of the sample space
using a simplified approach based on sensitivity of the output to parameter variations. We
also outline the possible algorithm improvements for sample space reduction using the
neighbourhood algorithm in Section 7.6.
Increasing the number of forward iterations is achieved by parallelising the sampling
and forward simulation steps of the IMC algorithm. Instead of taking one sample at a time,
we draw n distinct samples from the same prior and run a simulation for each at the same
time. At the end, we can accept the best sample as the next one and modify the mean and
standard deviation of the priors as already described.
Further optimisation can be achieved by examining the sensitivity of the release curve
for different simulation parameters (e.g. using a standard sensitivity analysis approach).
As it is common for small variations in parameter values to produce nearly identical results,
then if absolute precision of those values is of secondary importance we can reduce the
sample space by discretising it to some acceptable precision before sampling occurs. This
will drastically reduce the sample size and allow us to perform an exhaustive search in
realistic time. The discretisation and loss of precision could result in somewhat larger
standard deviation and thus less precise mean estimates of the parameter values, but these
are still useful for the purposes of modelling.
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7.5 Simulations and Results
In order to validate the approach presented above in a practical experimental setting, we ran
the inverse simulation of our double coated model described in Chapter 4 with comparison
function operating against a known in vitro sample. The sample represented averaged
data from 6 batches of double coated beads. The coating polymers used were Surelease R©
mixed with Pectin - X% of total weight gain - serving as a release control mechanism, and
Opadry R©, (Colorcon Inc, 2009), - 10% of total weight gain - used to prevent polymer
blocking reaction between the gelatinous core and the top coat. A bead contained 10.8% of
mass drug loading of the active substance - Cyclosporine A. An average diameter measured
in the batch was 1.65mm. The in vitro dissolution environment consisted of two different
solutions: 0.1 HCl concentration for the first 2 hours, and 0.75 SDS enzyme concentration
from 2 to 24 hours.
We varied four simulation parameters:
• The gelatin λ factor, indicating the mean lifetime value of core cells,
• The probability of water diffusion into polymeric chains of Surelease/Pectin outer
coating (PW ),
• The diffusion of water into core layer (PWG),
• The diffusivity of Cyclosporine A through the outer layer (PP ).
With the exception of the λ factor, which is known to lie within certain limits, the
rest are probabilities whose values are derived from the diffusion coefficients of various
polymers (according to rules similar to Equation (4.20)), and, as indicated in the Chapter 4,
Section 4.4, can be at best guessed using rather general data available from the literature.
Therefore, they make good candidates for inverse modelling. The λ factor was selected in
order to understand how inverse search applies to parameters with known limits.
The set of parameters that were varied, along with their initial mean, deviation,
boundaries and sampling precision used, is given together in Table 7.1.
The inverse simulations were performed under a set of known constraints used for
other parameter values, either specified as part of the experiment or derived from known
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Parameter Init. µ Init. σ Left bound Right bound Precision range
λ factor 100 50 50 200 100
PW 0.05 0.02 0.001 0.1 10−3 - 10−2
PWG 0.05 0.02 0.001 0.1 10−3 - 10−2
PP 0.5 0.2 0.01 1 10−2 - 10−1
Table 7.1: The inverse model parameter space. The initial mean, standard deviation,
bounds and precision of each investigated parameter are given. The truncated normal
distribution, defined by {µ, σ, left bound, right bound}, was used as the initial sampling
prior for each parameter.
literature. The list of constraints used, along with their values is given in Table 7.2. All
simulations were run with a cell matrix precision of 0.03 mm per cell in order to enable faster
forward simulation time. This has to be taken into account when analysing the results, as
according to Equation (4.20) smaller precision will lead to generally larger probability values
(as diffusion coefficients values are inversely proportional to the dimension of individual
cells). Deriving probabilities from values obtained at coarser precision for these of finer
precision simulations is straightforward, as the resulting probability along a direction of
drug movement can be obtained by multiplying the individual cell probabilities together.
Some accumulation of error is possible, as indicated in a similar case, (Barat, 2006). Of
course, coarser precisions do not allow for simulations involving small variations of drug
coatings, (something that would be a preferred target of investigation, originally flagged for
the direct model). However, since those parameters are used as constraints, then, as long
as the required thickness can be modelled at the given precision, the ability to vary the
drug coating parameter so finely is not needed.
Volumetric loading was derived from mass loading using a process, similar to that
described in Chapter 4, Section 4.4, and was found to be ≈ 20%. Also in line with the
double coated model data described, the diffusion coefficient of CyA was kept at a standard
value of 10−6cm2/s. The mean Opadry lifetime was assigned to be 30 minutes, based on
experimental in vitro observations. Swelling probability was chosen so that the swelling
of gelatine core is one of the more dominant processes affecting the release. Finally, the
blocking and clustering effects of gelatine, observed to significantly impact release rates
toward the latter end of the simulation have been removed, as the dissolving Opadry
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Parameter Value
cell size 0.03 mm
volumetric loading 20%
mass loading 10.8%
Df 10
−6cm2/s
Opadry R© lifetime 30 min
PS 0.5
PC 0.00
PD 1.00
surelease/pectin coat 0.06 mm
Opadry coat 0.06 mm
Table 7.2: Physical constraints for the inverse simulations. The coating thicknesses, Opadry
lifetime and volumetric and mass loadings were derived from existing batch data. The
swelling probability was set to enable controlled behaviour, influenced by both swelling
and erosion, as observed in the Direct MC experiments in Section 6.3. The probability
of gelatin blocking/clustering due to the low solubility inside the core is zero as dissolved
Opadry R© significantly enhances gelatin solubility. Finally, the diffusion was set to be the
fastest process.
coat causes better and more complete degradation of gelatin within the bead. Finally, we
assumed the CyA diffusion to be the fastest process in the bead, and therefore used it as
a reference value for measuring other relative diffusivities using the equations defined in
Chapter 4, Sections 4.3, 4.4.
We first examined the convergence properties of the Gibbs sampler used. Figure (7.4)
shows the change of χ2 value over approximately 1400 iterations, while Figures (7.5) and
(7.6) show, respectively, the comparison of experimental and simulated curves during
different convergence periods and χ2 convergence patters for different input parameter
ranges. Regression analysis using a locally weighted smoothing line (LOESS method) was
plotted against the data to show the convergence behaviour. Each point represents the χ2
value obtained for each forward simulation, with 10 sequential points representing each
parallel batch of iterations. The optimal values selected in each batch are visible as the
lowest points of the graph showing the optimal χ2 change. As expected, the algorithm takes
some time to converge. The burn-in period took around 800 iterations, after which the
sampling stabilised around values of χ2 between 70 and 80. Noting the vertical distribution
of points during the inverse simulation we can see how the sampling distributions are
getting narrower producing sample parameter vectors with decreasing standard deviations.
At around the 400th iteration there was a brief example of the sampler entering the local
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Figure 7.4: Changes of chi-square value indicating the correspondence between simulated
and experimental values in each iteration. The convergence trend is indicated using a
LOESS* smoothing line (blue). Selected chi-square values - the best ones in a given run -
are the lowest points of the graph. The first dip in the smoothing line indicates a point
where the Gibbs sampler exited from a local minimum.
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Figure 7.5: Comparison of selected samples of forward simulations during different con-
vergence periods. (Left) Initial configuration; (Centre) After burn in period (Right) After
stabilisation.
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Figure 7.6: Convergence patterns for different input parameter ranges.
minimum, and exiting it to continue converging. This shows the recovery advantage of
using the acceptance functions that take locally minimal χ2 values. Although convergence
to zero is ideal, we have to take into account the quality of the proposed constraints, which
will never completely reflect the actual values in the experiment, i.e. the variance never
reaches zero. With respect to data match for the simulation, using the converged vector of
parameter values against the experimental data, we observe this to be very good, (Figure
(7.5)). In the same figure, we demonstrate the same trend on selected samples of forward
simulations. The first comparison represents the release curve, which matches poorly with
experimental data from which the sampling algorithm started. At the end of the burn-in
period, slightly better agreement is achieved. Finally, after convergence has stabilised the
resulting release curve fluctuates only slightly around the optimal value found.
In order to understand how parameter convergence to best fit values with observed
experimental data depended on the initial priors used for their sampling, we analysed the
parameter variation rate for priors of different sizes. As the sampling of parameter values
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Figure 7.7: Comparison of the variation of λ sample (dependent on choice of priors) with
different bounds and parameter ranges. (left) Medium-sized initial prior using truncated
normal {µ = 80, σ = 50, a = 50, b = 150} (centre) Smaller-sized initial prior using
truncated normal {µ = 50, σ = 30, a = 50, b = 140} (right) Larger initial prior using
truncated normal{µ = 100, σ = 50, a = 50, b = 200}.
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at iteration k is dependent on χ2 convergence at iteration k − 1, which itself is influenced
by the entire set of parameter values changed up to that iteration, we cannot base the
analysis of parameter value correctness solely on comparison with resulting χ2 values, but
must take into account also the value variations within the sample parameter space. Thus,
small variations of the sampled parameter value can indicate one of two things: (1) the
parameter has converged around the optimal value or (2) the initial prior is too restricted
and the sampling algorithm cannot escape the local minimum. To understand which of
these apply, we need to look at the corresponding convergence of the acceptance ratio. Case
(2) is illustrated in Figures (7.7)(a) and (7.7)(b). If we look at the respective χ2 square
convergence patterns, (Figure (7.7)) overall, we see that convergence is clearly established
for the parameter range in (c) but is lacking for (a) and (b). This, along with the range of
samples explored in (c) gives a better indication that the parameter value found is suitable.
Finally, we examined credibility intervals of the resulting MCMC chain for the λ factor
values. Figure (7.7)(c) shows the resulting upper and lower bounds of the 95% credibility
interval in each sampling iteration, displayed as highest precision density (HPD) intervals.
The HPD intervals give the smallest credibility range and, although they are not invariant
under changes of the parameter value, we are usually only interested in the intervals of the
last few samples, (which indicate that the optimal parameter value has been found).
The next parameter examined was water permeability through the outer membrane.
Again, we used three intervals of decreasing size. Figure (7.9) shows the convergence
patterns for three different intervals. In contrast to the convergence of the λ factor, it is
much more difficult to establish a reasonable convergence pattern in this case. There is
no clear grouping of the results around a common cluster of values and the changes in the
mean are frequent. The standard deviation remains constant without decreasing further.
However, if we consider the results of the sensitivity analysis in Chapter 6, this pattern of
results can be inferred from the fact that the model output is not very sensitive to changes
in coating water permeability. Thus, the Gibbs sampler would often accept changes in P[W ]
as those would result in χ2 values not far away from the previous ones.
Another parameter that shows good convergence properties is the diffusivity of CyA in
the outer coating (PP ). Figure (7.10) shows the convergence for the three size intervals
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Figure 7.8: Convergence of mean and standard deviation of prior distribution used by
the Gibbs sampler, with 95% credibility intervals for λ values for case (c) of Figure 7.7.
Reduced standard deviation constrains possible optimal values of the parameter. High
probability density (HPD) credibility intervals were calculated for those MCMC samples,
generated using the resulting priors.
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Figure 7.9: Convergence pattern of PW values for three different initial priors. (left)
Large-sized initial prior using truncated normal {µ = 0.05, σ = 0.02, a = 0.1, b = 0.9}
(centre) Medium-sized initial prior using truncated normal {µ = 0.03, σ = 0.02, a = 0.01,
b = 0.06} (right) Small-sized initial prior using truncated normal {µ = 0.005, σ = 0.002,
a = 0.001, b = 0.01} Convergence pattern is not present for any of the used priors, and
parameter variation cannot be correlated with χ2 convergence trends.
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Figure 7.10: Convergence pattern of PP values for three different initial priors. (a) Large-
sized initial prior using truncated normal {µ = 0.3, σ = 0.3, a = 0.1, b = 0.9} (centre)
Medium-sized initial prior using truncated normal {µ = 0.1, σ = 0.1, a = 0.1, b = 0.8}
(right) Small-sized initial prior using truncated normal {µ = 0.05, σ = 0.03, a = 0, b = 0.2}
Convergence is improved with each sampling prior and corresponds to that of χ2.
mentioned before. The first two show convergence all the way to the lower boundary,
indicating that the lower sampling boundary can be lowered, and the precision of sampling
increased. Using a smaller sampling interval from [0, 2] shows good convergence around
the 0.04 mark and a good match with the respective χ2 convergence patterns.
Finally, the convergence intervals for diffusivity of water into the gelatin core (PWG) are
shown in Figure (7.11). Again, good convergence is established with narrowing intervals,
and in line with the overall convergence of the release curve.
Overall, we can say that we note that relatively good candidate values for three of the
four parameters investigated were found. In the case of PW we can see that the relatively
low model sensitivity to changes of the parameter does not give us sufficient confidence in
its values.
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Figure 7.11: Convergence pattern of PWG values for three different initial priors. (left)
Large-sized initial prior using truncated normal {µ = 0.05, σ = 0.02, a = 0.01, b = 0.09}
(centre) Medium-sized initial prior using truncated normal {µ = 0.02, σ = 0.01, a = 0.01,
b = 0.06} (right) Small-sized initial prior using truncated normal {µ = 0.005, σ = 0.002,
a = 0.001, b = 0.1} Convergence is improved with each sampling prior and corresponds to
that of χ2.
176
7.6 Extensions: Optimisation of parameter space search us-
ing Neighbourhood algorithm
7.6.1 The Neighbourhood algorithm (NA)
The IMC model presented so far depends on running the forward model for each sampling of
the parameter vector. If the forward model can be evaluated using an analytical expression
this does not present a problem. However, in the majority of models which solve the forward
problem stochastically by iterating many times over properties of a large discrete space,
(such as in Cellular Automata simulations) this results in a significant runtime overhead,
which impairs the effectiveness of the inverse approach.
Sambridge (1999) developed an inversion algorithm for multidimensional parameter
spaces that saves significant time by utilising the existing knowledge on data misfits from
previously run simulations. The search algorithm uses what is known as Voronoi cells
to derive the search in parameter space, (Voronoi, 1908). Given a set of points (“control
points”) in a parameter space, Voronoi cells represent nearest neighbour regions of the space,
each containing one of the control points, with all other points within a region defined as
having a smaller distance norm to one control point than to all the others.
Formally, this can be represented by the following. Let P = {X1, X2, ...Xnp} mark a
set of points in d-dimensional parameter space of interest, where 2 ≤ np ≤ ∞ and Xi 6= Xj
for i 6= j. The Voronoi cell around the control point Xi is given by:
V (Xi) = {X|||X −Xi|| ≤ ||X −Xj ||forj 6= i, (i, j = 1, 2, ..., np)} (7.9)
The Voronoi cells created in this way are used to approximate (i.e. interpolate) the
misfit function3 across the entire parameter space. The algorithm takes the following
simplified form:
• Create the approximation of the misfit surface from the np previous models for which
the forward simulation has been run,
3Misfit function can be considered as analogue of the “goodness of fit” function presented earlier in the
work. Larger values would indicate poorer match with the experimental results.
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• Utilise the resulting approximation, (instead of running forward modelling again),
together with the chosen search algorithm, (simulated annealing, M-H or Gibbs, for
example), to generate the next ns samples,
• Combine the real and approximate results and repeat.
The misfit function is set to a constant value within each of the Voronoi cells (NA-
surface). Therefore in order to find the value of the misfit function at any given point, we
only need to look up the Voronoi cell to which it belongs.
Integration of NA with M-H and Gibbs samplers
Let the sampling density function be S(X). Then, as noted earlier, the M-H algorithm
performs a move from point A to point B along one of the d parameter axes, according to
the probability distribution q(XB|XA), and the move is accepted if
r < min
[
1,
S(XB)q(XB|XA)
S(XA)q(XA|XB)
]
(7.10)
As the q is usually chosen to be symmetric (so q(x|y) = q(y|x)), we can simplify the
acceptance criterion to
r < min
[
1,
S(XB)
S(XA)
]
(7.11)
The acceptance/rejection step requires the misfit function to be evaluated at point B,
requiring one solution to the forward problem along each of the parameter axes. However,
a large number of parameter permutations will be rejected leading to the large “wasted”
computational cost.
The M-H method can be integrated directly into step (2) of the described “idealised”
algorithm. At each stage, the M-H method is used to draw nS statistically independent
samples from the current NA-misfit surface, thus using it as an approximation for the
actual misfit function, and to avoid solving the forward problem.
If we denote the computation time of forward modelling by TFM , that of the neigh-
bourhood search as TNN , and the number of iterations as IT , we can represent the cost of
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generating samples using the NA-surfaces as:
TNA = TFM + TNNITd (7.12)
On the other hand, the cost of using forward modelling each time is:
Tmisfit = TFMITd (7.13)
Leading to a cost reduction ratio of
TNA
Tmisfit
=
1
ITd
+
TNN
TFM
(7.14)
As in almost all relevant cases we expect ITd 1 and TFM  TNN the cost saving is
significant, and we can generate many more samples from the desired joint distribution for
the same computational cost.
The usefulness of this approach depends on the nature of the forward problem (its cost)
and the sample size of nS . Larger sample sizes lead to existing NA-surfaces being exploited
for longer. On the other hand, as nS is decreased the NA-surfaces are updated more rapidly
requiring more forward solutions to be computed.
In the case of applying NA algorithm as a step in the Gibbs sampler, the cost reduction
is even greater:
TNA
Tmisfit
=
1
nad
+
TNN
TFM
(7.15)
with na corresponding to the number of parameter samples generated along one of the
d axes.
7.7 Summary and Conclusion
In this chapter we have described the systematic development and examples of inverse
modelling algorithms, and we have designed and evaluated a possible approach to elucidating
unknown parameter values, based on analysing the results of hundreds of forward simulations.
We have shown that using the Gibbs sampler and Metropolis-Hastings algorithm as the
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basis for inverse methods gives good parameter estimates and can converge in reasonable
time, (which may yet be improved further). This makes these methods very useful in the
context of drug modelling since in practice, the actual value of many parameters, (usually
derived from theory) are subject to considerable experimental error. We have established
good convergence for several of the investigated parameters, giving good credibility intervals
on true parameter value.
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Chapter 8
Concluding discussion and future
work
8.1 Summary and Conclusions
Although modelling of DDS has been extensively studied, there is growing need for improved
models, which are able to accommodate more complex formulations as well as help expand
theoretical knowledge in the real world applications. The results from this research have
so far successfully facilitated comparison of simulated and experimental release curves,
allowing us to determine key parameters and their values for the novel drug formulation,
introduced by Sigmoid Pharma, and to reproduce qualitative release behaviour patterns
observed in experimental systems in vitro.
Initial models predicted the essential biphasic, sigmoidal nature of the release curves
for coated beads, and provided good insights into mechanisms affecting controlled drug
release. Model organisation allows independent investigation not only of superposition of the
phenomena of interest but also their individual contribution to release rates, supporting the
case for using probabilistic modelling methods in controlled drug delivery. Most importantly,
we have now introduced parallelisation in order to facilitate processing of large amounts of
data.
The models also allow us to look into the role of coating in controlled release, which is
one device design aspect less well addressed in the literature so far, yet widely used in the
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pharmaceutical industry.
Main findings
• The first three chapters of the thesis provided an in-depth assessment of the current
state of DDS modelling and outlined particular advantages of using stochasticity as
an integral part of drug dissolution modelling. The main methodologies that can
be utilised in this context were presented. Fundamental formulae used for all three
main modelling groups were discussed. In addition, status and limitations of existing
models were outlined. This led to identification of questions that need to be addressed
in new models, serving as the motivation for development of the further models
presented in this thesis.
• Chapters 4 and 5 presented a new integrative modelling process and framework,
flexible enough to accommodate not only the simulation of all major dissolution
phenomena, but also straightforward at very little “cost”. These are based on having
a unified, common, meta model which describes a basic set of rules intrinsic across
derived models. We showed the advantage of this approach by deriving three specific
models that address all main release phenomena, (erosion, swelling and diffusion)
with very good results when compared to experimental in vitro data. We have
shown that the influence of particular Cellular Automata update mechanism plays
an important role in the realism achieved in describing problem dynamics. Finally,
we have shown that adaptation of the framework for high performance execution
has a major impact in reducing the simulation time and allowing greater scalability
for multiple simultaneous solutions, or, equivalently, increasing spatial resolution at
which the simulations are performed. The HPC solution developed is adaptable to
the size of the available parallel infrastructure.
• Results presented in Chapter 6 validated the developed models against experimental
data and showed a very good match, with the majority of the results falling within
acceptable sampling range. Additionally, with models increasing in complexity, the
differences between simulation and experiment were shown to decrease demonstrating
that the progressive approach, towards incorporating additional details, was sound.
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• Finally, in Chapter 7 we introduced a novel application of Inverse Monte Carlo
methods to the field. We demonstrated a feasible approach for reverse engineering the
unknown model parameter values from generally noisy data by using a combination of
Gibbs sampling and Metropolis-Hastings algorithms. The approach gave good results
with reasonable time to convergence. It is clear that IMC methods can be very useful
in real world applications as direct models often suffer from trying to determine many
simulation parameters of the in vitro experiment from incomplete, sparse or noisy
data.
8.2 Future Work
The models developed here have permitted investigation of the role of coating in controlled
release, which is one of the device design aspects least understood so far in the literature,
yet widely used in the pharmaceutical industry. A number of follow-on projects is clearly
indicated.
Controlled vs. instant release for drugs of similar profiles
To evaluate model validity, simulation results should be compared to independent experi-
mental data (Seidenberger et al., 2011). The goal of such an auxiliary project would be
to understand how factors such as excipient choice, erosion/swelling mechanisms, drug
loading, different media, drug solubility and so on influence instant vs. controlled release
formulations. The question is whether we can use knowledge from one drug to predict
release aspects of another? For example, certain dissolution phenomena can be better
studied in isolation. Looking at instant release tablets will improve our knowledge of what
is happening in the first few hours of release. To our knowledge there are no models which
currently investigate these very different release profiles.
The influence of fragmentation and percolation on drug release from poly-
disperse matrix systems
Fragmentation processes and percolation of drug particle networks have been little modelled
to date. Probabilistic modelling of this aspect of release would provide more realistic simu-
lation of drug release from devices, where underlying dissolution phenomena are aggregated,
rather than occurring at an individual cell level. This is of considerable importance for
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pharmaceutical investigation.
The influence of Type IV dissolution apparatus on drug release from matrix
controlled release tablets
As mention in the thesis, the most widely used dissolution apparatus is the USP Type II, (The
United States Pharmacopeial Convention, 2007). However, its hydrodynamic conditions are
far from ideal. It was shown that there are highly variable shear distributions and velocity
gradients throughout the vessel, particularly in the area immediately surrounding the device.
The Type IV apparatus works on a “flow through method”, where the device is held in a
fixed position with the dissolution medium pumped through the device holder. This makes
the Type IV apparatus highly applicable for poorly soluble drugs and for detecting changes
in pH in the dissolution media, (Greco et al., 2011), (Shiko et al., 2011). A collaboration
with Pharmaceutical Department from University College Cork (UCC) is planned with the
idea of adapting the meta-model so that main features of Type IV can be simulated.
Sample space minimisation in Inverse Monte Carlo methods using neigh-
bourhood algorithm
In Chapter 7, we described one possible way to further optimise the speed of the inverse
algorithm. As shown in Figure (7.4) it takes a relatively large number of iterations to
pass the burn − in period and stabilise around the optimal value. Considering that for
high precision simulations runtime of individual forward simulation is significant, so that
the entire iteration set is relatively slow, (even if we consider parallelisation of individual
runs), reducing the parameter space becomes the primary way of speeding up the inverse
simulation. We can apply the neighbourhood algorithm and divide our space into Voronoi
cells to that end. This, and other means of sample space reduction would be an interesting
subject for future work in this area.
Pseudo-random number generation algorithms
Similar to the pattern observed when analysing different asynchronous update mechanisms,
it would be useful to investigate the influence of various pseudo-random number generation
algorithms on the properties of large populations of different cell types. As random number
generation forms the basis of the Monte Carlo approach used in the models, any bias initial
state generation patterns on the resulting models should be understood.
184
Model interface unification
The ideal, of course, would be integration of all described models into one unified general-
purpose system. This would facilitate use of the models as prediction tools through a single
interface, adapted for pharmaceutical scientists to investigate various dissolution scenarios.
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Appendix A
Framework and individual model
implementation details
The framework and models have been implemented using an object-oriented paradigm,
with model classes representing an extended version of the ones offered by the modelling
framework. The framework defines a set of common modules, including the definition
of the main Cellular Automata matrix, the parallel algorithms used for its traversal, the
visualiser used for graphical display of the state of each iteration and the configuration
block responsible for reading the simulation parameters from a file. Unified Modelling
Language (UML) class diagram of the framework and one of the derived models (MCES) is
represented in Figure A.1. Note that only the most important class methods and attributes
have been displayed for brevity purposes. What follows is a more detailed description of
each class:
CA Matrix
The CAMatrix is the abstract class holding the parameters and methods relevant to
describing the Cellular Automata space (matrix) itself. Besides the spatial (width, height,
depth, number of cells) and temporal (number of iterations, current iteration, global time)
attributes it defines several key simulation methods:
• Initialise() is a virtual method responsible for assigning the initial state of each cell
in the matrix. It must be derived by any class implementing the specific device model
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Figure A.1: UML diagram of the developed code. Thick dashed line shows the division
between the classes and methods provided by the framework and meta-model and the ones
derived by the individual models.
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and geometry.
• Update() is a method called during each iteration by either the Visualiser class
(if the graphical representation mode is enabled) or the main program. It uses the
UpdateOrder to traverse the CA matrix space and calls the virtual UpdateState()
function defined by derived geometry classes. The Update() function also handles
the scatter-gather logic of the MPI parallelisation and the division of matrix space
across individual threads within the single process using OpenMP.
• ComputeRelease() is a function that calculates the amount of released drug within
the matrix and calls the virtual method ComputeSpecific() implemented by the
derived models. ComputeSpecific() can then calculate model outputs specific to
the drug/geometry being modelled (e.g. dissolution fronts, coating porosity, gel
blocking amount, etc.)
• ProfileResults() gathers profiling parameters using several timers dispersed across
the code, such as the duration of single iteration, durations of iterations in each MPI
process and the amount of time spent in parallel and sequential code.
Sphere
Sphere is a class derived from CAMatrix() describing the specific device properties, in-
cluding its geometry. It defines the main model parameters (swelling probability, clustering
probability, probability of diffusion of water through ethylcellulose etc.) and is respon-
sible for setting up the initial state. It implements the virtual methods of Initialise(),
UpdateState() and ComputeSpecific() to add the logic specific to the model itself.
Visualiser
The Visualiser class is responsible for displaying the graphical representation of the
CAMatrix on the screen using OpenGL libraries. It does so by traversing the cross section
of the matrix and drawing each cell depending on the type of material, its lifetime and
number of drug packets present.
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Configurator
The Configurator class is responsible for parsing the configuration file with the simulation
parameters and making those available to other classes.
Cell and derived classes
Cell class represents the basic building block of the CA matrix. It contains information
about a particular cell, including the type of material (through specific subclasses) and the
amount of drug present. It also contains several attributes describing the position of the
cell within the matrix and whether it is shared between several processes for the purpose of
MPI parallelisation.
UpdateOrder
UpdateOrder implements the specific cell traversal algorithm, which can be either syn-
chronous (each cell in order) or asynchronous (random cells depending on the ACA algorithm
used). It has a single virtual method GetNext() which is responsible for returning the
next cell to update.
Distributions
Distributions is a static class that provides several random number generation methods
used for sampling from different distributions (uniform, Gaussian, Erlang, etc.)
Behaviour and derived classes
Behaviour is a virtual class providing a single virtual method Apply() which is used to
calculate the next state of the given cell as the traversal algorithm updates it. The derived
classes implement the method for specific behaviour desired (i.e. erosion, swelling, diffusion,
dissolution and so on).
Typical iteration algorithm
The simulation starts by initialising the MPI and OpenMP runtimes and setting up the initial
CA matrix state by calling the Initialise() method of the Sphere object. Depending on
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whether visualisation is enabled, theUpdate() method is set up to be called by the OpenGL
runtime before rendering each frame of the animation to the screen, or, if the visualisation
is disabled (in HPC cluster execution context for example), it is called sequentially as many
times as there are iterations. The Update() method itself distributes the matrix state
across all of the initiated MPI processes, which in turn execute an OpenMP parallel loop
over the individual sections received (thus dividing the space further across threads). Each
thread invokes the UpdateSpecific() method on the cell obtained via the UpdateOrder
object. This, in turn, applies all of the desired behaviours on the cell, setting its final state.
After the simulation goes through all cells, the main MPI process collects the resulting
state, performs release data calculations and writes the output into a file that can be later
plotted using any available tabular processing program (such as R). In case of cluster
executions, the plotting is performed automatically as part of the execution script thus
producing readily-available graphs once the simulation finishes.
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Appendix B
List of abbreviations
ABM Agent Based Modelling
ACA Asynchronous Cellular Automata
API Application Programming Interface
CA Cellular Automata
CyA Cyclosporine A
DDS Drug Delivery System
EC Ethylcellulose
EC/P Ethycellulose/Pectin
EXP Experiment
GI Gastro-intestinal
HPC High-Performance Computing
HPMC HydroxyPropyl MethylCellulose
IMC Inverse Monte Carlo
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LOESS Locally Weighted Scatterplot Smoothing
MC Monte Carlo
MCMC Markov Chain Monte Carlo
M-H Metropolis Hastings algorithm
MPI Message Passing Interface
MVN MultiVariate Normal distribution
NA Neighbourhood Algorithm
N-W Noyes-Whitney equation
PLA Polylactide
PLGA Polylactic-co-glycolic Acid
SA Simulated Annealing
SCA Synchronous Cellular Automata
SEM Scanning Electron Microscope
SMP Symmetric MultiProcessing
UML Universal Modelling Language
USP United States Pharmacopeia
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Appendix C
Glossary
• Biodegradable - capable of being decomposed by living organisms.
• Coating weight gain - amount of device mass increase (in %) after application of
the coating layer.
• EXP11/085, EXP11/086, EXP11/115, EXP11/180, EXP11/227, EXP12/111,
EXP12/119, FC008/09, FC015/09, FC021/09 - Laboratory designations of in
vitro experiments performed by Sigmoid Pharma. These experiments were used for
comparison with simulation results.
• In silico - via a computer simulation.
• In vivo - within a living organism.
• In vitro - in an artificial environment outside the living organism.
• Locally Weighted Scatterplot Smoothing - a set of regression methods combining
multiple regression models in a k -nearest-neighbour meta-model. Used for plotting a
smooth curve through a set of data points.
• Message Passing Interface - a computing standard for implementing parallelisation
across processes using message transfers. There are various implementations of the
standard, including OpenMPI and MPICH.
• Opadry R© - a complete film coating system that combines polymer, plasticiser and
pigment in a dry concentrate. Developed by Colorcon R©.
213
• OpenMP - application programming interface that provides shared memory multi-
processing. It is commonly used on SMP architectures.
• Parenteral - administration of pharmaceutics by intravenous routes.
• Process-level parallelism - code parallelisation methodology using heavy-weight
processes usually executing on different computers (nodes). Technologies such as
different MPI implementations are commonly used to achieve process-level parallelism.
• Surelease - aqueous coating system utilising ethylcellulose as a rate controlling
polymer. Developed by Colorcon R©.
• Symmetric MultiProcessing - hardware architecture where two or more processors
are connected to a single shared main memory. This allows the code executing on
each processor to access a common shared memory space.
• Thread-level parallelism - code parallelisation methodology using light-weight
threads (or strands of operation) to execute sections of the code concurrently. Tech-
nologies such as OpenMP are commonly used to achieve thread-level parallelism.
• Transdermal - administration of pharmaceutics through the skin.
• Volumetric loading - the volume of a drug relative to the volume of the device. A
more suitable description for the amount of drug for the case of spatial simulations,
as the mass loading does not give information on the amount of space consumed by
the drug.
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High-Performance Computing for Data Analytics, 2012 IEEE/ACM 16th
International Symposium on Distributed Simulation and Real Time Ap-
plications (DS-RT), pp.234 - 242, Dublin, October 2012.
URL: http://ieeexplore.ieee.org/xpls/abs_all.jsp?arnumber=6365069
Abstract One of the main challenges in data analytics is that discovering structures
and patterns in complex datasets is a computer-intensive task. Recent advances in
high-performance computing provide part of the solution. Multicore systems are now
more affordable and more accessible. In this paper, we investigate how this can be
used to develop more advanced methods for data analytics. We focus on two specific
areas: model-driven analysis and data mining using optimisation techniques.
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Abstract Cellular Automata (CA) properties facilitate the detail required for the
bottom-up approach to modelling and simulation of a broad range of physico-chemical
reactions. In pharmaceutical applications, CA models use a combination of discrete-
event rules based on probabilistic distributions and fundamental physical laws to
predict the behaviour of active substances (drug molecules) and structural changes
in Drug Dissolution Systems (DDS) over time. Several models of this type have
been described so far in the scientific literature. Yet practical applications are
lacking in the context of large-scale, high-precision, high-fidelity simulations. The key
obstacle to parallelisation of such models is not only the amount of data involved,
but also the fact that many of these models incorporate agent-like behaviour within
the CA framework in order to describe pharmaceutical components. This makes
communication across process boundaries expensive. In this paper, we apply different
parallelisation strategies to a large scale CA framework, used to model coated drug
spheres. We use two parallel-computing application programming interfaces (APIs),
namely OpenMP and MPI, to partition the simulation space. We analyse the
applicability of each API to the problem individually, as well as in the hybrid solution.
We examine speedup potential and overhead for local and global communication for
simulation speed and solution scalability. For these types of problems, our results show
that performance is much improved for appropriate combinations of parallelisation
solutions.
3. Bezbradica, M., Ruskin, H. J., and Crane, M. Applications of High Per-
formance Algorithms to Large Scale Cellular Automata Frameworks used
in Pharmaceutical Modelling. Submitted by invitation for journal Con-
currency and Computation: Practice & Experience. Expected to appear
in the 4th Quarter, 2013 (Tentative).
Abstract Background: Cellular automata (CA) frameworks have been gaining mo-
mentum as a promising tool in the field of in-silico Drug Dissolution System (DDS)
modelling. This is due to their inherent properties which facilitate the detail required
for a bottom-up approach to modelling as well as their ability to support simulations
of a broad range of physico-chemical reactions. In pharmaceutical applications, CA
216
models use a combination of discrete-event rules, based on probabilistic distributions
and fundamental physical laws, in order to predict the behaviour of active substances
and structural changes in a DDS over time.
Several models of this type have been successfully described so far in the scientific
literature. Nevertheless, practical applications are lacking in the context of large-scale,
high-precision, high-fidelity simulations requiring significant amount of data and
computing resources to execute. In the present high performance computing era,
such resources are readily available, but algorithmic solutions in the field tend to lag
behind. The key obstacle to parallelisation of such models is not only the amount
of data involved, but also the fact that many of these models incorporate agent-like
behaviour of pharmaceutical components within the CA framework, which makes
communication across process boundaries computationally expensive.
Methods: In this paper, we consider different parallelisation strategies for a CA
framework used in modelling coated drug spheres. Here, one of the main factors
influencing drug dissolution is sensitivity to the physical thickness of the spherical
coating. This is orders of magnitude smaller compared to the core sphere of drug,
so that large 3D models are needed to accommodate the measurement range. Two
parallel-computing application programming interfaces (APIs), namely OpenMP and
MPI, are used to partition the simulation space.
Results: We analyse individual applicability of each API to the problem, as well as in
the hybrid form. Speed-up potential and overhead for local and global communication
are also explored for simulation execution time and solution scalability. For these types
of problems, results indicate that performance can be greatly improved for appropriate
combinations of parallelisation strategies. This finding has important implications for
the scope of such models, enabling incorporation of diverse interactions at small-scale
within the global framework.
4. Bezbradica, M., Ruskin, H. J., and Crane, M. Modelling Drug Coatings:
A parallel cellular automata model of ethylcellulose-coated microspheres,
Proceedings of The International Conference on Bioscience, Biochemistry
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and Bioinformatics, ICBBB 2011 5, pp.419 - 424, Singapore, February
2011.
URL: http://www.etlibrary.org/?m=fbook&a=details&aid=2923
Abstract Pharmaceutical companies today face a growing demand for more complex
drug designs. In the past few decades, a number of probabilistic models have been
developed, for the purpose of giving a better insight into the microscopic features
of these complex designs. Of particular interest are those models that simulate
controlled release systems to provide targeted dose delivery. Controlled release is
achieved by using polymers with different dissolution characteristics. We present here
a model of a drug delivery system based on Monte Carlo methods, as a framework
for Cellular Automata mobility, and show a solution for model enhancement through
parallelisation. The objective is the high performance simulation of targeted drug
release in the gastro-intestinal tract, from a capsule composed of ethylcellulose coated
microspheres. The overall aim is to understand the importance of various molecular
effects with respect to system evolution over time. Important underlying mechanisms
of the process, such as erosion and diffusion, are described.
5. Bezbradica, M., Ruskin, H. J. and Crane, M. Probabilistic models for
dissolution of ethylcellulose coated microspheres, in Proceedings of The
European Simulation and Modelling conference, ESM’2010, pp.408 - 412,
Hasselt, Belgium, October, 2010.
The book edited by Janssens, G. K., Ramaekers, K. and Caris, A. ISBN 978-90-77381-
57-1
Abstract In the last few decades, a number of probabilistic models for drug delivery
have been developed. Of particular interest are those that model controlled release
systems to provide targeted dose delivery. Controlled release is achieved by using
polymers with different dissolution characteristics. We present here a model based
on Monte Carlo and Cellular Automata approaches, for simulating drug release from
coated microspheres in the gastro-intestinal tract. Controlled release is obtained
using ethylcellulose as the coating polymer. Modelling features, such as the drug and
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coating dissolution are nontrivial, since material is non-homogenously dispersed and
the dissolution exhibits complex behaviour. Important underlying mechanisms of the
process, such as erosion, are described here.
6. Bezbradica M., Crane M. and Ruskin H. J. Probabilistic modelling of
drug dissolution, ERCIM news, 84, pp.42 - 43. January, 2011.
URL: http://ercim-news.ercim.eu/en84/research-and-innovation/
Abstract The project at Dublin City University aims to establish new computational
models for drug dissolution systems, specifically for sustained release drugs used
in the gastro-intestinal tract. It seeks to improve existing algorithms and develop
improved ones to predict the release curves of active substances. High-performance
computing and cellular automata are used to investigate probabilistic drug dissolution
phenomena. The project is an ongoing collaboration with industrial partner, Sigmoid
Pharma Ltd.
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